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This dissertation examines the effect of dementia on the treatment of coronary heart disease 
(CHD) in elderly Medicare beneficiaries. It specifically tests whether rates of utilization of 
evidence-based secondary preventive medication treatment (chemoprophylaxis) for CHD are 
different in patients with dementia compared to those without dementia.  Data from the 
Cardiovascular Health Study were used to investigate the long-term effect of dementia on the use 
of four types of low burden and low risk chemoprophylaxis for CHD over time (ACE inhibitors, 
beta-blockers, lipoid-lowering medications and antiplatelet medications).  The multivariate 
analyses employed a range of predictors including predisposing patient characteristics such as 
age, race, sex, education and the interaction of age and dementia status. Enabling variables 
included in the analyses are study site, income, supplemental insurance status, and residence in a 
nursing home.  The care need variables include functional status, measured by activities of daily 
living, and comorbidites. The main findings reveal that the presence of any type of dementia, 
comorbid with CHD, has an effect on the use of beta-blockers and lipid-lowering medications.  
Additionally, patients with CHD and vascular type dementia are less likely to report taking beta-
blockers, lipid-lowering medications, and antiplatelet medications, but more likely to report 
using ACE inhibitors. The results are mixed regarding the effect of timing of dementia onset of 
the use of chemoprophylaxis.  Those who developed dementia before CHD were less likely to 
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report using a beta-blocker and lipid-lowering mediation, yet, those who developed dementia 
after CHD did not discontinue use of chemoprophylaxis after the onset of dementia. The results 
of this dissertation provide new empirical evidence of the difference in the rate of secondary 
chemoprophylaxis for CHD among elderly patients with dementia compared to those without 
dementia. Information about the effect of dementia on the treatment of CHD, as well as factors 
that predict utilization, could inform health policy to improve care for the millions of Americans 
living with dementia and CHD.   
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1.0  INTRODUCTION 
This dissertation focuses on the effect of dementia on the treatment of coronary heart disease 
(CHD) in elderly Medicare beneficiaries. It specifically tests whether rates of utilization of 
evidence-based secondary preventive medication treatment (chemoprophylaxis) for CHD are 
different in patients with dementia compared to those without dementia.  Although it does not 
test hypotheses about the causes of variation, this research does examine a range of potential 
factors and contributes to our understanding of the significant clinical, ethical, and policy 
implications of differences in utilization of health care services for patients with dementia and 
CHD. Section 1.1 includes a discussion of the unique characteristics of chronic illness in patients 
with dementia. Section 1.2 includes a summary of what we know about the impact of dementia 
on health services utilization, and section 1.3 discusses the factors that are hypothesized to affect 
the use of health services in patients with chronic illness and dementia. Section 1.4 presents the 
specific aims and the contribution of this research.  
1.1 NONDEMENTIA ILLNESSES IN PATIENTS WITH DEMENTIA 
Medical decision-making for older patients with multiple comorbidities is a difficult task. Often, 
there are competing risks for different conditions and the best available treatment for one may be 
constrained or even contradicted by another (Hoffman, 1996). Making treatment decisions for 
 2 
patients with dementia and other comorbidities represents one of the most complex scenarios in 
medical decision making and is a potentially important area of inquiry for three reasons. First, 
dementia is unlike other chronic and progressive diseases that are eventually fatal because it 
attacks both a person’s physical and mental capacities. Second, the progression of dementia is 
characterized by an extended period of deterioration that can last as long as a decade. Over the 
period of intellectual and physical decline, many opportunities arise for making medical 
decisions about everything from screening, to management of other non-dementia comorbidities, 
to treatment decisions at the end of life. The third potential importance of this work is based on 
the prevalence of dementia and the wide-ranging impact the disease has on individuals, families 
and the health care system.  
1.1.1  Characteristics of dementia and their influence on the medical decision-making 
 Dementia is a disease that is characterized by a decline in memory and other cognitive 
functions. In many cases, loss of cognitive function can happen years before the physical body 
dies, leaving the person with end-stage dementia with very few of the characteristics that define 
personhood. Living with dementia is perceived by many people as living with low quality of life 
(Fried, 2002). The perception that people with dementia have poor quality of life is supported by 
the reality that a great majority of patients with dementia spend their final years in nursing 
homes, bed-bound, incontinent, and unable to recognize their family members (Post, 2000). 
We believe that these perceptions about quality of life influence the medical decision-
making process for patients with dementia and alter the choices about medical treatment that are 
offered by the physicians and accepted by patients and families. In particular, value judgments 
by the physician about the patient’s present or future quality of life affect how physicians 
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analyze evidence (Eisenberg, 1979), present information to patients and families about treatment 
decisions (Pearlman, 1988), and how they use cues from families regarding treatment 
recommendations (Nelson, 1995). 
1.1.2 Prolonged progression of dementia  
The second potential importance of examining the effect of dementia on the treatment of 
comorbidities in general, and CHD in particular, is that dementia has a prolonged progression 
often spanning years, exposing patients to many other conditions that are common in older adults 
(Plassman, 2007). Epidemiological studies have estimated the overall median survival time from 
onset of dementia to death is 4.1 years for men and 4.6 years for women making it comparable to 
other terminal diseases that have longer progressions, such as class III heart failure and some 
malignancies (Xie, 2008; Larson, 2004). The extended period of life with dementia presents 
multiple opportunities for decision making about treatments. Physicians, patients and their 
families are faced with decisions than span the ranges of health services, from preventive 
screening to life-sustaining treatment.  
The difference between dementia and other terminal diseases is that treatments that might 
otherwise be considered futile treatment for someone with shorter prognosis may be viewed 
more favorably for someone in the early stages of dementia. It is also true that treatment 
decisions made throughout the progression of dementia may alter the outcomes for patients and 
are likely to have a substantial impact upon the length or nature of the life to be lived. 
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1.1.3 Prevalence of dementia   
The third potentially important implication of this research is that care of patients with CHD and 
dementia has a large impact on the health care system. It is estimated that 13.9% of people over 
age 71 have some form of dementia, comprising about 3.4 million individuals in the United 
States (Plassman, 2007). In an analysis using Medicare claims data, Maslow found that 30% of 
Medicare beneficiaries who had at least one claim with a dementia diagnosis also had a diagnosis 
of coronary heart disease (Maslow, 2002).Additionally, it is estimated that as many as 54% of 
dementia patients have had a myocardial infarction at some point in their life making them 
eligible for guideline-recommended chemoprophylaxis for CHD (Brauner, 2000).  
1.2 EFFECT OF DEMENTIA ON HEALTH SERVICES UTILIZATION 
Only a few studies have directly investigated the effect of dementia on the use of health services, 
and the findings from these studies vary.  Some show that people with dementia have similar 
rates of utilization, especially for hospital and long-term care services (Weiner, 1998; Eaker, 
2001). Other studies have produced results that show that people with dementia are less likely to 
use services, especially when the treatment is more invasive (Sloan, 2004; Gorin, 2004; Gupta, 
2005). In some cases, utilizing health services at the same rate as those without dementia may be 
appropriate based on individual patient needs and goals of care. In other cases this may be a 
result of patients with dementia being exposed to care that is not beneficial and could be harmful.  
Of the literature that has looked at the effect of dementia on treatment, five studies 
included patients with CHD and included guideline-recommended chemoprophylaxis as an 
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outcome. Sloan (2004) found that among patients hospitalized with acute myocardial infarction, 
those who had a diagnosis of dementia in their hospital chart were 50% less likely to receive 
invasive cardiac procedures than peers with no cognitive impairment. That study also reported 
that use of Angiotensin-Converting Enzyme (ACE) inhibitors during the hospital stay and at 
discharge was slightly lower for patients with a history of dementia, but that use of aspirin and 
beta-blockers was the same.   
Other studies that have investigated the effect of dementia on treatment have included 
cardiovascular medications as a sub-class in the analyses. Hanlon (1996) and Schmader (1998) 
studied a community-dwelling cohort and found that overall use of prescription medications was 
lower for patients with dementia.  Their results differed for cardiovascular medications as 
Hanlon found no difference in use and Schmader found lower use among those with dementia. 
Additionally, Schamader found that those with more severe impairment were less likely to use 
cardiovascular medications.  Landi (1998) found similar results to Schmader in a study of 
medication use among nursing home residents. This study showed that after controlling for 
CHD, the more severe the dementia the less likely the resident was to be taking a cardiovascular 
medication.   
These studies have various limitations. Sloan used medical record review to identify 
dementia diagnoses, which may have misclassified patients with respect to the presence of 
dementia, which would have led to underestimating the variation in chemoprophylaxis. 
Identifying dementia through medical charts alone or Medicare claims-based data has been 
shown to underestimate the prevalence of dementia by as much as 70% because these methods 
are likely to identify only people with advanced dementia or those who are admitted to the 
hospital from a long-term care facility (Taylor, 2002).  The studies by Hanlon and Schmader 
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used a cohort of individuals from a five county area in North Carolina making the results 
difficult to apply broadly given that rates of chemoprophylaxis have been shown to vary by state 
and by region (Krumholz, 1998). The study by Landi only included nursing home residents with 
an official diagnosis of dementia and impairment severe enough to necessitate nursing home care 
making it difficult to apply to a community dwelling population. 
Each of the studies are limited analytically in that they only employed cross-sectional 
analyses for patients with dementia.  As a result, none are able to distinguish between the 
patients who developed CHD after their diagnosis of dementia from those with CHD who later 
developed dementia.  We believe that it is possible that this distinction makes a sizable 
difference in treatment.  The reasoning for this belief is that patients who experience symptoms 
of dementia first (memory loss, behavioral changes, dependence on others for activities of daily 
living, etc) may not consider initiating treatment for a new chronic condition if the treatment 
offers no direct benefit on quality of life or presents a new risk or burden. 
This dissertation will overcome the methodological limitations of previous studies by 
using a cohort of people in which both CHD and dementia have been clinically validated.  
Additional information not available in previous studies also will be used, including a measure of 
severity of dementia, change in cognitive status over time, functional status, and the rate of 
secondary preventive treatments for CHD over a ten year time period. With a prospective cohort 
study, we are able to determine the sequence of developing dementia and CHD to evaluate 
whether the timing of the development of dementia plays a role in the treatment for CHD. 
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1.3 PREDICTORS OF HEALTH SERVICES UTILIZATION FOR PATIENTS WITH 
DEMENTIA 
The studies described above that investigated the effect of dementia on use of health services 
found mixed results. None investigated potential causes that might be influencing patterns of 
utilization for patients with dementia. We believe that these findings may be the result of both 
physician-related predictors and individual patient characteristics that predict use. While the 
empirical analyses in this dissertation investigate utilization of chemoprophylaxis for CHD, the 
discussion surrounding this research includes possible predictors of use.  Two conceptual models 
are used to organize the discussion. They include a conceptual model proposed by Eddy (1990) 
for evidence-based medical decision-making and the model designed by Andersen (1995) to 
understand patient characteristics that influence the use of health services. The Eddy model 
includes elements such as analysis of evidence, and judgments about the evidence and its 
application to the patient. This model is used to frame the discussion regarding physician-related 
factors that may influence utilization of health services, in general, and chemoprophylaxis for 
CHD in particular, for people with dementia.  The predictive factors discussed here and in 
following chapters include how physicians analyze and apply evidence in medical decision-
making and the role of their subjective judgments about the patient’s quality of life.   
The Andersen model of health services utilization is used in this research to inform and 
organize patient-level predictors that may impact use of chemoprophylaxis for patients with 
CHD and dementia.  Elements of the model include predisposing factors, such as age, sex, and 
race, enabling factors such as access to health care and income, and care need factors that 
account for a patient’s health care needs as defined by their functional and cognitive status, 
comorbidites, and their perceived need for care.  
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1.3.1 Physician-related predictors of health services utilization for patients with dementia 
The first physician-related predictor is variation in geographic practice patterns.  Research on 
variation in health care utilization has found differences for a variety of different types of health 
care services across different geographic regions (Wennberg, 2004, Fischer, 2003).  In some 
cases, these differences reflect the extent to which medicine lacks a firm evidentiary base for 
treatments.  When the evidence base is strong, treatment differences tend to be much smaller 
(although the impact of new evidence is often disappointingly small).  The push to develop more 
“evidence-based guidelines” for treatment grows out of these findings.  From this perspective, 
greater uniformity in chemoprophylaxis for patients with dementia would, in general, be 
desirable, although it is often unclear how to incorporate competing risks of treatment and 
patient’s goals for care. In the case of secondary prevention for CHD, systematic application of 
the best evidence for chemoprophylaxis has been shown to improve outcomes (MI and death) 
(Smith, 2001), reduce geographic treatment variability (Chassin, 1987), and potentially, improve 
overall quality across the entire health care system (Fischer, 2003). Because no medical 
recommendations exist for treating CHD for patients with dementia, those with both diseases are 
likely be treated the same as those with only CHD.  
The second physician-related predictor includes the use of clinical information about 
dementia that may predict how physicians analyze and apply evidence to treat comorbidities in 
people with dementia. For example, it is known that patients with dementia have a shorter life 
expectancy than their age-matched peers without dementia (Larson, 2004). This is relevant to the 
medical-decision process in that if a patient is not expected to live long enough to achieve benefit 
from a particular treatment, it may not be presented to them as an option.  This was demonstrated 
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in a study by Marwill (1996) that found lower rates of guideline-recommended breast cancer 
screening for older women with dementia. 
Third, physicians may have a heightened sense of therapeutic caution based on the 
increased risk of a treatment, especially for more invasive procedures that may be perceived by 
patients with dementia as an assault if they have little insight into the purpose or intention of the 
treatment (Rango, 1985). Although subtle, even less invasive treatments, such as medications for 
people with dementia, may have a different risk-benefit ratio given potential issues with patient 
adherence and their inability to recognize or report serious side effects (Brauner, 2000). 
The fourth physician-related predictor is the subjective influences on the medical 
decision-making process. These include judgments by the physician regarding a patient’s quality 
of life or social worth.  Perceptions that a patient’s quality of life is poor or will shortly become 
poor due to dementia may result in less aggressive treatment for comorbidities.  The influence of 
this predictor is consistent with previous research that has shown the influence of physicians’ 
personal perceptions and judgments about a patient on the medical decision-making process and 
on treatment outcomes (Ubachs-Moust, 2008; Brock, 1993).  Research done by Crane (1975  that 
asked physicians to recommend medical treatments for hypothetical cases found that when the 
patient has irreversible mental disability as compared to physical disability, they were less 
aggressive in their treatment recommendations.   
1.3.2 Patient-related predictors of health services utilization for patients with dementia 
The second conceptual model used in this research is the Andersen model of health services 
utilization (Andersen, 1995). This model presents the ideal framework for organizing the 
discussion about the role of individual patient and social level correlates that may predict 
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utilization of chemoprophylaxis for CHD among patients with dementia.  This model was 
originally created to explain the use of formal health services such as hospital care, but has been 
adapted and applied to predict and explain the use of other types of health services, including 
medication (Sleath, 2004) and long-term care (Bradley, 2002). It was selected for the research in 
this dissertation because its framework acknowledges the importance of the external 
environment as well as the individual patient and family characteristics.  
The relevance of patient level predictors on the use of chemoprophylaxis for CHD among 
those with dementia is that differences in the use of a variety of health care services have been 
observed across a number of individual characteristics such as age, race, sex, and insurance 
coverage (Gornick, 1996; Federman, 2001).  Additionally, we believe that for patients with 
dementia and CHD, observed differences in the use of health services can also manifest from a 
patient’s own knowledge, attitudes, beliefs and judgments about their disease and quality of life. 
The parallel predictor of the physician’s perception of quality of life is that of the patient’s own  
perception of their quality of life as a predictor of use. For example, a patient may be less likely 
to accept or adhere to a treatment if they perceive their current or future quality of life as poor 
(Fried, 2002). This influence may likely be extended to the knowledge, attitudes, beliefs and 
judgments of the family member about the patient given the impact of dementia on decision-
making and the role of the family in medical decision-making (Nelson, 1995 ).  Although it is 
reasonable to assume that even if the patient is able to participate in the decision-making process, 
they are part of a family that has a set of collective goals, purposes and interests for all of its 
members, so few decisions are ever made individually. Given this, unless otherwise noted, 
patient and family knowledge, attitudes, beliefs and judgments are collectively considered, 
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although a section in Chapter 2 will discuss the literature on the differences between patient 
preferences and their preferences as perceived by family members. 
1.4 CONTRIBUTION OF THIS RESEARCH 
This dissertation will test differences in low burden, low risk evidence-based secondary 
preventive medication treatments for CHD between those with dementia and those without 
dementia. Additionally, these medications are low cost from a societal perspective. We expect to 
find smaller differences for medications than might be found for more intensive life-extending 
interventions or expensive treatments for CHD such as bypass surgery.  We also might expect to 
find a bigger difference for preventive screening procedures such as mammography and 
colonoscopy, where even those with mild dementia would be unlikely to live long enough to 
achieve any benefit from screening (Braithwaite, 2007; Holmes, 2006).  
This dissertation research is the first to examine the long-term effect of dementia on the 
use of low burden and low risk chemoprophylaxis for CHD.  The results of this dissertation will 
provide new empirical evidence of the difference in the rate of secondary chemoprophylaxis for 
CHD among elderly patients with dementia compared to those without dementia. Information 
about the effect of dementia on the treatment of CHD, as well as factors that predict utilization, 
could inform health policy to improve care for the millions of Americans living with dementia 
and other conditions.    
The empirical analyses in this research compare self-reported use of chemoprophylaxis 
for two distinct groups of community-dwelling Medicare beneficiaries over a ten year period; 
those who only develop CHD and those who develop both CHD and dementia during the study 
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period. Among the sample with both diseases, there are two sub-samples: (1) those who develop 
dementia before CHD and (2) those who develop dementia after CHD.  The three specific 
research questions in this dissertation are: 
1. Are Medicare beneficiaries with dementia and coronary heart disease (CHD) less 
likely to use guideline-recommended medications for the secondary prevention of CHD 
compared to those with CHD only? 
We predict that after controlling for confounding factors, people with dementia will be 
less likely to report using chemoprophylaxis for CHD because the co-morbidity of 
dementia will have a negative effect on the treatment. 
 
2. Are Medicare beneficiaries who develop dementia before CHD less likely to use 
guideline-recommended medications for the secondary prevention of CHD compared to 
those who develop dementia after CHD? 
We hypothesize that the order of the disease development is an important predictor in the 
use of chemoprophylaxis given that physicians and families may find it harder to reduce 
or stop treatment for an existing co-morbidity compared to initiating a new treatment for 
a new disease. Thus, we predict that patients who develop dementia first will have lower 
rates of utilization compare to those who developed CHD first. 
 
3. Are Medicare beneficiaries who develop dementia after they develop CHD more likely 
to discontinue guideline recommended medications for the secondary prevention of CHD 
after they develop dementia? 
 13 
We hypothesize that some people who have CHD and are taking chemoprophylaxis will 
discontinue the use of medications after the development of dementia. We predict that 
although the rate of use may be higher than those who develop dementia first and never 
start the medications, those who develop dementia after CHD will be more likely to 
discontinue medications for the secondary prevention of CHD. 
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2.0  LITERATURE REVIEW 
The literature reviewed for this dissertation is organized into four sections. Section 2.1 is a 
summary of the evidence-base for the four subclasses of cardiovascular medication that are 
guideline-recommended for the secondary prevention of CHD. Section 2.2 provides an overview 
of the Eddy model for evidence-based medical decision making by physicians and describes the 
elements of the model based on their potential contribution to variation in the use of 
chemoprophylaxis for people with CHD and dementia. Section 2.3 includes a description of the 
Andersen model of health services utilization. The findings from the literature in this section are 
organized around the elements of the Andersen model that we predict contribute to the variation 
in the use of chemoprophylaxis for people with dementia and CHD. Although these two models 
were created to explain different constructs (physician decision making and predictors of health 
services utilization, respectively), each model contains elements that are relevant to the 
exploration of the effect of dementia on the use of chemoprophylaxis for CHD. Section 2.4 
introduces a modified conceptual framework that combines elements from both the Eddy and 
Andersen models and includes a summary of the literature that directly looks at the effect of 
dementia on differences in health services utilization for older adults. 
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2.1 SECONDARY CHEMOPREVENTION OF CHD IN OLDER ADULTS: A 
SUMMARY OF THE EVIDENCE 
Coronary heart disease (CHD), also called ischemic heart disease (IHD), coronary artery disease 
(CAD), or coronary atherosclerosis is one of the most common chronic conditions among older 
Medicare beneficiaries (American Heart Association, 2004). Coronary atherosclerosis is the 
hardening and narrowing of the coronary arteries that supply the blood that carries oxygen and 
nutrients to the heart muscle. When coronary arteries are narrowed or blocked by atherosclerosis, 
adequate amounts of blood flow to the heart muscle are compromised. Disease caused by the 
lack of blood supply to heart muscle is called coronary heart disease. Coronary heart disease 
includes myocardial infarction, sudden unexpected death, stable and unstable angina pectoris, 
abnormal heart rhythms, and heart failure due to weakening of the heart muscle. It is estimated 
that 19% of all Medicare beneficiaries aged 65 to 74 have CHD and among those 75 and older, 
25% have prevalent CHD (American Heart Association, 2004), making them eligible for 
secondary preventive treatment. 
The pharmacological management and secondary prevention of CHD has been 
revolutionized in the past few decades as a result of more patients surviving initial myocardial 
infarction (MI) events. Evidence for the use of medications that preserve heart function, stabilize 
plaque in the arteries, and prevent recurrent atherothrombotic events continues to grow. Several 
subclasses of cardiovascular medications have undergone rigorous evaluation in large, 
randomized, controlled trials (RCTs) and have been designed to improve the clinical features of 
CHD as well as outcomes after an MI. While most of these “gold standard” RCTs have 
specifically excluded older adults with dementia, the evidence generated serves as the basis for 
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how physicians should effectively treat and manage patients with CHD, despite the presence of 
other comorbidities.  
The four subclasses of cardiovascular medications selected as dependent variables for 
this research include those with the strongest evidence of reducing mortality from CHD 
following an MI. This evidence serves as the basis for the recommendations put forth in clinical 
practice guidelines (CPGs) regarding the treatment and management of patients following an MI. 
These CPGs emphasize the early initiation and continued use of angiotensin-converting enzyme 
inhibitors (ACE inhibitors); beta-adrenergic blocking agents (beta-blockers); HMG-CoA 
reductase inhibitors (lipid-lowering medications [statins and non-statins]); antiplatelet 
medications such as cyclooxygenase inhibitors (aspirin); and adenosine diphosphate (ADP) 
receptor inhibitors (such as Plavix®) (Giugliano & Braunwald, 2004; Pollack & Gibler, 2001; 
Smith, 2001; Ryan ., 1996; Hunt, 2005). Sections 2.1.1 to 2.1.4 present a brief summary of the 
evidence for each of these medications, and focuses, when that information is available, on the 
evidence of effectiveness in older adults. No results include information about effectiveness of 
these medications for patients with dementia. Given the lack of evidence, it is assumed, for the 
purposes of this research, that these medications are equally effective in people with dementia in 
the secondary prevention of CHD.  
2.1.1 ACE inhibitors 
The results of well-conducted, randomized, controlled clinical trials on the effectiveness of ACE 
inhibitors in reducing mortality following an MI have been so consistent and so conclusive that 
much of the recent literature emphasizes implementation rather than research. For example, the 
results of a comprehensive meta-analysis of 32 randomized trials, including a total of 7,105 
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patients, showed that ACE inhibitors significantly reduced mortality by 23% in patients 
following an MI (Garg, 1995). Studies such as the Heart Outcomes Prevention Evaluation Study 
(Yusuf, 2000) have shown that in a cohort of 5,069 persons aged ≥65 years use of ACE 
inhibitors decreased the incidence of subsequent MIs by 22%. The conclusion of most of the 
large trials is that unless systolic blood pressure is <100 mm Hg, ACE inhibitors should be 
initiated within 24 hours of an MI and continued indefinitely, since benefits have been shown to 
persist years after an MI (Flather, 1995; Pfeffer, 1997).  
2.1.2 Beta-blockers  
The role of beta-blockers in the treatment and management of patients post-MI is well 
established (Yusuf, 1985). The beneficial effects result from decreasing heart rate, blood 
pressure, myocardial oxygen demand, and arrhythmogenesis (Park, 1995). In aggregate, the data 
suggest that beta-blocker use reduces nonfatal MI by approximately 25%, which is paralleled by 
a 25% reduction in the mortality rate. A retrospective study of Medicare beneficiaries in New 
Jersey from 1987 to 1992 found that people ≥65 years who were treated with beta -blockers after 
an MI had a 43% decrease in 2-year mortality and a 22% decrease in 2-year cardiac related 
hospital readmissions. These results were in comparison to an age-matched cohort who were not 
treated with beta-blockers (Chadda, 1986). One of the largest trials on the effectiveness of beta-
blockers following an MI, the Beta-Blocker Heart Attack Trial (BHAT), found that any 
reduction in mortality holds for up to 3 years following an MI (Soumeri, 1997). The ACC/AHA 
guidelines recommend that all patients without clear contraindications (hypotension, sinus 
bradycardia, partial atrioventicular blockage, etc.) should receive beta-blocker therapy within a 
few hours of an MI and continue them indefinitely (Smith, 2001).  
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2.1.3 Lipid-lowering medications  
Lipid-lowering medications are strongly indicated for use as secondary prevention after acute 
MI, for those with and without elevated cholesterol. The Cholesterol and Recurrent Events 
(CARE) trial demonstrated that a statin lipid-lowering medication, compared with placebo, 
reduced the rate of death or MI in patients with previous MI by 24% (95% CI, 9% to 36%) over 
a 5-year follow-up (Sacks, 1996). In a study of 1,238 older adults aged 65–75, those treated with 
the lipid-lowering medication pravastatin had a 45% reduction in death and a 32% reduction of 
other major coronary events compared to those treated with a placebo 5 years following their 
initial MI (Lewis, 1998). No studies to date have produced positive results of the efficacy of 
administering lipid-lowering medications immediately after an MI, as all data are based on 
longer-term efficacy and follow-up post-MI. Evidence of the effectiveness of long-term 
treatment is of particular relevance when considering application of the data to patients with 
dementia. Given the shortened life expectancy of patients with dementia, it is likely that the 
benefits of lipid-lowering mediations may not be realized for dementia patients. For example, a 
study by Collins (2003) found that treatment with a statin may not be effective at reducing 
cardiovascular events until 5 years of treatment. 
2.1.4 Antiplatelet medications 
Based on years of evidence, ACC/AHA guidelines recommend the use of aspirin for an 
indefinite period of time following an MI, unless there is some contraindication to its use. 
Randomized trials involving 20,006 patients have shown that aspirin and other antiplatelet drugs 
administered to patients after an MI decreased the incidence of recurrent MI by 36 deaths per 
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1,000 patients treated for a 2-year period (Antithrombotic Trialists’ Collaboration, 2002). These 
benefits were found to be irrespective of age, sex, blood pressure, or history of diabetes. The 
most comprehensive and concise source of data about the effect of antiplatelets for the secondary 
prevention of CHD is the Antiplatelet Trialists’ Collaboration (1988). This meta-analysis of 172 
randomized trials conclusively demonstrated the value of aspirin use after an MI (4% relative 
risk reduction of MI found between years 1 and 3 post-MI). Studies of other antiplatelet 
medications, clopidogrel in particular, have shown an overall 8.7% relative risk reduction of 
mortality compared to aspirin after 1.9 years of follow-up (CAPRIE, 1996). 
While the evidence base is strong regarding the effectiveness of these medications in 
reducing subsequent MIs and cardiovascular related mortality, none of the studies cited above 
included patients with dementia. Unless life expectancy is compromised by some other non-
CHD factor, hence affecting the time until benefit, it can be assumed that those with dementia 
would experience the same secondary preventive benefits as cited in the studies.  
2.2 ANATOMY OF A MEDICAL DECISION 
The analytical goal of this dissertation is to explore the effect of dementia on the use of 
evidence-based chemoprophylaxis for CHD. The evidence summarized above is from RCTs that 
exclude patients with other comorbidities. This evidence is often what informs the creation of 
physician decision aids, such as clinical practice guidelines. Given this, these guidelines are often 
“blunt” and provide no suggestions on how to individualize the recommendations based on 
relevant clinical factors such as comorbidities that affect life expectancy or increased risk of 
adverse event (Braithwaite, 2007; Walter, 2001; Roberts, 2009).  
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Additionally, guidelines rarely address the contribution of personal patient factors in the medical 
decision-making process about treatment, such as patient preferences and goals of care (Boyd, 
2005). In a conceptual framework developed by Eddy (1990), Eddy describes the components 
that physicians use to make evidence-based medical decisions. The model considers (1) analysis 
of the evidence and (2) value judgments as primary ingredients. The inputs into the process 
include: (a) evidence, (b) the physician’s scientific judgments about the evidence, and (c) 
preferences of all parties involved. In the case of decision making for patients with dementia, this 
would include the physician, patient, and patient’s family. Outcomes of the process include how 
the evidence is presented to the patient and then the final treatment decision. Figure 2.1 provides 
a graphical representation of the framework. 
 
 
In some respects, this model is ideal for examining the effect of dementia on medical decision 
making for chemoprophylaxis because it acknowledges both the use and the interpretation of 
scientific evidence as well physician value judgments about the patient. Evidence from the 
literature, summarized below, supports the theory that physician judgments about a patient may 
affect their treatment decisions (Crane, 1975; Ubachs-Moust, 2008; Marwill, 1996). Applying 
Analysis 
Of 
Evidence 
 
Value 
judgments 
 Preferences 
Evidence 
Treatment 
decisions or 
policy Presentation 
of 
information 
about 
outcomes 
Scientific 
 
Figure 2.1 Components of an Evidence-based Medical Decision. 
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the Eddy model to this dissertation research involves first gathering and reviewing the evidence 
for the treatment and management of CHD. This step shapes what and how evidence about 
potential treatments is presented to the patient. The second step involves the incorporation of 
personal value judgments of the patient, family, and physician. This mix of value judgments may 
likely include very different concerns about such things as the amount of burden to impose on a 
patient with dementia (Walter, 2001), judgments about the marginal benefit of care (Raik, 2004; 
Holmes, 2006; Post, 2000; Brauner, 2000), and judgments by the physician, and potentially the 
family, about the diminished social worth of people with dementia (Callahan, 1992; Crane, 
1975). While the Eddy model does not focus on the distinct difference between the preferences 
and values of the patient, family, and physicians and their effect on the final decision about how 
best to treat, Section 2.2.1 expands these elements of the model by focusing the discussion on 
how they might differ and their impact on use of health services.  
2.2.1 Analysis of the evidence 
The Eddy model presents medical decision making as a linear process that begins with review 
and analysis of the best available data. The evidence originates from the best available external 
evidence that is clinically relevant research that is scientifically sound and can be used to 
evaluate the consequences or outcomes of each of the potential treatment. Findings from the 
literature on variation of health services have shown that when there are differences in the degree 
of evidence and high levels of uncertainty about the effectiveness of a treatment or procedure 
variation in treatment is greater (McPherson, 1982; Wennberg, 1982).  
Evidence also is generated and analyzed based on the individual clinical expertise of the 
physician (Sackett, 1996). Since outcomes associated with different treatments may be 
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conflicting, Eddy believes that this step should involve principles and methods to ensure that, to 
the greatest extent possible, population-based policies and individual medical decisions are 
consistent with evidence of effectiveness and benefit. Presumably the physician considers 
whether the evidence supports a conclusion to determine if treatment “X” is more effective than 
treatment “Y” in improving survival. Other important health outcomes such as risks and side 
effects are also evaluated. Using lipid-lowering medications as an example, in the analysis of the 
evidence stage in the Eddy model, would include the effectiveness data about the benefits of 
long-term statin use in reducing subsequent MIs as well as data on the time until benefit and the 
realizable benefit that a statin can provide someone with a limited life expectancy.  
When the evidence is synthesized into decision aids that are intended to help physicians 
analyze the evidence, such as clinical practice guidelines, it is important to note that at some 
level, value judgments about the evidence itself are made, for example, which study results to 
consider and what is considered the threshold for effectiveness (Tunis, 2007; Eddy, 1990).  
2.2.1.1 Clinical practice guidelines for CHD  
The most common sources of summarized and organized evidence are in the form of consensus 
statements or clinical practice guidelines (Woolf, 1993). Clinical practice guidelines (CPGs) are 
defined as systematically developed statements that integrate the best research evidence with 
clinical expertise. Their purpose is to assist physicians in systematically applying the evidence 
when making decisions on how best to treat a particular patient. It is important to note, however, 
as discussed above, that in the context of “evidence and values” as part of the medical decision-
making process, determining what evidence to use in establishing a clinical practice guideline 
introduces subjectivity into the interpretation and translation of the evidence. 
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The most cited CPG for the treatment of CHD with MI and angina is from the American 
College of Cardiology/American Heart Association (Smith, 2001). As noted above, this 
guideline recommends for all patients, unless contraindicated, the use of secondary 
chemoprevention with platelet-inhibitors, beta-blockers, lipid-lowering mediation, and 
angiotensin-converting enzyme inhibitors (Hunt, 2005; Smith, 2001).  
Not unlike guidelines for other diseases, the ACC/AHA guideline does not address 
dementia as a condition that may be comorbid with CHD, nor does it provide guidance on how to 
adjust the recommendations for someone with dementia. Some guidelines make relevant 
adjustments based on morbidity and mortality and consider the time-until-benefit for a treatment 
for people with a limited life expectancy (Holmes, 2006), but most are “blunt” and not consider 
how a patient’s goals of care may adjust the recommendation (Boyd, 2005; Mast, 2000). These 
missing components may make it especially difficult for physicians to apply them to patients 
with dementia and can even put patients at risk of receiving inappropriate treatments or 
treatments that are inconsistent with their goals (Walter, 2004).  
While guidelines originated as a way for physicians to easily apply the evidence in real-
time medical decision making, they are increasingly being used in health policy initiatives to 
measure and reward quality of care. Programs such as pay-for-performance (P4P) programs that 
financially reward adherence to guidelines may have an impact on chemoprophylaxis for patients 
with dementia. The positive effect of these programs may be that patients with dementia, who 
were at risk of under-treatment owing to value judgments by the physician, may now be treated 
similarly to those without dementia. On the other hand, a negative consequence may be that 
those with CHD and dementia would be put at risk of excessive and inappropriate treatment that 
does not align with their goals. Although not a central theme of this research, it is important to 
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consider that using CPGs to measure quality within the health care system may create a conflict 
of interest in the treatment of patients if the quality indicators being used do not account for the 
unique and complex needs and preferences of patients with dementia (Boyd, 2005).  
2.2.2 Value judgments  
It seems intuitive that medical decisions should be informed by the best available scientific 
evidence, as outlined in step 1 of the Eddy model. However, it is important to consider the 
framing of evidence when applying it to a clinical decision. A procedure with a demonstrated 
advantage by one metric may not be the best choice for all patients and in all circumstances. In 
the Eddy model, the first step of the decision-making process is the “evidence-based medicine” 
phase. The second step in the process involves additional factors that are used to judge the best 
treatment for a particular patient. While much of the literature on evidence-based medical 
decision making mistakenly assumes that decisions are free of value judgments, value judgments 
made by the physician naturally play a part in the decision-making process (Eisenberg, 1979).  
Medical decision making for people with dementia is especially susceptible to the 
influences of value judgments given that dementia often provokes moral questions about quality 
of life, social worth, and even the meaning of life, given its progressive attack on both mental 
and physical abilities. These judgments affect the interpretation of the evidence when weighing 
the benefits, harms, and costs of a treatment (Eddy, 1990). In the model, evidence about the 
consequences of the treatments is examined alongside patient preferences, values, and beliefs; 
family preferences, values, and beliefs; and physician values and beliefs. For patients with 
dementia this step in the process includes relevant clinical judgments about problems of 
adherence to medications, communication issues that may affect a person’s ability to report 
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adverse effects, the ability of the patient to appreciate the reason for the treatment, and the 
patient’s capacity to make an informed choice about treatment. Additional value judgments that 
raise ethical issues surrounding the treatment of people with dementia may include physician 
perceptions about the patient’s quality of life (Uhlmann, 1988) as well as family members’ 
perception of the patient’s quality of life. The following sections (2.2.2.1 and 2.2.2.2) review the 
literature on the role of patient and family preferences and physician value judgments as it relates 
to medical decision making for people with dementia.  
2.2.2.1 Patient preferences in medical decision making 
In medical decision making, the term patient preferences has two different definitions. The first 
is the patient’s preferred choice of treatment based on his or her values and beliefs. The second is 
the patient’s preferred degree of involvement in the decision-making process. Both definitions 
are relevant for the discussion regarding the role of preferences in medical decision making for 
patients with dementia. First, patients with dementia, like all patients, have values and beliefs 
that shape their preferences for care. Second, the etiology and inevitable progression of the 
dementia requires that others (physicians, family, or other surrogates) take an active role in 
making decisions about medical care. The following sections address both aspects of patient 
preferences in the decision-making process and how they might contribute to predicting the use 
of chemoprophylaxis for CHD. 
Patient preferences are the manifestation of individual and familial values and beliefs 
about medical care and treatments. The plurality of preferences have been cited as a potential 
sources of variation in the utilization of health care services, especially for treatments that have 
uncertain evidence about the ratio of harm to benefit, or the potential options are sensitive to the 
value that patients place on benefits and harms (Wennberg, 1982).  
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Honoring patient preferences for treatment is based on the ethical principle of patient 
autonomy and the belief that people have a right to control what happens to their body 
(Beauchamp, 2008). For many decades the dominant approach to making decisions about 
treatment, especially for those with compromised cognition, has been one of paternalism. In 
recent years this model has been challenged by doctors, patients, medical ethicists, and 
researchers who advocate different models between doctors and patients such as shared treatment 
decision making (Charles, 1997). Through a process such as shared decision making (Charles, 
1997) patient autonomy is promoted by a two-way exchange of information that includes the 
solicitation of patient preferences.  
For patients who cannot actively participate in the decision-making process or 
communicate their preferences, advance directive documents have been presented as a tool that 
can be used to convey information about specific treatment preferences. There is disagreement in 
the literature on the usefulness of advance directives or prior discussions for guiding decision 
making. For example, a study on the use of advance directives found that many individuals 
prefer to express general preferences (e.g., values, goals for care) rather than document specific 
medical treatment preferences (Hawkins,  2005).  
Other research about the usefulness of advance directives in providing information about 
preferences suggests that eliciting patient preferences in advance of care is limited, since 
patients’ preferences about treatment options often change when faced with a particular decision 
and are dependent on the outcomes of the potential treatments (Fried, 2002). In a study of 226 
people aged ≥60 years who had a limited life expectancy due to cancer, congestive heart failure, 
or chronic obstructive pulmonary disease, participants were asked to describe preferences for 
treatment under certain scenarios. The first scenario would be whether they would want to 
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receive a particular treatment if the outcome was known with certainty, but had different 
likelihoods of adverse outcomes. The outcome without treatment was death. Nearly all 
participants (98.7%) chose treatment if the burden of treatment (i.e., length of hospital stay, 
extent of testing, and invasiveness of intervention) was low and the outcome was restoration of 
current health. If treatment burden was high, 11.2% of the sample did not want treatment even if 
their current state of health could be restored with the treatment. If the outcome of the treatment 
changed and resulted in severe physical impairment, despite the low burden of the treatment, 
74.4% of the sample did not want treatment. If the outcome of the treatment was severe cognitive 
impairment, 88.8% of the sample did not want treatment, even if the treatment was low burden. 
Cognitive impairment was described as the participant being unaware of his or her surroundings 
and unable to recognize family members.  
The findings from this study are particularly relevant to the discussion of the role of 
patient preferences in treating CHD in people with dementia. For example, asking patients with 
dementia their preference for managing their CHD and preventing another MI, after they have 
already experienced an MI or angina, would require information about the possible outcomes for 
treatment vs. no treatment. While chemoprophylaxis for CHD is low burden (i.e., medications 
are taken orally and have few side effects) and reduces the likelihood of another MI or death 
from CHD, it may potentially increase the likelihood of living longer with dementia and 
experiencing more of its effects and dying of its complications. 
A second relevant finding from the Fried study is that patients in the study sample were 
already older and already had a serious life-threatening illness. Despite this, 88.8% said that they 
would refuse even a low-burden treatment if the outcome was cognitive impairment. While an 
outcome of chemoprophylaxis is not cognitive impairment for patients who already have 
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dementia, treating CHD may likely extend their experience with dementia by warding off a more 
sudden death from an MI or cardiac event. These types of trade-offs are likely important aspects 
of patient preferences but are rarely cited in the literature as something to consider in the medical 
decision-making process.  
In the Eddy model, patient preferences for health care impact the application of the 
evidence by imposing different priorities for outcomes. For example, if the evidence for 
treatment “Y” shows that mortality is lowest but the burden of treatment is high and quality of 
life following the treatment is altered owing an effect on mobility, it is conceivable that someone 
with moderate dementia who is still able to ambulate independently would not prefer this option. 
This example highlights that medical decision making for people with dementia and CHD 
requires weighing the evidence in different scenarios, including the scenario of not treating the 
CHD, and the impact on important outcomes relative to values and beliefs such as length of life, 
quality of life, and implications for the patient and the family regarding long-term care needs. 
An alternative definition of “patient preferences” in medical decision making refers to the 
patient’s preferred degree of involvement in the process. For patients with dementia, there is a 
high level of certainly that at some point during the disease progression other people will need be 
involved in decision making. In most cases, others are family members. It is also true that the 
outcomes of particular treatment decisions will have an impact on the family given their 
extensive role in care giving (Ory, 1999).  Some patients with dementia may never choose an 
active role in medical decision making and defer all decisions about treatment to medical 
professionals or family members even when they are still cognitively able to participate. Others, 
when still able, may take an active role and participate in shared decision making with their 
physician, with or without involvement from family. Despite the different levels of potential 
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participation, virtually all patients with dementia, unless they die in an earlier stage of cognitive 
decline, will require others to represent their preferences in the decision-making process.  
Reference to “patient preferences” in the dementia literature often includes a discussion 
of “substituted judgment.” The important distinction in this dissertation research is the inclusion 
that a discussion of patient preferences in the decision-making process in many cases might be 
represented by a family via substituted judgment or may actually be the preference of the family 
and not the patient. The following section includes a review of the literature on the distinction 
between patient and family preference and their overlapping role in making treatment decisions 
for people with dementia.  
2.2.2.2 Family preferences in medical decision making   
For patients with dementia, the loss of cognitive function, decisional capacity, and physical 
function usually develop gradually, progressively, and somewhat predictably (Rabins, 2006). 
The cognitive and physical declines necessitate that family be involved in providing care and 
serve as surrogates in the medical decision-making process.  
Two assumptions underlie surrogate decision making in the current model of biomedical 
ethics in the United States. Both assumptions are intended to honor the autonomy of the patient 
by basing real-time decisions on preferences expressed previously, thus using the ethical and 
legal standard of substituted judgment (Beauchamp, 2008). The first assumption is that patients 
have, or are able to generate, well-formed preferences about treatment in future hypothetical 
situations. Second, potential surrogates are assumed to be able to ascertain from patients what 
their goals for care and treatment preferences are.  
The principle of substituted judgment assumes that surrogates understand patient 
preferences and correctly represent the wishes of the patient. Underlying accurate substituted 
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judgment, however, is the assumption either that patient preferences are stable over time or that 
surrogates understand the most recent and salient preferences of the patient. However, findings 
from the literature have shown that, when faced with hypothetical decisions about life-sustaining 
medical care, family members are not able to predict a patient's preferences at levels of accuracy 
beyond those expected by chance alone (Ditto, 2001; Sulmasy, 1999). Family surrogates 
consistently overestimate the frequency with which patients would want to receive treatment 
(Uhlmann, 1988). They also project their own preferences onto the patient. As such, the 
decisions that family members make often bear little resemblance to those that the patient would 
make (Ditto, 2001; Pruchno, 2008).  
These findings are not much of a surprise. There is no clear-cut or deductive relationship 
between a person’s overall values and beliefs and a particular set of medical choices. This is 
even more salient when the choices are subtle, the outcomes are uncertain, and the benefits are 
often delayed, as with chemoprophylaxis for CHD. With the rare exception of a patient and 
family who have had extensive and imaginative discussions of preferences for an array of 
treatments, knowing exactly what type medical treatment a person would chose given their 
current state is impossible. It is even more difficult when levels of treatments are introduced, 
such as less aggressive forms of treatment that have fewer risks but still have implications for 
quantity and quality of life.  
The literature on surrogate decision making has contributed evidence and theories about 
factors that may influence treatment decisions of surrogates of older patients. They include the 
severity of the patient’s cognitive status, perceived quality of life, and caregiver burden (Kayser-
Jones, 1989; Uhlmann, 1991; Tomlinson, 1990). A study by Mezey (1996) found that spouses of 
dementia patients were more likely to forgo a particular treatment if the patient’s cognitive 
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function was more severe (e.g., irreversible coma), the treatment was considered more 
burdensome (e.g., CPR), and their perception of the patient’s quality of life was low. These 
findings were consistent for all of the life-sustaining treatments presented to spouses 
(resuscitation, breathing machine, feeding tube). Results for spousal beliefs on treatment were 
less consistent. Sixty-eight percent of spouses said that they would forgo antibiotics if their loved 
one was in a coma, but less than 10% said that they would forgo antibiotics if their loved one had 
a critical illness.  
These results are relevant to our understanding of the effect of dementia on use of 
chemoprophylaxis for CHD. Unlike decisions about burdensome life-sustaining treatments that 
are often clear for families, treating or not treating CHD with medications is not so obvious to 
families. The outcome of continuing or foregoing chemoprophylaxis is unknown, and the 
treatment is lower burden. Yet, it is conceivable that if families are pressed to consider stopping 
or not starting chemoprevention, the same factors noted above—cognitive status, perceived 
quality of life and caregiver burden—would contribute to the decision-making process.  
2.2.3 Physician value judgments 
2.2.3.1 Physical vs. cognitive disability  
Despite the promotion of autonomy, studies suggest that the values and beliefs of physicians may 
also play in a role the medical decision-making process. In one of the first studies of sociological 
elements on physician decision making, Crane found that in cases where seriously ill 
hospitalized patients had more cognitive disabilities physicians were less aggressive in treating 
the underlying disease as well as other complications (Crane, 1975). In a more recent study of 
Dutch physicians, the decision to not treat pneumonia nursing home patients with dementia with 
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antibiotics was influenced by the severity of the cognitive impairment. Patients with more severe 
dementia and less physical capacity for self-care, as measured by the Bedford Alzheimer’s 
Nursing Severity scale, were less likely to receive antibiotics to cure pneumonia (van der Steen, 
2002).  
These studies demonstrate that the patient’s cognitive level plays a role in the medical 
decision-making process, yet few have made claims as to the cause. Crane (1975) hypothesized 
that humans define “personhood” based on the ability to interact with others and participate in 
society. In the context of medical decision making, when patients lose cognitive capability and 
the traits that make them people, or what she describes as “social worth,” they are less valued by 
physicians and not treated as aggressively.  
Wolf-Klein and colleagues (2007) put forth a related medical-model explanation as to the 
variation in health care services for people with dementia. In an epidemiological review article, 
Wolf-Klein adopts the conceptual model that people with irreversible forms of dementia, no 
matter what their disease stage or level of cognitive or physical functioning, should be 
considered as having a terminal disease. This conceptualization justifies protocols for limiting 
the treatment of underlying conditions and focusing on palliative care and symptoms, hence 
following the similar pathways as those with terminal cancer (National Comprehensive Cancer 
Network and American Cancer Society, 2003).  
2.2.3.2 Futility  
The conceptualization of dementia as a terminal illness relates to the issue of futility and the 
question of “why treat” CHD if the patient is dying of dementia. For patients with dementia and 
CHD, observed variation in health services may very well be the outcome of futility judgments 
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being made by the physician. In one of the most cited articles on futility, Schneiderman and 
colleagues (1990) define futility in two forms: quantitative futility and qualitative futility.  
Relative to the Eddy model, quantitative futility lies in the realm of gathering the 
evidence and is statistically based. For instance, if an intervention has shown to be ineffective in 
the past 100 cases, it would be regarded at futile. Qualitative futility is more subjective, yet there 
are few, if any, published studies of medical interventions that have failure rates of 100%. Most 
reasonably considered interventions do work at least occasionally. The question then becomes at 
what (lower) level of success can an intervention be said to be futile? And what other patient 
characteristics affect the determination of successful treatment? The answers to these questions 
are no longer objective measures of futility but rather subjective ones. Different physicians with 
different personal experiences, values, and definitions of “social worth” will define an 
“acceptable lower limit” and “success” differently. 
An example of the variation in defining quantitative futility is a 1994 study by McCrary 
and colleagues. In this study 760 physicians were surveyed in three tertiary-care medical centers 
and asked to respond to the question, “Regarding terminally ill patients, I consider a treatment 
‘futile’ if the likelihood of success is X percent or below.” Thus, while 19% of the surveyed 
physicians would consider a treatment futile only if it had a zero percent chance of success, 23% 
would consider it futile if it had a better than 10% chance, and 5% of respondents would consider 
it futile even if it had an approximately 50-50 chance of success. Even if there were studies 
showing that an intervention had a success rate of zero percent, some physicians would still ask 
how similar the patients in the studies were to the patient under treatment, and if they were 
different in any potentially substantive way, the zero percent chance of success might not apply. 
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The concept of qualitative futility is even more subjective. As Truog (1998) has pointed 
out, it is not useful when making medical decisions to ask whether an intervention is futile. The 
question must be, “Futile in relation to what?” If the effectiveness of chemoprophylaxis for CHD 
for patients with dementia is judged by its success in preventing a future MI (a common clinical 
goal), physicians could consider the guideline recommended treatment effective. If, however, it 
is judged in relation to quality of life and the patient’s experience at the end of life (a common 
patient goal), it may be ineffective given that the medication could increase the patient’s length 
of time living with dementia and experiencing its effects.  
2.2.3.3 Quality of Life  
Many difficult choices in medical decision making include asking the involved parties to make 
an assessment of a patient’s present or future quality of life. There is an expansive literature that 
attempts to define and measure quality of life as a construct or factor for making medical 
decisions (Walter, 1990; Thomasma, 1984; Pearlman, 1991). Research on quality of life in older 
patients, with and without dementia, has found that physicians frequently rate their patient’s 
quality of life lower than their patients rate their own quality of life (Uhlmann, 1991). While 
many people believe that those with dementia live a life of negligible quality, findings show that 
people living with dementia who are able to communicate on some level have positive self-
perceptions of their quality of life (Lawton, 1991, 1997; Rabins,1997; Rabins,1999; Ready, 
2003).  
The patient’s quality of life at the time of medical decision making and predicated for the 
future are frequent considerations in medical decision making. Assessments of and judgments 
about the patient’s quality of life, with or without a particular treatment, are often difficult to 
predict owing to uncertainties about the patient’s diagnosis, response to treatment, disease 
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progression, and overall prognosis (Pearlman, 1983; Thibault, 1980). Other factors may also 
make quality of life difficult to accurately predict. These include physician’s subjective values 
relative to the patient’s characteristics, such as cognitive status (Crane, 1975), inadequate 
communication between the physician and patient (Anderson, 1999), and the physician’s own 
fear of illness and death (Thomasma, 1984). These subjective values may impact the way 
physicians interpret and apply evidence about the risks and benefits of treatments and the way 
they present treatment recommendations to patients and families.  
Pearlman and Jonsen (1985) conducted a study to better understand physician 
considerations of quality of life in medical decisions by presenting internal medicine and family 
physicians (n=205) with a patient management problem case study modeled after American 
Board of Internal Medicine certification examination questions. The case presented was a male 
patient with an acute exacerbation of chronic obstructive pulmonary disease. The patient was an 
elderly-looking 69-year-old who lived in a nursing home, was easily incapacitated by shortness 
of breath, and had recently had a 2-month hospitalization because of a similar respiratory 
episode. Other clinical data about respiratory performance were presented. The patient had no 
written documentation regarding preferences for treatment (i.e., advance directive) and had not 
expressed any information about treatment preferences to the physicians on this or previous 
hospital stays. Additional information about the patient was available but had to be requested by 
the physician study subjects.  
The physicians performed several tasks during the study exercise, including (1) indication 
of treatment preference after the initial reading of the case, (2) indication of potential value of 
available (but unknown) case information, (3) selection of a limited amount of case information 
to acquire more detailed data about the case, (4) indication of a treatment decision as to whether 
 36 
to use intubation or current therapy without intubation (after acquiring additional data), (5) 
explanation of the rationale for treatment decision, (6) prognostication regarding the patient’s 
expected survival time. The results indicate that 37% of all physicians justified their decision 
about treatment, at least in part, by an explicit reference to the patient’s quality of life. Of those 
physicians who decided to withhold mechanical ventilation, 49% stated quality of life as a 
rationale for their decision. Among the physicians who chose to intubate the patient, 29% cited 
quality of life as an influential factor. Additionally, physicians who considered the patient’s 
survival time and social information were more likely to cite quality of life as a rationale for their 
treatment decision. The results from this study provide evidence that the consideration of quality 
of life in medical decision making is systematically observed and a common rationale for 
medical decisions to both treat and not treat a patient.  
Evidence of the use of quality-of-life judgments in medical decision making in a 
hypothetical case was established by Pearlman, but actual assessment of quality of life in real-
world decisions are complicated by the lack of good and consistent measures of quality of life. 
As a result, physician use of quality of life is often based on their subjective perception of the 
patient’s quality of life. In a study of chronically ill elderly patients, Ulhmann and Pearlman 
(1991) investigated whether perceived quality of life by the physician is actually associated with 
patients’ preferences for life-sustaining treatment. Participants included chronically ill, elderly 
outpatients (n =258) and their primary physicians (n=105). Patients and physicians were 
independently administered a questionnaire regarding patient quality of life and preferences for 
cardiopulmonary resuscitation and mechanical ventilation for the patient. Physicians rated 
patients’ global quality of life, physical comfort, mobility, depression, anxiety, and family 
relationships significantly worse than did patients. Nearly all perceptions of the patients’ quality 
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of life were significantly associated with the perceptions of their physician. Patient-physician 
agreement on patient global quality of life was not significantly associated with agreement 
regarding treatment preferences. From this study we can conclude that primary physicians 
generally consider their older outpatients’ quality of life to be worse than what patients 
themselves state. Furthermore, physicians’ estimations of patient quality of life are significantly 
associated with physicians’ attitudes toward life-sustaining treatment for the patients. For the 
patients, however, perceived quality of life does not appear to be associated with their 
preferences for life-sustaining treatment. 
The results from these two studies demonstrate that quality of life is a consideration of 
the physician in making treatment decisions, but that physicians’ perception of quality of life 
may vary from and be lower than that of the patient and the family. These conclusions are 
important when considering the effect that dementia has on patients receiving chemoprophylaxis 
for CHD given the perception of low quality of life that many have about the experience of 
living with dementia. Section 2.3.3.2 discusses the implications of the patient’s own judgment of 
quality of life on the use of health services as well the family’s perception of the patient’s quality 
of life. 
2.3 PREDICTORS OF HEALTH SERVICES UTILIZATION 
As discussed in the previous sections, the medical decision-making process by physicians for 
patients with dementia entails a variety of factors. The process includes combining the evidence 
of risks and benefits of treatment with subjective value judgments about the patient. While the 
Eddy framework considers each of these elements, we believe it excludes some important 
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patient-level factors that have been cited in the literature as possible predictors of health services 
utilization. The following section introduces the Andersen model, which is used in this 
dissertation research to understand and analyze the patient-level factors that may predict the use 
of chemoprophylaxis for patients with dementia. 
The Andersen and Newman Behavioral Model of Health Service (Andersen & Newman, 1973) 
was first developed to predict and explain the use of formal personal health services (e.g., 
hospital services). It has since been refined and expanded (Andersen, 1995) and has been used to 
explain patterns of utilization for many types of health services, including medications (Sleath, 
2004; Smith, 1999). This model, as shown in Figure 2.2, suggests that health care needs of the 
patient precipitate the use of health services and it assumes that a sequence of conditions 
surrounding the patient contribute to the type and volume of health services that a patient uses. 
The Andersen model also acknowledges the importance of external environments (e.g., the 
economic structure of health care or supply-driven variation) and individual patient 
characteristics that are categorized as predisposing, enabling, and care needs. 
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Figure 2.2: Andersen Behavioral Model of Health Services Use (1995). 
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2.3.1 Predisposing factors 
In the Andersen model predisposing factors include exogenous variables such as patient 
demographics and variables that measure the social structure that directly affects an individual’s 
need for a particular health service. These include age, sex, marital status, education, 
race/ethnicity, and occupation as well as a set of beliefs and attitudes toward health services and 
knowledge about health and disease. Because we believe that certain predisposing patient 
characteristics may have an impact on use of chemoprophylaxis for patients with dementia, 
section 2.2.1 uses the Andersen model to organize and summarize the findings from the literature 
regarding the predisposing factors that are included in the empirical analyses in this dissertation 
research.  
A number of predisposing factors such as age, sex, and race have been shown to have an 
effect on the use of health services in general and on medications specifically (Lipton, 1988; 
Chrischilles, 1992; Fillenbaum, 1993). Each of these factors has its own vast literature regarding 
its predictive strength on the use of health services. The summary of the literature in the 
following sections focuses on the findings most salient to variation in health services for older 
adults in general, and, when available, specifically on variation in health services and medication 
for people with dementia. Many of the factors are correlated and difficult to “tease apart” and 
summarize individually, so applicable findings from the literature that present results for 
multiple factors will be reviewed jointly. 
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2.3.1.1 Age  
Although age by itself is not a contraindication for most medical interventions, the ratio between 
treatment and benefit shrinks as people get older and experience comorbidity and frailty. Age is 
the strongest predictor and is the most significant risk factor for both the development of 
dementia and CHD.  
Literature on the effect of age in predicting the use of health services spans the range of 
treatments from screening to life-sustaining treatments at the end of life. The impact of patient 
age, even in the absence of comorbidities, is important if it is shorter than the time period of 
achieving benefit from a particular screening (Sox, 1998). In this scenario, variation is 
appropriate and guidelines should explicitly exclude those who are not expected to live to realize 
the benefit from screening. An additional consideration for older patients is the reduction in 
benefit from screening that may be accompanied by an increase in burden. 
Walter (2008) found that regular mammography rates among women ≥80 years old were 
associated with earlier stages of cancer, and of the 12,000 women who were diagnosed with 
cancer in the study sample, survival was not associated with mammography use. A summary of 
randomized trials on which current clinical practice guidelines for breast cancer screening are 
based (Coleman, 1992), demonstrate that the difference in breast cancer mortality between 
screened and unscreened women does not become noticeable until 5 years after screening, 
making it unlikely that older women with a life expectancy of less than 5 years will benefit from 
mammography.  
A recent cross-sectional study of screening for colon cancer found that of 1,244 
asymptomatic individuals in three age groups (50–54 years, 75–79 years, and ≥80 years) who 
underwent screening colonoscopy the prevalence of cancer was highest in the oldest group 
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(28.6%), yet the benefit achieved from the screening was only 15% of that achieved by the 
youngest group (.13 life years) due to shorter life expectancy, risk of immediate harm from the 
procedure, and time-until-benefit of the screening (on average 10 years) (Lin, 2006). Given the 
evidence on the benefits of screening, it is reasonable that age is a predictor of health services 
use.  
In studies that look at the role of age in treating life-limiting illness, results consistently 
show that age affects the type of treatment and the overall rate. In a study of initial treatment 
patterns for lung cancer in Medicare beneficiaries, Smith and colleagues found that age had a 
direct effect on patterns of care for lung cancer and survival according to the type of therapy. 
Age was associated with lower likelihood of getting any treatment for lung cancer (OR=0.35, 
95% CI=0.29–0.43) and among those who received treatment, older beneficiaries were less 
likely to receive more aggressive surgical therapy (OR=0.27, 95% CI=0.21–0.34) but more 
likely to receive less burdensome radiation treatment (OR=1.69, 95% CI=1.39–2.03) (Smith, 
1995).  
In research involving life-sustaining treatment, age has also been shown to be prominent 
negative predictor, especially in the presence of comorbid conditions (Vrakking, 2005). In a 
study of 271 cases from Dutch medical charts, Ubachs-Moust and colleagues (2008) found that 
age-related value judgments by physicians when deciding on treatment decisions were 
ubiquitous and present in all phases of the reasoning used by physicians to describe and justify 
the treatments they offered to patients. Setoguchi (2007) showed that among a cohort of 28,754 
Medicare beneficiaries with at least one hospitalization for MI older beneficiaries were less 
likely to be prescribed a lipid-lowering medication, as were males and African Americans, after 
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controlling for other comorbidities. Krumholz (1998) demonstrated similar results for beta-
blockers for adults ≥85 years of age.  
Interestingly, age has not been found to be a positive predictor of patient adherence to 
chemoprophylaxis once the drug is prescribed. After controlling for comorbidities and number of 
prescribed medications, Sharkness and Snow (1992) and Coons (1994) found no relationship 
between age and rates of patient adherence. 
2.3.1.2 Sex  
Gender differences in the use of health services, such as cardiac revascularization procedures, 
have been noted, and it appears that they have persisted through time (Vaccarino, 2005). The 
literature on gender-based differences in the use chemoprophylaxis for CHD are mixed and 
reveal differences based on the class of medication. For example, McLaughlin (1996) conducted 
a study using the ACC/AHA guidelines as eligibility criteria for a study of 2,409 individuals 
hospitalized with MI. The results showed that of all eligible patients, women as well as patients 
over 74 years of age were less likely to receive antiplatelet medication (OR=0.7, 95% CI=0.6–
0.9) and beta-blockers (OR=0.4, 95% CI=0.2–0.8). 
Few studies look only at the effect of a single predisposing factor. In a study that looked 
at the effect of gender, race, and income, Rathmore and colleagues (2000) found that among 
169,079 Medicare beneficiaries with CHD and at least one hospitalization for an MI, female 
patients were less likely to receive antiplatelet medication at admission (RR=0.98, 95% 
CI=0.97–0.99) and at discharge (RR=0.98, 95% CI=0.96–0.99). Subsequently, the same study 
showed that poorer patients and black patients were less likely to receive antiplatelet therapy and 
beta-blockers on admission and at discharge. 
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2.3.1.3 Race  
Race has been studied as a predictor of health services both in terms of overall utilization of 
health services (Smedley, 2003) and regarding specific types of treatments, such as 
cardiovascular procedures (Whittle, 2003). 
Variation among racial groups has also been cited for use of medications. Some studies 
have found that older American minorities are less likely than older whites to utilize prescription 
drugs or to increase their numbers of prescriptions over time (Briesacher, 2003).  
Hanlon (1992) found, among an older community-dwelling cohort, that fewer African 
Americans reported the use of over-the-counter medications and total medications than did 
Caucasian Americans and that African Americans were less likely than Caucasian Americans to 
use cardiovascular drugs, as well as analgesic and central nervous system medications.  
Among the studies that have looked specifically at chemoprophylaxis for CHD, Cooper 
(2002) showed in a national sample of patients hospitalized with acute myocardial infarction 
(AMI) that African American patients were less likely to be treated with lipid-lowering 
medication: 28.9% in comparison with 31.9% of non–African American patients (OR=0.87, 95% 
CI=0.83–0.91). Cooper also found in a multivariate analysis that female sex (OR=0.97, 95% 
CI=0.94–1.00), African American race (OR= 0.94, 95% CI=0.89–0.93), and older age (OR=0.82, 
95% CI=0.78–0.86) are predictors of lower rates of lipid-lowering medications.  
In contrast, Sanderson (2007) found no differences in the rates of aspirin, beta-blockers, 
or lipid-lowering medications, and higher rates of use of ACE inhibitors among African 
Americans. In a study across eighty-one acute care Veterans Administration hospitals, Peterson 
(2002) found that African American patients were equally likely to receive beta-blockers, more 
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likely than white patients to receive aspirin (86.8% vs. 82.0%; P<0.05), and marginally more 
likely to receive ACE inhibitors (55.7%). 
2.3.1.4 Education  
As a predictor of health services use, level of education is rarely studied as an independent 
factor. Findings from the literature reveal that to have a complete picture of which factors have 
an effect on variation in health care services utilization (e.g., race, ethnicity, sex, geographic 
region), the role of socioeconomic factors, such as education, income, employment, and 
insurance status, must be accounted for (Kaplan, 1993). In a study by Opotowsky and colleagues 
(2007) that looked at aspirin use for those with CHD, having a higher level of education was a 
significant predictor of aspirin use for men, but it had no effect for women. Studies that have 
investigated chemoprophylaxis use by race have found that even when level of education is 
controlled, non-whites have lower rates of use for aspirin (Rodondi, 2005), and among only 
women, African American women had lower rates of use for aspirin (OR=0.84, 95% CI=0.58–
1.19; P=0.33) and lipid-lowering medications (OR=0.62, 95% CI=0.44–0.87; P=0.006) and 
slightly lower rates for beta-blockers (OR=0.83, 95% CI=0.61–1.16; P=0.30) but higher rates for 
ACE inhibitors (OR=1.32, 95% CI=0.92–1.90; P=0.12 [Jha, 2003]). 
2.3.2 Enabling Factors 
Enabling factors include the variables that describe a patient’s ability to secure health services. 
These entail both community resources and personal resources such as personal finances, 
insurance status, informal or formal support for care, and socialization. These types of variables 
include both individual patient-level characteristics as well as health care system characteristics. 
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They are important in analyses of predictors and rates of utilization for health services, since 
some factors may have a direct relationship (e.g., number of nursing homes in a region and rate 
of utilization of nursing homes) or an indirect relationship (e.g., insurance status and site of 
care). The following section reviews the literature on enabling factors that we believe may 
predict use of chemoprophylaxis for patients with dementia. 
2.3.2.1 Availability of health care providers and facilities and regional practice patterns 
The differential supply of specialists and hospital capacity has been described in the literature as 
a cause of geographic variation in health care services across the U.S. (Wennberg, 1982). It is 
likely that differences in number of physicians, specialists, hospitals, and other types of care 
facilities could be an enabling factor that predicts health services utilization in different 
geographic regions. Research in quality of care for Medicare beneficiaries often uses variation as 
a proxy for the quality and efficiency of the care provided in a region. In the literature on 
variation, quality of health care is commonly measured by examining the care provided in a 
region that is low cost, highly effective, and of known medical benefit and is rarely 
contraindicated; in other words, evidence-based. The relevant literature for this research are 
findings that demonstrate that where Medicare beneficiaries live can impact the level and quality 
of health care services they receive in general (Baiker, 2005) and in terms of chemoprophylaxis 
for CHD more specifically (Krumholz,1998). Results from the National Cooperative 
Cardiovascular Project describe chemoprophylaxis utilization rates for Medicare beneficiaries 
with CHD across nine different geographic regions in the U.S. Among eligible beneficiaries who 
met the ACC/AHA criteria for use of beta-blockers, the overall rates varied from 43.6% in the 
Mountain region to 72.6% in New England (Krumholz, 1998). 
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2.3.2.2 Income  
As noted above, measures such as income and education are often used as general measures of 
socioeconomic status, and at times in place of race, as a way to measure disparities in care. A 
study by Gornick and colleagues (1996) that looked at general rates of utilization among 
Medicare beneficiaries by income level found that less affluent non-minorities were more likely 
to be hospitalized for CHD episodes than more affluent non-minorities, but no differences were 
observed in the rates of cardiovascular procedures such as revascularization and angioplasty. In 
the same study, less affluent African Americans were less likely to be hospitalized for CHD 
episodes and to receive angioplasty and coronary artery bypass surgery. These findings about the 
effect of affluence on treatment patterns inform the research in this dissertation, since cognitive 
status is an individual characteristic that is being tested as a predictor of variation, and although 
all participants had Medicare as their primary insurance, other predictors must be considered and 
controlled. 
2.3.2.3 Insurance status  
The CHS study was conducted prior to the enactment of the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003 (Medicare Part D). As a result, the cost of 
chemoprophylaxis was borne either by the study participant or by their supplemental insurance, 
if they had a plan with drug coverage. Before Medicare Part D, data from the literature showed 
that the cost of drugs for Medicare beneficiaries was an important feature of under-utilization of 
prescribed cardiovascular medications, even among those with supplemental drug coverage 
(Federman, 2001). In a cross-sectional study of 1,908 Medicare beneficiaries with CHD, lipid-
lowering medication ranged from 4.1% in patients with no supplemental drug coverage to 27.4% 
in patients with employer-sponsored drug coverage (P<0.001). The same study found less 
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variation for beta-blockers, but utilization was lowest for the group with no supplemental drug 
coverage to their Medicare insurance. Beneficiaries with Medicare and Medicaid had higher 
utilization of both drugs than those with only Medicare, yet lesser utilization than those with 
employer-sponsored drug coverage (Federman, 2001). 
2.3.2.4 Living in a nursing home  
In this dissertation research, the status of living in a nursing home is an important enabling 
variable for three reasons. The first is the prevalence of dementia among nursing home patients. 
It is estimated that between one-half and two-thirds of nursing home residents have dementia 
(Magaziner, 2000). Although CHS participants were not eligible for the study if they were in a 
nursing home at the time of enrollment into the study, 3% of the population were in a nursing 
home at some point during the study. It is possible that nursing home status may be a proxy for 
cognitive impairment or decline.  
Second, data on patients in nursing homes show that are they are high users of 
prescription drugs. Two studies by the same investigator of twenty different U.S. nursing homes 
found that the average number of prescription drugs was 7.7 per patient (Beers, 1988; Beers, 
1992). Higher rates may be an indicator of nursing home patients’ multiple comorbidities as well 
as more advanced stages of illness. In a recent study of severely demented patients living in a 
nursing home, residents had an average of 14.6 medications prescribed in the 6 months prior to 
death. This same study found that as patients approached death, the types of medications change 
but not the overall number. Presence of cardiovascular disease among the study population was 
significantly associated with the total number of medications. Of those who were on a lipid-
lowering medication 6 months before death (10%), utilization did not decline before death 
(Blass, 2008). 
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The third reason is related to the organizational structure in nursing homes. As compared 
to people in the community, multiple people have input into the medications that patients are 
prescribed and are involved in medication administration. Nurses, pharmacists, and social 
workers all contribute to the care planning process of nursing home patients and may influence 
physician prescribing. Additionally, if a nursing home patient is prescribed a medication, there is 
detailed documentation on when, where, by whom, and how the medication was administered. If 
a prescribed medication is not administered or is administered incorrectly, the facility (as per 
federal regulation) must document that episode as a medication error and must document how it 
happened and what steps were taken to correct and prevent it from happening again. This level of 
oversight is not routine for patients living in the community. A study of patients from the 
community entering a nursing home found that as many as 50% who had been prescribed 
medications were not taking them either at all or as prescribed (Sackett, 1979). We hypothesize 
that CHS participants with CHD who are in a nursing will be more likely to report taking 
chemoprophylaxis, despite their cognitive status, as a result of the oversight of medication 
administration in that setting. 
2.3.3 Care need factors 
Need factors include objective measures of a patient’s health status as well as their self-perceived 
health status. Objective measures of a patient’s health status, such as the presence of comorbid 
diseases, may be one of most useful and significant predictors of health outcomes (Walter, 
2008). Yet the presence of comorbidities often produces complex situations in medical decision 
making, since the optimal care of one disease may be constrained or even contraindicated by 
another (Hoffman, 1996). 
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As predictive factors for receipt of chemoprophylaxis for CHD among patients with 
dementia, need factors include other comorbidities, the severity of their dementia as measured by 
things such as activities of daily living (ADLs), and functional status. Also included among need 
factors are clinical indicators that measure disease burden and have been found to positively 
predict disease severity and life expectancy. The following section summarizes the literature on 
the role of comorbidities, disease burden, and patient and family perception of health status on 
health services utilization. When available, specific data about people with dementia are 
reviewed.  
2.3.3.1 Comorbidity  
It has been well documented that rates of comorbidity among older people are higher than in 
younger populations and are associated with poor quality of life, multiple medications, high 
health care utilization, and mortality (Gijsen, 2001; Hoffman,1996; Field, 2004). Boyd (2005) 
estimates that 50% of all Medicare beneficiaries have at least two comorbid chronic diseases. 
Some evidence suggests that the degree of physician adherence to clinical practice guidelines 
may vary, depending on the presence of a comorbid condition. Frequently, the evidence to 
support decision making in a complex patient with multiple comorbidities may not be available, 
as complex patients are often excluded from the randomized controlled trials used in the 
development of guidelines. Carter and colleagues (2000) found that patients with CHD and 
diabetes were less likely to be taking ACE inhibitors, as compared with patients with CHD only. 
Some of the most relevant research on the effect of comorbidity on utilization of heath 
services for older beneficiaries is in the area of primary prevention. In a study of female 
Medicare beneficiaries, those with a history of MI or diabetes or with limitations of ADLs and  
instrumental ADLs (iADLs) were less likely to receive a mammogram. Although this study did 
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not include any measures of cognitive status, limitations in ADLs and iADLs are common 
among those with both mild and moderate dementia (Ives, 1996).  
A second study looking at primary prevention found that among eligible women 43 years 
or older, the likelihood of compliance with breast and cervical cancer screening decreased by 
17% with every one unit of decline on the Charleson comorbidity index. Additionally, the rate of 
mammograms for women with stable angina was only two-fifths of that in women without 
angina (Kiefe, 1998). 
With comorbidities come increased opportunities for burden of disease and symptoms. In 
a study of guideline adherence for diabetes, Piette and Kerr (2006) suggest that when comorbid 
conditions have a greater symptom burden than diabetes, the comorbid condition can dominate 
the medical decision-making process and have a negative impact on adherence to guideline-
recommended care in diabetes. For patients with dementia, burdens of disease that may affect 
receipt of or adherence to guideline-recommended chemoprophylaxis begin at the earliest stages 
and persist. These include loss of procedural memory and inability to remember to take a 
medication; dysnomia, or inability to effectively communicate side effects due to medication; 
and dysphagia, or inability or refusal to swallow pills. 
When dementia is the comorbidity with CHD, the treatment outcomes may be different 
than if the comorbidity is another disease that has only physical manifestations owing to value 
judgments about quality of life and social worth. For example, in a study that looked at 
adherence to guidelines regarding lipid-lowering medications, patients with dementia were more 
likely to have lower adherence over time, while the opposite was true for those with 
hypertension, stroke, CHF, or diabetes. Additionally this study found that patients who resided in 
a nursing home were significantly more likely to remain on their prescribed regimen (Benner, 
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2002). In another study, Heflin and colleagues (2002) investigated the effect of comorbid 
illnesses on the receipt of cancer screening for people over 65 years. The general findings from 
this study showed that the presence of comorbid conditions in older adults is not associated with 
a decreased rate of screening. Specific findings about the type of comorbidity were that when 
cognitive impairment is at least one of the comorbidities, lower rates of fecal occult blood tests 
(FOBTs) (OR=0.71, 95% CI=0.54–0.94) were reported as well as a trend toward lower rates of 
mammography. 
2.3.3.2 Patient and family perceptions of health status and quality of life  
The empirical work in this dissertation research tests the effect of dementia on the use of 
chemoprophylaxis and uses patient self-report as a proxy for physician-prescribed guideline-
recommended therapy. Yet, research shows that when a patient is prescribed a medication and 
has the means to fill that prescription, he or she must perceive a need to adhere. Embedded in 
this perception are patients’ knowledge, attitudes, beliefs, and expectations regarding disease 
progression with and without treatment (Byrne, 2005). Patients are more likely to adhere if they 
(1) perceive their illness to be serious, (2) expect the medication to help them or improve their 
quality of life (Andersen, 1995), or (3) feel as if they have some control over the disease 
(Leventhal, 1980). A study of adherence to cardiac rehabilitation showed that the more patients 
believe they have control over the symptoms and progression of their disease, the higher the 
levels of adherence (Cooper,1999). Applying these findings to patients with dementia and CHD, 
it is reasonable to think that patients may be less likely to adhere to chemoprophylaxis for CHD 
if they acknowledge their dementia as a progressive, terminal condition that they are unable to 
control. This acknowledgment may lessen their beliefs about the necessity of the medications, 
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given that preventing a subsequent MI in the short term may only extend their experience with 
and death from dementia in the long term.  
Quality of life for patients with dementia is a well-studied area that has looked at 
numerous types of interventions to enhance a patients’ ability to participate in and enjoy daily 
activities, including self-care and leisure, and improve opportunities for pleasure and interest 
(Albert, 1996; Lawton, 1997). The focus on patient quality of life for this dissertation research is 
to understand the role that patient quality of life has on the use chemoprophylaxis for CHD. No 
studies have looked at how a patient’s quality of life, or their perceived quality of life by a family 
caregiver, influences the use of medications for CHD. The relevant literature on quality of life 
and adherence to treatment for patients with dementia reveals that if a patient (or caregiver) 
believes a treatment will improve quality of life, they are more likely to seek it out and adhere to 
it (Dooley, 2004).  
Given the nature of dementia and the involvement of patients’ families in caregiving and 
medical decision making, it is important to note that findings from the literature show positive 
correlations between the quality of life of patients with dementia and the quality of life of their 
family caregivers (Dunkin, 1998; Stuckey, 1996; Walker, 1998). This information is important, 
since when the patient’s quality of life is difficult to assess, family caregivers are often used as 
proxy respondents (Berlowitz, 1995; Logsdon, 1995; Zimmerman, 1994). Applying these 
findings allows us to assume that if a family caregiver involved in medical decision making 
believed that a treatment would improve the patient’s quality of life, the caregiver would be more 
likely to assist the patient in adhering to treatment. Two concerns with this theory are that family 
members, like physicians, have been found to underrate a patient’s quality of life and the 
potential of improved quality of life from secondary chemoprophylaxis (with the exception of 
 54 
nitrates for angina) is unknown. So, if a family member who is involved in medical decision 
making or in assisting their loved one with medication adherence, perceives the patient to have a 
low quality of life and is unsure about any benefits of the medicine to quality of life, lower 
utilization is likely. This may be amplified if the patient is unable to unwilling to take the 
medication and the burden on the caregiver to administer the chemoprophylaxis is greater. 
2.4 UTILIZATION OF CHEMOPROPHYLAXIS FOR CHD AMONG PATIENTS 
WITH DEMENTIA 
Elements of the Andersen and Eddy models provide some guidance in describing the effect of 
dementia on guideline-recommended chemoprophylaxis for CHD, yet neither model provides a 
comprehensive or complete framework. For people with dementia, the relevant medical factors 
as well as personal characteristics and value judgments by the physician, patient, and patient’s 
family that complicate adherence to guidelines may also impact the use of chemoprophylaxis. 
The following section presents findings from specific studies that have investigated variation in 
use of health services for people with dementia both in general and for cardiovascular medication 
and treatments in particular. Section 2.4.2 includes a revised model that combines predictive 
factors from the Andersen and Eddy models as well as other potential predictors drawn from the 
literature and proposed in this dissertation research. 
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2.4.1 Variation in use of health services utilization for people with dementia 
The association between cognitive impairment and use of health services has not been 
thoroughly investigated. Only a few studies have looked directly at the effect of cognitive 
impairment from dementia on the use of health services (surgical, medical, or 
pharmacotherapeutic). The following section is a comprehensive review of the studies that have 
investigated variation of health services among those with dementia and is organized based on 
the type of health service—cardiovascular or non-cardiovascular. When the results concern any 
type of treatment for CHD, those results are highlighted. Table 2.1 presents a summary of all 
studies.  
2.4.1.1 Variation in cardiovascular health services   
The most comprehensive study that has looked at differences in cardiovascular health services is 
a retrospective chart review by Sloan and colleagues (2004). This study used detailed clinical 
data from the Cooperative Cardiovascular project, combined with Medicare claims, to identify 
patients who were admitted to a nonfederal hospital between February 1994 and July 1995 with 
an MI. The sample included 123, 241 patients, of whom 5,851 (4.5%) had a history of dementia 
noted in their inpatient medical chart.  
Descriptive findings of the sample reveal that, on average, patients with dementia tended 
to be older and were less likely to be white, less likely to be male, and much more likely to be 
admitted to the hospital from a nursing home (27% vs. 2%, P<0.001) and have a higher Charlson 
comorbidity index (P<0.001). For patients with dementia, higher mortality at 30 days and at 1 
year post-hospitalization was observed.  
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Results from the analyses regarding treatment reveal differences in all outcomes, with the 
exception of aspirin and beta-blockers. The largest variation in treatment was observed for the 
more intense and aggressive treatment. Patients with a history of dementia were less likely to 
receive catheterization (RR=0.51, 95% CI=0.47–0.55), coronary angioplasty (RR=0.58, 95% 
CI=0.51–0.66), and cardiac bypass surgery (RR=0.41, 95% CI=0.33–0.50) than were patients 
without a history of dementia. Additionally, during hospitalization, patients with a history of 
dementia were less likely to receive thrombolytic therapy (RR=0.82, 95% CI=0.74–0.90). 
For the less intense chemoprophylaxis, patients with a history of dementia were less 
likely to receive ACE inhibitors during their hospitalizations (RR=0.89, 95% CI=0.86–0.93) and 
at discharge (RR=0.90, 95% CI=0.86–0.95). 
Applying these findings widely is limited because they include only those hospitalized 
with AMI, leaving out those who may have chosen less aggressive cardiovascular treatment and 
did not seek inpatient care. While the study does include measures of medication use at 
discharge, it does not account for subsequent treatment patterns for preventing future MIs. This 
may be particularly important in assessing the effect of dementia on setting goals of care for 
patients with CHD. Finally, a major limitation of the study is that dementia is identified via 
Medicare claims and does not include type, stage, duration, or severity of dementia. This method 
is likely to underestimate the number with dementia and overestimate the effect of dementia on 
use of health services utilization.  
A second study that included cardiovascular health services as an outcome is a 1996 
study by Hanlon and colleagues. In this study, medication use was compared in a cohort of 4,110 
people ≥65 years living in five adjacent counties in North Carolina. Fifteen percent of the sample 
(n=564) had cognitive impairment as defined by the Short Portable Mental Status Questionnaire 
 57 
(SPMSQ). Medication use was obtained by participant (or proxy) self-report and was compared 
by prescription vs. non-prescription, and then by class for all prescription medications. 
Cardiovascular medications were one class of medications assessed. 
After controlling for age, sex, race, education status, functional status, comorbidities, and 
number of physician visits per year, the study showed that participants with cognitive 
impairment were 34% less likely to use any prescription medications. Unadjusted results reveal 
that participants with dementia report slightly greater use of cardiovascular medications (57% vs. 
54%), although in the multivariable analyses, the results were not significantly different. 
Participants with dementia were more likely to report taking a lipid-lowering medication. Those 
with cognitive impairment were less likely to take analgesics (OR=0.66, 95% CI=0.52–0.83) but 
more likely to report taking central nervous system (CNS) drugs (OR=1.55, 95% CI=1.18–2.04). 
Within the CNS category, the largest variation was for antidepressants (7% vs. 3.2%, P≤0.0001). 
These findings are consistent with a study by Semla and colleagues (1993), who found that 
among a community with dementia, those with higher levels of cognitive impairment were more 
likely to use CNS medications.  
The findings from the Hanlon study are limited for four reasons. First, and similarly to 
Sloan (2004), this study was cross-sectional and precludes any conclusions about causality and 
whether the dementia or mild cognitive impairment was the result of the differences in rates of 
utilization. Second, the categorization of cardiovascular drugs was broad and does not allow for 
any examination of differences among specific drugs, each of which has a different risks, 
benefits, and financial considerations. Third, dementia was assessed using only one measure and 
does not include stage or type of dementia to differentiate those with mild cognitive impairment 
from those with severe dementia. Fourth, the sample was representative of only one small region 
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in the southern U.S. As described in previous sections, regional differences in physician practice 
patterns may have an effect on overall utilization, making these findings difficult to apply 
broadly.  
A third study conducted by Schmader, using the same dataset as the Hanlon (1996) study, 
looked at patterns of medication use among a community cohort with dementia (n=100), mild 
cognitive impairment (n=117), and intact cognition (n=303). A unique aspect of this study is the 
distinction between those with dementia and mild cognitive impairment using three levels of cut 
points on the Mini-Mental State Examination (MMSE). The participants were selected sample 
members of the Duke EPESE (“Established Populations for Epidemiologic Studies of the 
Elderly”) who participated in face-to-face interviews in 1986–1987 for a separate study of 
incidence and prevalence of dementia in North Carolina.  
Results reveal no significant differences among the three groups in the relative odds of 
using any prescription medications. However, the demented group took significantly fewer 
prescription medications than the mildly cognitively impaired group. Similar to the results found 
by Hanlon (1996), Schmader found that those with dementia were more likely to use CNS drugs 
and less likely to use analgesics (OR=0.54, 95% CI=0.39–0.75) than those without dementia and 
mild cognitive impairment. These similar findings may be due to patients with dementia under-
reporting pain or to the undertreatment of pain due to the difficulty of assessing pain in patients 
with dementia (Frampton, 2003). Schmader’s results differed from Hanlon’s in that those with 
more sever impairment were significantly less likely to use cardiovascular drugs than those with 
only mild cognitive impairment (OR=0.70, 95% CI=0.49–0.99). 
The limitations of this study are similar to those from the Hanlon study, given the use of 
the same dataset. An exception was the inclusion of a more sensitive measure of dementia due to 
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the creation of a category for those with mild cognitive impairment rather than combining these 
subjects with the dementia group or the cognitively intact group.  
A study published in 2002 by Rodriguez and colleagues looked at the use of lipid-
lowering medications among a community cohort of older Pennsylvanians with and without 
dementia. The study was based on a secondary data analysis from the longitudinal Monongahela 
Valley Independent Elders Survey (MoVIES). The sample for the Rodriguez study was drawn 
from participants who were still alive in wave 5 of the study (1996–1999). Dementia status was 
established during an in-home interview that included a battery of cognitive testing. Subjects 
identified in the interview as being demented or probable cases of dementia were referred for a 
clinical (diagnostic) evaluation. Use of lipid-lowering mediations was obtained by participant 
self-report and information gathered directly from the medication bottle during the in-home 
interview. 
The sample included 845 subjects of which 170 (20.1%) were diagnosed with dementia. 
The dementia cohort was older (83.5 years vs. 79.6 years) and reported lower rates of use for 
lipid-lowering medications (3.5% vs. 10.8%, P=0.004). Multivariable analyses controlled for 
age, sex, education, self-reported heart attack or angina pectoris, stroke or TIA, hypertension, 
alcohol consumption, and smoking. Overall, participants with dementia were significantly less 
likely than those without dementia to report using a lipid-lowering medication (OR=0.39, 95% 
CI=0.16–0.95). Subanalyses that included only those with more severe dementia reveal no 
differences in the use of lipid-lowering medications.  
Type of lipid-lowering medication, statin versus non-statin, was investigated to see if the 
patterns of overall use remained. Models that included only statins showed that those with 
 60 
dementia were less likely to report using a statin, but the results were not statistically significant 
(OR=0.54, 95% CI=0.22–1.33, P=0.179). 
The findings from Rodriguez support the general hypothesis that patients with dementia 
report lower rates of lipid-lowering medications. Some limitations of the study include sampling 
issues. Like the Hanlon and Schmader studies, this study included participants from only a single 
region in the U.S. Also, despite the longitudinal panel, analyses were essentially cross-sectional 
and did not account for changing dementia status or changing use of lipid-lowering medications 
over time. A final study limitation is that it did not control for relevant biomarkers, such as 
measures of serum cholesterol, that indicate clinically appropriate use of lipid-lowering 
medication. This is an important oversight, given the focus on utilization of only lipid-lowering 
medications. 
Each of the studies summarized above included patients living in the community. Landi 
(1998) conducted a study to investigate the prevalence of comorbidities and treatment patterns 
among residents in nursing facilities. The retrospective cross-sectional study used data from the 
Health Care Financing Administration’s (HCFA) Multi-state Case Mix Demonstration Project, 
which included nursing home resident data from facilities in five states (Kansas, Maine, 
Mississippi, New York, and South Dakota). The study variables included clinical information 
and functional status as well as other data from the Minimum Data Set (MDS) assessment for 
each resident in each faculty. Cognitive performance for residents was evaluated using the six-
item Cognitive Performance Scale (Morris, 1994). In addition to the MDS data, the study 
included data about all medication use for the residents, organized by therapeutic class.  
Of the 260,628 residents, 61% had some level of cognitive impairment, and not 
surprisingly, the more severe the cognitive impairment the more physical impairment and 
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assistance needed with ADLs. Overall, comorbid clinical conditions were more prevalent in the 
cognitively intact group than in the moderately or severely cognitively impaired group (3.0 vs. 
2.8 vs. 2.4) (P<0.001). Regarding medications, Landi found that overall the average number 
medications per resident was significantly lower among those with moderate and severe 
cognitive impairment (6.2 ± 4.3 and 5.9 ± 4.6, respectively) as compared to residents with no 
cognitive impairment (7.3 ± 4.4). Results for medications by class reveal that residents with 
cognitive impairment are less likely to be taking medications in any class, with the exception of 
antipsychotics. For cardiovascular medications in particular, the group with the most severe 
cognitive impairment had the lowest rates of use compared to those with moderate impairment 
and no impairment (76% vs. 70% vs. 60%) despite similar rates of CHD (22% vs. 23% vs. 23%). 
Results from the Landi study are in agreement with those found by Hanlon (1996) and 
Schmader (1998) in that demented patients were less likely to use cardiovascular medications 
and analgesics. However, opposite results were found for medications in the CNS class. 
Limitations of the Landi study include the inability to draw definite conclusions owing to the 
cross-sectional design. Additionally, the analyses did not control for duration of cognitive 
impairment or other comorbidities. 
2.4.1.2 Variation in non-cardiovascular health services   
The most recent study we reviewed that looks at variation of health services for patients with 
dementia was published in 2005 by Gorin . This study used the National Cancer Institute SEER 
registry to identify Medicare beneficiaries who were newly diagnosed with breast cancer stage I–
III between January 1992 and December 1993. In this cohort, women who had at least two 
Medicare claims involving Alzheimer’s disease (AD) before the diagnosis of cancer were 
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identified as having prevalent dementia. The sample included 50,460 breast cancer patients ≥65 
years of age of whom 1,935 (3.8%) had dementia.  
Descriptive findings from the study show that women with AD were more likely to be 
older, non-white, and have more comorbidities than those without AD (Deyo-Charlson index >3, 
7.1% vs. 2.4%, P<0.001). Regarding the timing of diagnosis, women with AD were diagnosed 
with breast cancer at later stages, as measured by larger tumors and more likely involvement of 
lymph nodes.  
Findings regarding treatment patterns reveal that patients with AD were 40% less likely 
to have surgery (OR=0.60, 95% CI=0.46–0.81). Additionally, patients with AD were less likely 
to receive radiation therapy (OR=0.31, 95% CI=0.23–0.41) and chemotherapy (3% vs. 11%; 
OR=0.44, 95% CI=0.34–0.58). The greatest variation occurred among those 80–89 years old. 
Analyses of all treatments show that the length of time with AD is related to the likelihood of 
receiving any treatment for breast cancer. The only instance in which AD patients did not receive 
lower rates of treatment compared to those without AD was for chemotherapy for those without 
metastases to the axillary nodes (Gorin, 2005). 
The study’s findings may be limited in general by biases in the SEER database, but also 
by the identification of dementia from Medicare claims data. Studies examining dementia 
diagnoses in medical claims have found that they have strong specificity but poor sensitivity 
(Wilcheksy, 2004). Additionally, the study lacked any data on the stage of dementia or the 
method of diagnosis (e.g., psychometric test or diagnostic imagining). Despite these limitations, 
they add to the literature of the likelihood for patients with dementia to experience lower 
utilization of health services.  
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Gupta and colleagues (2004) conducted a similar study to Gorin using the National 
Cancer Institute’s SEER database to assess the prevalence and treatment patterns of colon cancer 
for patients with dementia. The cohort consisted of all patients ≥67 years of age in the SEER 
database diagnosed with stage I–IV colon cancer between January 1993 and December 1996 
(n=17,507). Dementia among the cohort was 6.8% (n=1,184) and established by at least one 
Medicare claim with a dementia-related ICD-9 Clinical Modification Code.  
Descriptive findings from the study show that those with dementia with were more likely 
to be older, female, reside in a lower income and/or urban neighborhood, and have more 
comorbidities.  
Results from the multivariable analyses regarding diagnosis show that dementia patients 
were twice as likely to have colon cancer reported only after death (i.e., by autopsy or death 
certificate). Of those with cancer reported before death, patients with dementia were twice as 
likely to be diagnosed by use of noninvasive techniques rather than direct tissue biopsy 
(OR=2.02, 95% CI=1.77–2.55).  
Findings about treatment variation reveal that living patients with dementia were 43% as 
likely to receive surgical resection (OR=0.43, 95% CI=0.33–0.70). Furthermore, among the 
patients with resected stage III colon cancer, dementia patients were only 20% as likely to 
receive adjuvant chemotherapy (OR=0.21, 95% CI=10.13–20.36). 
Results from this study show that patients with dementia have distinct patterns of 
presentation, diagnosis, and treatment of colon cancer that differ from those without dementia. 
The limitations of this study are similar to Gorin in that claims data was used to identify 
dementia and the analyses lacked any information about severity of dementia, which may greatly 
affect diagnostic and treatment decisions. 
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Table 2.1: Summary of Literature on Dementia and Treatment of Non-dementia Diseases 
  
Author, Year 
 
Design 
 
Sample 
 
Utilization Measures 
 
Results 
 
Limitations 
Gorin, 2005 Cross-sectional, 
retrospective cohort 
study, SEER 
database 
N=50,460 Medicare 
beneficiaries with 
breast cancer; 
CON n=48,525 
AD n=1,935 (3.8%) 
 
Surgery (breast-
conserving or 
mastectomy, if 
known), irradiation, 
and chemotherapy 
Participants with AD 
had lower rates of any 
treatment (OR=0.55, 
95% CI=0.42–0.74). 
The odds of AD 
patients having 
surgery were 40% 
less; irradiation, 31% 
less; and 
chemotherapy, 44% 
less than controls. 
The longer the 
amount of time with a 
diagnosis of AD the 
less likely the patient 
is to receive any 
treatment.  
AD identified by 
Medicare claims. 
Analyses did not 
include stage or type 
of dementia. Method 
of AD diagnosis was 
unknown and not 
validated.  
Gupta, 2004 Cross-sectional, 
retrospective cohort 
study, SEER 
database 
N=17,507 Medicare 
beneficiaries with 
colon cancer; 
CON n=16,323 
Dementia n=1,184 
(6.8%) 
 
Surgical resection 
and Adjuvant 5FU 
among those with 
stage III 
Participants with 
dementia were 43% 
as likely to receive 
surgical resection 
(OR=0.43, 95% 
CI=0.33–0.70). 
Among patients with 
resected stage III 
colon cancer, those 
with dementia were 
only 20% as likely to 
receive adjuvant 
chemotherapy 
(OR=0.21, 95% 
CI=10.13–20.36). 
Dementia identified 
by Medicare claims. 
Analyses did not 
include stage or type 
of dementia. Method 
of dementia diagnosis 
was unknown and not 
validated. 
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Table 2.1 (continued) 
 
 
Author, Year 
 
Design 
 
Sample 
 
Utilization Measures 
 
Results 
 
Limitations 
Sloan, 2004 Cross-sectional, 
retrospective chart 
review, Cooperative 
Cardiovascular 
project 
N=129,092 Medicare 
beneficiaries 
hospitalized for AMI; 
CON n=123,241 
Dementia n=5,851 
(4.5%) 
Cardiac 
catheterization, 
coronary angioplasty, 
cardiac bypass 
surgery, 
thrombolytics, aspirin, 
β-b, and ACEi during 
hospitalization and at 
discharge 
Patients with a history 
of dementia were less 
likely to receive 
catheterization 
(RR=0.51, 95% 
CI=0.47–0.55) 
coronary angioplasty 
(RR=0.58, 95% 
CI=0.51–0.66), 
cardiac bypass 
surgery (RR=0.41, 
95% CI=0.33–0.50), 
thrombolytics 
(RR=0.82, 95% 
CI=0.74–0.90), and 
ACEi in hospital 
(RR=0.89, 95% 
CI=0.86–0.93) and at 
discharge (RR=0.90, 
95% CI=0.86–0.95). 
Only includes those 
hospitalized with an 
AMI, not subsequent 
treatment. Dementia 
was identified via 
Medicare claims data 
and does not include 
type, stage, duration, 
or severity of 
dementia. 
Rodriguez, 2002 Cross-sectional 
analyses of 1 time-
point from a 
longitudinal panel 
study, MoVIES 
database 
N=845 participants 
who were alive in 
study wave 5 (1996-
99); 
CON=675 
Dementia n=107 
(20.1%) 
Number and type of 
LLM (statin vs. non-
statin) 
Participants with 
dementia had lower 
rates of use of any 
LLM (3.5% vs. 10.8%, 
P=0.004). In the 
adjusted model, 
participants with 
dementia were less 
likely to take LLM 
(OR=0.39, 95% 
CI=0.16–0.95). Of 
those with dementia 
all were taking a non-
statin LLM. Severity 
did not impact use. 
Did not differentiate 
between different 
types of dementia or 
disease severity or 
LLM use over time. 
Given the detail of 
type of LLM, the study 
did control for 
measures of serum 
cholesterol to assess 
for clinical 
appropriateness. 
 66 
Table 2.1 (continued) 
 
 
Author, Year 
 
Design 
 
Sample 
 
Utilization Measures 
 
Results 
 
Limitations 
Landi, 1998 Cross-sectional, 
retrospective cohort 
study, HCFA Multi-
State Case-Mix 
Demonstration project  
N=260,628 nursing 
home residents from 
five states during 
1992-1995; 
CON=101,532 
Moderate cognitive 
impairment 
n=106,054 
Severe cognitive 
impairment n=53,042 
(20.3%) 
Medications by class 
and five different 
types of special 
treatment or care 
programs 
Residents with 
cognitive impairment 
were less likely to 
receive 
cardiovascular 
medications, as well 
as respiratory 
medications, 
antidiabetic 
medications, narcotic 
analgesics, and 
NSAIDs, after control 
for prevalence of 
relevant 
comorbidities.  
Included only a 
nursing home 
population, making it 
difficult to extrapolate 
management of 
community population 
with dementia.  
Schmader, 1998 Cross-sectional, 
retrospective cohort 
study, Duke EPESE 
N=4,110 people ≥65 
years old living in five 
adjacent counties in 
North Carolina; 
CON n=303,  
mild cognitive 
impairment n=117 
dementia n=100 
(19.2%) 
Prescription and non-
prescription 
medications; nine 
different classes of 
prescription 
Those with dementia 
were significantly less 
likely to use any 
prescription drugs 
(OR=0.65, 95% 
CI=0.45–0.93), 
cardiovascular drugs 
(OR=0.70, 95% 
CI=0.49–0.99), and 
analgesics (OR=0.54, 
95% CI=0.39–0.75) 
compared to those 
with mild cognitive 
impairment. 
Cross-sectional study 
of a single region in 
the U.S. Does not 
include timing of 
onset to make casual 
inferences about 
time-order 
relationships. 
Medication classes 
are broadly grouped 
without differentiation 
between individual 
medications.  
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Table 2.1 (continued) 
 
 
Author, Year 
 
Design 
 
Sample 
 
Utilization Measures 
 
Results 
 
Limitations 
Hanlon, 1996 Cross-sectional, 
retrospective cohort 
study, Duke EPESE 
N=4,110 people ≥65 
years old living in five 
adjacent counties in 
North Carolina; 
CON n=3,546 
Cognitively impaired 
n=564 (15.9%) 
Prescription and non-
prescription 
medications; 15 
different classes of 
prescription 
Participants with 
cognitive impairment 
were less likely to use 
any prescription 
medications 
(OR=0.66, 95% 
CI=0.48–0.90). Those 
with cognitive 
impairment were less 
likely to take 
analgesics (OR=0.66, 
95% CI=0.52–0.83) 
but more likely to 
report taking CNS 
drugs (OR=1.55, 95% 
CI=1.18–2.04). 
Cross-sectional study 
of a single region in 
the U.S. Does not 
include timing of 
onset to make casual 
inferences about 
time-order 
relationships. 
Dementia is assessed 
using only one 
measure and does 
not include stage or 
type. 
Abbreviations: ACEi, ACE inhibitor; AD, Alzheimer’s disease; AMI, acute myocardial infarction; β-b, beta-blocker; CNS, central nervous system; 
CON, control; EPESE, [Duke] Established Populations for Epidemiologic Studies of the Elderly; LLM, lipid-lowering medication; MoVIES, 
Monongahela Valley Independent Elders Survey; SEER, Surveillance, Epidemiology, and End Results cancer-based registry. 
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2.4.2 Revised model 
The evidence-based decision-making model created by Eddy to describe the process of physician 
decision making and the patient-specific model created by Andersen to predict use of health 
services are helpful when considering the effect of dementia on variation in chemoprophylaxis 
for CHD. While the evidence from the literature supports the importance of each element 
contained in the two models, it is clear that describing them as two separate processes and 
parceling out the elements singularly is incomplete, given the confounding relationship of many 
of these factors are (e.g., age and comorbidity). For example, a study by Marwill (1996) that 
attempted to identify patient factors that influence physician recommendations for 
mammography reported that patient age alone does not predict fewer recommendations for 
mammography screening. When age was combined with cognitive impairment, it was a stronger 
predictor for not to screen with mammography for breast cancer (P<0.001). Similarly, physical 
functional status did not deter physicians from recommending screening with mammography, but 
when combined with residence in a nursing home it was a strong predictor against 
recommending mammography. This study emphasizes the importance of confounding patient 
factors that may, jointly, impact the use of chemoprophylaxis for patients with dementia. 
Figure 2.3 presents an amalgamated model of the Eddy and Andersen models, and 
includes other important elements cited in the literature. The bolded elements represent those 
included in the empirical analyses of this dissertation research and are described in greater detail 
in Chapter 3. This model is used in this research to help conceptualize the range of factors that 
may predict use of evidence-based treatment for non-dementia illness for people with dementia.  
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Figure 2.3: Conceptual Model for Predicting Use of Secondary Chemopreventive Treatments for 
CHD for Patients with Dementia. 
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3.0  DATA AND METHODOLOGY 
This chapter outlines the dissertation’s data and methodology. Section 3.1 describes the research 
design and data source. Section 3.2 defines the Cognition Study subsample of the Cardiovascular 
Health Study used in the analyses. Section 3.3 presents an overview of the analyses and research 
plan. Section 3.4 presents the strategy for preparing the data for analysis, and Section 3.5 
describes the dependent and independent variables. Section 3.6 addresses issues of correlation 
and measurement reliability and validity. Section 3.7 discusses multivariate model specifications. 
Section 3.8 details the study’s multivariate analytic methods. Finally, Section 3.9 describes the 
sensitivity analyses that were performed and presented in Appendix C, F, G, and H. 
3.1 RESEARCH DESIGN AND DATA DESCRIPTION 
This dissertation analyzes data from the Cardiovascular Health Study (hereinafter called CHS), a 
population-based, longitudinal study of risk factors for the development and progression of 
coronary heart disease and stroke in adults over the age of 65 years.1
                                                 
1 This dissertation uses a secondary data analysis as the method of research. Secondary data analysis is the 
utilization and analysis of existing data or information that was collected for the purposes of a prior study, in order 
to pursue a research interest which is distinct from that of the original work.  Sources of secondary data analysis 
often include official records collected by government agencies and previously collected measures from private or 
federally funded research projects (Cnossen, 1997). 
 Initially funded by the 
 71 
National Heart Lung and Blood Institute (NHLBI) in 1988, it was renewed for a six-year period 
for data collection in 1994 with all analyses scheduled completed by 2009.   
The National Institutes of Health describe the CHS as the most extensive study 
undertaken by the NHLBI to study cardiovascular disease exclusively in an older population. It 
originated from the recommendations of a 1986 NHLBI workshop on the management of 
coronary heart disease in the elderly.  
The CHS study recruited 5,888 men and women from four US communities (Forsyth 
County, North Carolina/Wake Forest University; Sacramento County, California/University of 
CA-Davis; Washington County, Maryland/Johns Hopkins University; and Pittsburgh, 
Pennsylvania/University of Pittsburgh) who participated in extensive clinic examinations for 
evaluation of markers of subclinical cardiovascular disease. The original CHS cohort totaled 
5,201 subjects. A supplemental cohort of 687 subjects, who were predominately African-
American, was recruited in year five of the study (1992). The population from the Pittsburgh 
Field Center was entirely urban while the other three sites recruited a mixture from urban and 
rural populations.   
Eligible subjects were sampled from Medicare eligibility lists in each of the four field 
center sites. Those eligible included all persons living in the household sampled from the Health 
Care Financing Administration (HCFA, now known as the Centers for Medicare and Medicaid 
Services, CMS) sampling frame, who were 65 years or older at the time of examination, were not 
living in an institution (such as a nursing home or assisted living), were expected to remain in the 
area for the next three years, and were able to give informed consent and did not require a proxy 
respondent for any questionnaires at baseline. Potentially eligible individuals who were 
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wheelchair-bound in the home at baseline or were receiving hospice care, radiation therapy or 
chemotherapy for cancer at baseline were excluded.  
All subjects were examined annually from 1989 through 1999 with the exception of the 
supplemental cohort, who were examined from 1992 to 1999. A major emphasis of the CHS 
study is its focus on subclinical cardiovascular disease. Subclinical disease is an illness that stays 
below the surface of clinical detection with no recognizable clinical findings. The most extensive 
evaluations were at study entry and again in 1992-1993 to assess change in subclinical disease 
measures. From 1999-2009 the cohort was followed with bi-annual phone calls to assess study 
endpoints, including: myocardial infarction (MI), stroke, congestive heart failure, peripheral 
claudication (pain in the legs when walking, due to insufficient oxygen delivered to muscles), 
angina, transient ischemic attack (TIA) and death.   
Additional data collected at the annual clinic examinations were measures of cognitive 
function using the Modified Mini-Mental Status Examination (3MSE) and the Digit Symbol 
Substitution Test (DSST).  The 3MSE is a measure that uses an index of global cognitive 
performance with scores ranging from 0 to 100 (Teng, 1987).  It is widely used in clinical 
settings to screen for dementia. The 3MSE provides a summary score that evaluates various 
dimensions of cognition (memory, calculation, orientation in space and time, language, and word 
recognition). The DSST explores attention and psychomotor speed.  Subjects are given a code 
table displaying the correspondence between pairs of digits (from 1 to 9) and symbols, and they 
have to fill in blank squares with the symbol that is paired to the digit displayed above the square. 
The subjects have to fill in as many squares as possible in 90 seconds. The range of scores is 
from 0 to 90 (Wechsler, 1981).  For subjects in the CHS who died or were unable to complete a 
3MSE at their annual visit, a proxy measure of cognition was collected using the Information 
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Questionnaire for Cognitive Decline in the Elderly (IQ CODE) (Jorm, 1989). The IQ CODE lists 
26 everyday situations where a person has to use their memory or intelligence. Examples 
include: “Remembering where to find things which have been put in a different place from 
usual” and “Handling money for shopping”. Each situation is rated by the proxy for amount of 
change over the previous year, using a five point scale of: much improved, a bit improved, no 
change, a bit worse, and much worse (Jorm, 1989). 
Other relevant data collected by CHS includes functional status, measured by activities of 
daily living (ADLs), pharmaceutical drug use, and information on clinical outcomes, such as MI, 
dementia, and death.  The CHS included adjudication committees for all events that were 
suspected as cardiovascular events, the development of dementia, and deaths.  CHD adjudication 
committees provided disease specific “end point” information in the study. Information from 
participant’s next of kin regarding the circumstances and history of any illness was also 
collected.  
Data from the CHS are available to investigators who have a demonstrated research 
interest and who identify a CHS sponsor.  To obtain data for this dissertation, approval from the 
University of Pittsburgh’s Institutional Review Board was obtained (University of Pittsburgh 
IRB #0408086) and an ancillary CHS study proposal was submitted to and approved by the CHS 
Coordinating Center.  Appendix A includes the IRB approval for this dissertation research. 
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3.2 SUBSAMPLE DEFINITION 
The sub-population of interest for this research includes data from the Cardiovascular Health 
Study Cognition Study (CHS-CS). CHS-CS is an ancillary study to CHS that tested a series of 
specific hypotheses related to the incidence and determinants of dementia.  
The CHS-CS subsample includes 3,602 participants from the CHS study who had both a 
cerebral magnetic resonance imaging (MRI) and Modified Mini-Mental Status Examination 
(3MSE) as part of the annual CHS data collection from 1991-1994. 
Identification of dementia within the sample was made by a standardized protocol that 
was developed in 1998-1999 (study year 11) for the CHS-CS ancillary study.  All eligible 
participants (n=3602) were divided into categories of high or low risk for developing dementia 
based on cognitive testing from previous years, changes in 3MSE and DSST scores, nursing 
home admissions, being dead or alive, and history of stroke. Table 3.1 describes the criteria used 
to determine high risk for dementia. 
Due to sample size restrictions in three of the study site centers (Forsyth County, North 
Carolina; Sacramento County, California; Washington County, Maryland) only the whites 
classified as high risk for dementia were subjected to detailed neuropsychological and 
neurological testing for the diagnosis of dementia, but all of the participants belonging to a 
minority group were subjected to detailed neuropsychological and neurological testing for the 
diagnosis of dementia.  At the Pittsburgh site (n=927) all participants were subjected to a detailed 
evaluation regardless of classification of high or low risk. Those labeled as low risk had no 
further follow-up other than routine CHS data collection.  Following the neuropsychological and 
neurological testing at each of the sites, cases of dementia were reviewed by the dementia 
adjudication committee who reviewed all data and made a final determination of cognitive status. 
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Table 3.1: Criteria for defining high risk of dementia within CHS-CS cohort 
Subject Alive 1998-1999 Subject Dead 1998-1999 
 
At least 1 of the following criteria must be met to be classified as high risk 
3MSEa score <80 during at least 1 of last 2 clinic 
examinations. 
3MSEa score <80 during within 2 years of death. 
> 5  point decline in 3MSE from time of MRI to 
last contact 
> 5 point decline in 3MSE from time of MRI to the 
year closest to death 
TICSb score of <28 and IQ CODEc score >3.6 TICSb score of <28 or an IQ CODEc score >3.6 
within 2 years of death, Diagnosis of dementia in at 
least 1 medical record (inpatient or outpatient, 
admission or discharge), a history of incident strike 
during the CHS study, belonging to a minority. 
Had an incident stroke 
Diagnosis of dementia in at least 1 medical 
record (inpatient or outpatient, admission or 
discharge) 
Residing in a Nursing Home 
Abbreviations: 3MSE, The Modified Mini-Mental State Examination. 
a The 3MSE has been found to be an efficient screen to determine persons at high risk of dementia 
(Lopez, 2003).   
bThe Telephone Interview for Cognitive Status (TICS) is an 11-item screening test that was developed for 
the assessment of cognitive function in patients with dementia who are unwilling or unable to be 
examined in person (Brandt, 1988). 
cInformant Questionnaire for Cognitive Decline in the Elderly (IQ CODE) is a questionnaire that can be 
filled out by a proxy of an older person to determine whether that person has declined in cognitive 
functioning. The IQ CODE is often used as a screening test for dementia (Jorm, 1989). 
 
Following dementia status adjudication, the distribution of the sample consisted of 707 
subjects with dementia, 2318 without dementia, and 577 with mild cognitive impairment, but not 
classified as having dementia (n=3602). For the analyses in this dissertation, participants 
identified as having dementia at entry into the study (1989 or 1992) are labeled as having 
dementia at baseline and those who have a date of onset for dementia at any year after their 
baseline are and labeled having dementia starting in the year of onset.  To be consistent with 
other published studies using CHS-CS data, participants identified with mild cognitive 
impairment but who never develop dementia during the study period are considered not 
demented (Lopez, 2003).   
Of the 3602 participants in the CHS-CS, 1087 had CHD at baseline or developed CHD 
sometime during the study making them eligible for guideline-recommended chemoprophylaxis 
for CHD.  Given that the main outcomes of interest for this research are use of four sub-classes 
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of chemoprophylaxis for CHD, only those participants who develop CHD are included the 
analyses. Figure 3.2 presents the sampling for this research. 
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CHS Cohort 
1989-90 
 
 
 Had an MRI and 3MSE exam at some point from 
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Sample Eligible for Guideline-
Recommended Chemoprophylaxis for CHD 
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CHS Cognition Cohort 
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Develops CHD during 
study 
n=496 (14%) 
 
Figure 3.1: Analytical sample of participants with Coronary Heart Disease in the CHS-CS cohort 
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The CHS-CS study data are unique compared to other secondary datasets that include 
cognitive status information because they provide clinically adjudicated dates of disease onset 
for both dementia and CHD.   In previous research that investigated the effect of dementia on 
treatment for CHD (Sloan, 2004; Hanlon, 1996, Schmader, 1998) the inclusion of dementia as a 
main variable of interest was limited to people with a diagnosis of dementia in a medical chart or 
identified in secondary administrative databases, such as Medicare claims data, or based on 
cognitive test scores only. A major strength of the CHS-CS data used in the analyses for this 
dissertation is that it provides a rich sample of subjects where both the CHD and the dementia 
diagnoses are defined by a standardized research protocol, and a committee of experienced 
clinicians who reviewed all data.  
Despite the strength of the CHS-CS data, it is important to note from a study design 
perspective, that there are still many difficulties in establishing the true date of onset for 
dementia, particularly retrospectively. By definition, the onset of dementia is insidious and 
progression is gradual (McKahnn, 1984).  Dating the onset based on the criteria used in this 
study (and certainly based on primary care physicians’ identification) likely underestimates the 
duration of illness for most patients, because the majority of people with dementia have 
symptoms for several years before receiving a diagnosis (Boustani, 2003; Corrada, 1995). 
Having a date of onset for both CHD and dementia across all ten years of the CHS-CS 
allows for time series analyses to explore whether the timing of disease onset has an impact on 
use of chemoprophylaxis for CHD.  For those who develop dementia first, we predict that they 
will be less likely to initiate chemoprophylaxis.  Of the subjects who develop CHD first, we 
predict that the rate of chemoprophylaxis for CHD will decease following the onset of dementia.  
These predications are based on theories from the medical ethics literature that differentiate 
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between acts of commission and omission regarding the discontinuation of medical treatment.   
While there is no moral difference between not starting medical treatment versus stopping 
medical treatments that people are receiving, data show that patients, families and physicians are 
often more willing to make a passive decision to not initiate a treatment  than they are to make an 
active decision to stop a treatment (Brock, 1994). In the case of participants with dementia, we 
predict that not starting chemoprophylaxis for CHD is more prevalent than stopping 
chemoprophylaxis for CHD once it has been initiated.  
3.3 ANALYSIS OVERVIEW 
Three interrelated research questions concerning the use of chemoprophylaxis for CHD direct the 
empirical analyses for this dissertation. The dependent variables for all three questions are four 
sub-classes of cardiovascular medications recommended by the American College of 
Cardiology/American Heart Association (Ryan, 1996) for people with CHD (incidence of a 
myocardial infarction (MI) or unstable angina). They include Angiotensin- Converting Enzyme 
(ACE) Inhibitors, beta-adrenergic blocking agents (Beta-blockers), HMG-CoA Reductase 
Inhibitors (lipid-lowering medications), and anti-platelet medications such as Cyclooxygenase 
inhibitors (Aspirin) and Adenosine diphosphate (ADP) receptor inhibitors (such as Plavix®). 
Two additional outcome variables were created to measure compliance with these medications.  
For those participants who had CHD, if they reported taking two, three or all four of the 
medications they were labeled as 50-100% compliant and those with CHD who reported taking 
none of the four medications were labeled 0% compliant.  
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The main independent variable for all three analyses is dementia status. Given the 
different focus in each research question, dementia status and the interaction variables between 
dementia status and age was measured differently in each analysis.  Independent variables were 
selected for the multivariable analyses based on their theoretical relevance, their statistical 
properties (significance and confounding) and by using the Eddy framework for medical decision 
making (Eddy, 1990) and the Andersen Behavioral Model of Health Services Use (Andersen, 
1995) as guides. 
 Descriptive, bivariate, and multivariable analytic techniques were used in this 
research.  Analyses for three empirical research questions generally proceeded in the following 
stages: (1) inspection of the data, (2) descriptive analyses, (3) bivariate and confounding 
analyses, (4) multivariable analyses, and (5) post estimation parameter tests and model 
predictions.  To investigate the relationships among dementia and use of chemoprophylaxis, we 
first examined bivariate associations between all predisposing, enabling and care need covariates 
and each sub-class of chemoprophylaxis and the two compliance measures (0% and 50%-100%) 
and calculated unadjusted odds ratios (OR) for each pair. To better understand the specific role 
of certain covariates as confounders for the association between dementia status and use of 
chemoprophylaxis, we examined the unadjusted odds ratio of chemoprophylaxis for each 
covariate, the change in the odds ratios after adjusting for dementia status, and the fully adjusted 
odds ratios controlling for the remaining covariates that demonstrated a significant association 
with use of chemoprophylaxis (p value ≤<0.10) in bivariate analysis and covariates that were 
forced into the model based on theoretical significance.   All analyses were performed using 
Stata/SE, version 10 (Statacorp 2006). Table 3.2 presents the dissertations research questions, 
hypotheses, rationale and associated analytical approach.   
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Table 3.2: Research questions, hypotheses, rationale and analytic strategy 
Research Question Hypotheses Rationale Analytic Strategy 
Q1: Are Medicare beneficiaries with 
dementia and CHDa less likely to 
report use of evidence-based 
chemoprophylaxis for CHD compared 
to those with CHD but without 
dementia? 
 
 
Medicare beneficiaries who have 
dementia and CHD will have lower 
rates of chemoprophylaxis for CHD 
than their non-demented peers. 
 
When physicians make treatment 
decisions they will be less likely to 
follow evidence-based guidelines for 
people who have dementia because 
(1) CHD guidelines do not address 
how to treat patients with a limited life 
expectancy due to dementia; (2) 
value judgments about decreased 
quality and lessened social worth will 
make treating co-morbidities a lower 
priority and make them less likely to 
offer treatment. 
Longitudinal panel analysis of 
subjects with CHD.  The model uses 
10 years of data and compares 
dementia status with use of 
chemoprophylaxis. Weighted GEEb 
models for ACEic, βBd, LLe, and APf 
drugs and 0% and 50-100% 
compliance.  Assessment of the 
significance of the beta standardized 
coefficients and odds ratios with 
supplementary graphical 
presentations.  
Q2: Are Medicare beneficiaries who 
develop dementia first then develop 
CHD less likely to report using 
evidence-based chemoprophylaxis for 
CHD compared to those who develop 
CHD first then develop dementia? 
Medicare beneficiaries who develop 
dementia before CHD are less likely 
to take secondary preventive 
medications because (1) it is easier to 
not start a medication than to stop 
one that has already been started and 
(2) their dementia will be more severe 
at the time of CHD onset. 
The ordering of the disease 
development matters in medical 
decision -making given that 
physicians and families find it harder 
to stop a treatment for a preexisting 
disease than they do initiating a new 
treatment for a new disease, 
especially for low burden, low risk 
treatments like chemoprophylaxis. 
Longitudinal panel analysis of 
subjects with CHD that includes the 
timing of disease onset. The model 
uses 10 years of data and compares 
the time of dementia onset with use of 
chemoprophylaxis. Weighted GEE 
models for ACEi, βB, LL, and AP 
drugs and 0% and 50-100% 
compliance that adjust for timing of 
dementia onset, presence of 
dementia at baseline, and within 
subject correlation. 
Q3: Are Medicare beneficiaries who 
develop CHD first more likely to 
discontinue evidence-based 
chemoprophylaxis for CHD after they 
develop dementia? 
The rate of chemoprophylaxis will be 
higher for Medicare beneficiaries who 
develop CHD before dementia, but 
discontinuation of evidence-based 
chemoprophylaxis will occur as their 
number of years with dementia 
increases and cognitive function 
declines. 
 
It is easier for physician to not start a 
treatment (a passive act of omission) 
for someone with a life-limiting illness 
such as dementia than it is to stop a 
treatment (active act of commission) 
given that the later requires explicit 
conversions about the patient’s 
terminal status and futility of 
chemoprophylaxis.   
Longitudinal panel analysis of only 
subjects who develop CHD before 
dementia. The model uses 10 years 
of data and compares discontinuation 
of chemoprophylaxis among subjects 
who develop CHD before dementia 
using the number of years with 
dementia as the independent 
variable.  Weighted GEE models for 
ACEi, βB, LL, and AP drugs. 
Assessment of the significance of the 
beta standardized coefficients and 
odds ratios with supplementary 
graphical presentations. 
Abbreviations: CHD, Coronary Heart Disease; GEE, Generalized estimating equations; ACEi, Angiotensin- Converting Enzyme Inhibitors (ACE inhibitors); βB, Beta-blockers; LL, HMG0CoA 
Reductase Inhibitors (lipid-lowering drugs); AP, aspirin and other anti-platelet drugs. 
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3.4 DATA PREPARATION 
This section describes the steps used to prepare the CHS data prior to analysis.  Primarily this 
involved reviewing the data that was available from the CHS, preparing a proposal and data 
request form and submitting it to the CHS Coordinating Center, inspecting the structure of the 
data as well as the collection tools and instruments used to collect the data. All of the primary 
independent variables were created from the original CHS database while some existing 
variables were recoded, such as race, education, insurance status and income. For example, date 
of dementia onset was provided in the original CHS file, and the binary dementia status variable 
measuring dementia each year (yes or no) was crated from the date of onset variable. 
Preparing the data involved becoming familiar with the technical language of the study, 
studying the details of the CHS and CHS-CS sampling, reviewing all data and the corresponding 
codebook, and reviewing the levels of measurement for each potential variable. All original data 
were provided by the CHS Coordinating Center in a “wide file”, meaning that each record, or 
row in the dataset contained all years of data of the information about an observation. For 
example, questions 1 and 2 in Table 3.3 were asked of every participant in each year in the study.  
In the original wide file, there was one row per study participant and that question was coded 
MIY2, NEWMIY3, NEWMIY4…….,NEWMIY11.  
After review of all potential variables, relevant variables for the analyses were identified 
and converted to a “long file.” Converting the wide data file to a long file created a single row 
for each observation for each year in the study so there is one observation per unit for each time 
period in the study. 
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Table 3.3: Sample questions  from the CHS annual medical history form 
Selected Medical History Questions Selected Medication Use Questions 
MIY2  
Has a Dr. ever told you that you had a MI or 
myocardial infarction?  
 
NEWMIY3-11 
Since we saw you last year, has your doctor told 
you that you have had an MI or myocardial 
infarction? 
 
ANGY2 
Has a doctor ever told you that you had angina? 
 
NEWANGY3-11 
Since we saw you last year, has your doctor told 
you that you have had angina? 
 
ASPRY2-11 
Have you taken aspirin in the last 2 weeks? 
 
      DAYASPY2-11 
       If yes, on how many days? 
 
 
 
CHS provided a codebook with the dataset and most survey instruments used to collect 
the data were accessible online. None of the variables used in the analyses were affected by skip 
patterns in the instruments, but given the number of years data was collected and the advanced 
age of the cohort, missing data were examined to ensure that it was random or due to death or 
drop out of the study. No deaths occurred prior to study year 5 (1992) and by study year 11 
(1999) 21% of the sample was dead. 
3.5 MEASURES 
As described in Chapter 2, conceptual models for evidence-based medical decision-making 
(Eddy, 1990) and to predict the use of health services among individuals (Andersen, 1995) were 
used in this research. Elements of these models guided the organization of the literature review 
and the selection of variables for the analyses.  
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3.5.1 Dependent variables 
The Eddy model of medical decision-making consists of two main steps. The first step involves 
the processes of gathering and analyzing available evidence about the possible outcomes that are 
associated with different treatments. The four guideline-recommended medications and measures 
of compliance of these medications that are the dependent variables in this research represent the 
best available evidence for the medical management for the secondary prevention of CHD 
(Ryan, 1996).  
3.5.1.1 Guideline-recommended chemoprophylaxis for CHD  
The dependent variables include self-reported use of ACE inhibitors, beta-blockers, lipid-
lowering medications, antiplatelet medications. While each drug has their own contraindications, 
none are contraindicated based on the cognitive status of the patients. Table 3.4 presents 
descriptive statistics for study years 5-11 for all participants in the CHS-CS with CHD and their 
use of chemoprophylaxis.  All years can be found in Appendix B. 
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Table 3.4: Unadjusted use of chemoprophylaxis among participants with CHD, No. (%) 
 
Dependent Variable 
Study 
Year 5 
Study 
Year 6 
Study 
Year 7 
Study 
Year 8 
Study 
Year 9 
Study 
Year 10 
Study 
Year 11 
 
ACE inhibitors 
110 
(15) 
120 
(16) 
138 
(18) 
151 
(20) 
151 
(21) 
175 
(24) 
181 
(24) 
 
Beta-blockers  
185 
(26) 
197 
(26) 
207 
(27) 
203 
(27) 
213 
(29) 
239 
(32) 
256 
(35) 
 
Lipid-lowering medications 
84 
(12) 
107 
(14) 
113 
(15) 
125 
(17) 
146 
(20) 
181 
(24) 
206 
(28) 
 
Anti-platelet medications 
445 
(62) 
457 
(62) 
475 
(63) 
455 
(62) 
419 
(59) 
443 
(62) 
445 
(65) 
Abbreviations: CHS-CS, Cardiovascular Health Study-Cognition Sample; ACE Inhibitors, Angiotensin- 
Converting Enzyme Inhibitors 
 
For purposes of the analyses, all dependent variables were dichotomized and expressed as 
taking the drug (1) or not taking the drug (0) in each study year or as compliance (0% yes or no 
or 50-100% yes or no).  The CHS medication data is based on participant self-report.  CHS data 
did not include prescriptions (unless part of the hospital record) or outpatient medical records 
that may have included prescription information.  These methods of measurement raise two 
study limitations. The first is that use of chemoprophylaxis is based on participant self-report not 
what was actually prescribed to them by a physician.  Studies have reported that older patients 
adherence to prescription medications may range from only 26% to 59% (Cooper, 1982; Col, 
1990). Given this, the data used in this study may underrepresent rates at which physician 
prescribe guideline -recommended chemoprophylaxis for CHD.  
Second, any medication reported by the participant would have been prescribed by a 
physician in the community, and we were unable to assess or control for the community 
physician’s knowledge about the patient’s cognitive status.  There is likely a disconnect between 
the community physician’s awareness of the patient’s cognitive status vs. the documentation of 
dementia in the CHS study given their focus on dementia and detailed diagnostic procedures. For 
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patients with mild dementia, cognitive status may have little to no effect on physician 
prescribing. 
3.5.1.2 Compliance with chemoprophylaxis for CHD  
Two additional dependent variables were created to measure compliance with the four sub-
classes of medications.  These variables were calculated by summing the total number of 
medications reported for each year for all participants with CHD and divided by the total number 
of non-missing medications for that year. For example, a subject would be labeled as 100% 
compliant for a study year if they had CHD in that year and reported taking all four medications 
in that year. The compliance variable was then organized as either 0% compliant (i.e. report 
taking none of the four medications) or 50-100% compliant (i.e. report taking at least two, three 
or all four medications). 
3.5.2 Independent variables 
3.5.2.1 Main independent variables   
Dementia status is the main independent variable for the three empirical analyses.  The analyses 
for the three research questions include different measures of dementia that address three 
different, but connected concepts: binary and categorical measures of dementia status each year 
based on date of onset and cognitive status and decline based on a widely used and validated 
measure over time observed throughout the study. Table 3.5 presents the primary independent 
variables selected for each aim and the alternative specifications that were tested in sensitivity 
analyses for each aim.  
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Table 3.5: Primary and secondary measures of independent variable by study aim 
 
Dementia Status Measures 
 
Study aim 1 
 
Study aim 2 
 
Study aim 3 
Dementia (present in that year)a    
Dementia at baseline b †   
Prevalent Dementia c †   
3MSE Score Less than 80d †  † 
DSST Score Less than 30e †  † 
Dementia before CHD f    
Disease status each year g  †  
    No disease (suppressed category)    
    CHD only    
    Dementia only     
    Both diseases    
Number of years since dementia diagnosis h  †  
 Signifies primary independent variable selected for study aim and † signifies alternative specification tested for each study aim. 
Abbreviations:3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test; CHD, Coronary Heart Disease.  
a Dementia status each year (yes or no) based on adjudicated CHS date of onset (e.g. labeled as having dementia from year of onset until death). 
b Upon entry into the CHS-CS cohort (e.g. dementia baseline year 1989 or 1992). 
c Prevalent dementia (e.g. the CHS-CS retrospective classification based on date of initial study evaluation). 
d 3MSE score of less than 80. The Modified Mini-Mental State Examination (3MSE) is a 100 point questionnaire test used to screen for cognitive 
impairment. The 3MSE samples a range of cognitive abilities from short-term and delayed recall to temporal and spatial orientation. It is used in 
clinical settings to screen for dementia and to estimate the severity of cognitive impairment at a point in time and to follow the course of cognitive 
changes in an individual over time (Teng, 1987). A score of < 80 was selected as a cut point to measure dementia and change in cognitive status 
based on previous research methods used in the CHS-CS (Kuller, 1998; Lopez, 2003). 
e DSST score of less than 30.  The DSST is a measure of attention and speed. In previous CHS-CS studies the Spearman correlation between the 
DSST and the 3MSE at study year 5 was .55. A low digit symbol score was classified as <30 and was selected as a cut point to measure dementia 
and change in cognitive status based on previous research methods used in the CHS-CS (Kuller, 1998; Salthouse, 1978)  
f Sequence of dementia onset in relation to date of CHD onset (e.g. a binary static measure of developing dementia before CHD, yes or no) 
g Disease status each year for CHD and dementia (e.g. a categorical measure that captures a participant’s disease state in each year) 
h The number of years since the CHS-CS date of onset. Year of onset labeled as 1. 
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3.5.2.2 Control variables  
Selection of additional control variables was guided using the Andersen Behavioral Model of 
Health Services Use (Andersen, 1995). This conceptual model framework consists of three 
central constructs: predisposing, enabling, and need-for-care or factors that predict the use of 
health services.  
Predisposing variables are characteristics of the patient that contribute to the propensity 
to use health services. These include demographic characteristics, social structure variables, and 
attitudes and beliefs about health. The predisposing variables included in this research include: 
age, sex, race, and level of education. 
Consistent with the majority of published research using CHS data, the race variable was 
coded as white (1) and non-white (0). Different of functional forms (age2, age3, etc.) of the age 
variable were reviewed, as well as the continuous age variable and creating different cut points 
for age (See section 3.7.1 for more details).  For the analyses, the age variable was centered on 
the mean age of the sample for each year.  Centering on the mean subtracts the mean value from 
all of the age data points and shifts the scale of a variable to adjust for multicolinearity.  The 
education status variable was dichotomized as high school or less (1) or more than high school 
(0).  Some research has noted that level of education is an important variable to include when 
investigating the effect of cognitive impairment since it has been documented that higher rates of 
dementia have been found among people who have lower levels of education. It has been noted 
that these findings may be a result of their lower cognitive status throughout life and poor 
performance on cognitive status measures such as the 3MSE and DSST (Fitzpatrick, 2004).   
As defined by the Andersen model, enabling variables are conditions that permit an 
individual to use health services. In most health services research, insurance status or other 
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“access to care” measures are included as enabling variables. The four enabling variables used in 
this research include supplementary insurance, income, CHS study site, and residence in a 
nursing home. 
Access to care is not a major predictor for this research since all participants (as defined 
by CHS recruitment eligibly) had Medicare as their primary health insurance for both inpatient 
and outpatient medical care.  Additionally, the data was collected before the enactment of 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Medicare Part D), 
so there was no uniform insurance that was available for Medicare beneficiaries that covered 
prescription medications.  Nonetheless, some participants may possess supplementary insurance 
coverage that they purchased, have as part of a retirement package, or qualify for based on 
income (Medicaid) that could include some coverage of prescription drugs.  Two different 
measures of supplemental insurance were tested in the models: (1) a categorical variable that 
measures type of supplemental insurance in each year that the data was collected (study years 6-
7 and study years 9-11) and (2) a dichotomous variable that measures if a participant ever had a 
form of supplemental insurance (private, Medicaid, other) or was ever without supplemental 
insurance.  Selection of which insurance variable to include in the multivariable model was 
based on results of the bivariate analyses and the effect of missing data on the model since the 
insurance information was only collected in five of the ten study years.  
Income was included as an enabling variable despite the fact that the effect as a predictor 
was minimized due to the low cost of the medications examined in this research. We believe it is 
important to test in the full model since other research has demonstrated income as a predictor of 
medication compliance in the elderly (Balkrithnan, 1998), especially prior to Medicare Part D.  
Income was coded as a “1” if a participants annual income was $24,999 or below and “0” if 
 90 
$25,000 or higher. These cut points were based on data from the Census Bureau’s annual Current 
Population Survey (CPS) that showed the mean household income for Medicare beneficiaries in 
1996 (CHS study year 8) was $29, 280 although the median was significantly lower at $19,448 
(US Census Bureau, 2009).  
CHS was a national multi-center study with four locations.  Study site was included in the 
models to control for variation in sampling and to serve as a proxy for geographic variation of 
prescribing patterns since the four sites represent different regions of the US (Forsyth County, 
North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh, 
Pennsylvania) and studies have found geographic variation in use of chemoprophylaxis for CHD 
(Krumholtz, 1998). 
The final enabling variable included in the multivariable models measures residence in a 
nursing home.  Living in a nursing home, in each year, was coded as a binary variable “1” for 
yes and “0” for no.  This variable is important for two reasons.  First, residence in a nursing 
home is correlated with severity of dementia. Second, participants in a nursing home have their 
medications managed by the nursing home staff. This management includes getting the 
medication prescribed, getting the medication paid for (source varies), and administering the 
medication to the resident.  It is likely that any disconnect (as a result of the study design 
limitations) between what is prescribed and what a participant reports taking is eliminated for 
those participants in a nursing home.   
Care need variables are arguably the most important predictors of use of health services 
for patients with dementia and include both the patient’s perception of their illness and quality of 
life as well as objective measures of functional and cognitive status.  The CHS data did not 
include patient self reported quality of life or their beliefs about their illness. Care need or illness 
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level variables that were available and included in the multivariable models are dementia status 
(measured differently for each study aim), activities of daily living, hypertension, diabetes, and 
kidney disease. 
Activities of daily living (ADLs) refer to the basic tasks of everyday life, such as eating, 
bathing, dressing, toileting, and ambulating. In the CHS data, ADLs are measured on a scale 
from 0 (no assistance with ADLs) to 6 (severe physical disability and requires full assistance 
with ADLs). 
There are a number of health conditions, some of which are comorbid with CHD, that 
could increase the likelihood of a person using chemoprophylaxis for CHD.  Each model 
controlled for these clinical factors including: history of hypertension, diabetes, or kidney 
disease, or cancer.  For the antiplatelet and compliance models, any form of arthritis was also 
included since aspirin (one of the antiplatelt medications) is a common medication used to treat 
the symptoms of arthritis.  
3.5.2.3 Interaction variables 
It is well documented that the likelihood of dementia increases with age (Mitchell, 2009). Given 
this correlation, an interaction variable of age and dementia status was tested for inclusion in 
each model to assess if the causal effect of age on chemoprophylaxis differs by dementia status. 
3.6 RELIABILITY AND VALIDITY OF THE MEASURES 
In general it is difficult for researchers conducting secondary data analyses to perform reliability 
and validly checks on data.  Of the two measurement properties, the evidence for validity is 
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generally weaker and more controversial for secondary data (Carmines, 1979). The CHS data 
were collected in a variety of methods over a ten year time period.  Built into the CHS were 
mechanisms to ensure reliability and validity of the data.  As described above, the dependent 
variables in this research, use of chemoprophylaxis for CHD, was collected based on report from 
the subjects. At the annual visits, subjects would bring with them all of their prescriptions and 
the information was recorded by the CHS staff. Data collected regarding medications included 
drug type, name, and dose. 
Measurement error and the associated problems of reliability and validity are concerns of 
researchers using secondary data (Carmines, 1979). While few studies have addressed 
measurement issues regarding prescription drug use and older persons with dementia, the general 
consensus in the literature is that self-report health data from community dwelling older adults is 
an acceptably reliable and valid method of measuring prescription drug use (Lubeck, 2005).  
The data for the independent variables used in this dissertation were collected using a 
combination of methods. Some variables, such as the predisposing variables sex, race, date of 
birth, and highest level of education achieved were self-reported survey data collected at entry 
into the study, while other clinical variables, such as hypertension, diabetes and renal 
insufficiency were asked each year and documented based on participant self-report and then 
adjudicated by the CHS through confirmation from treating physicians or from hospital 
discharge summaries.  
The measures for dementia status were created using CHS-CS dates of onset and 
classifications that have been published by Lopez (2003) and described in Section 3.2.  An 
important feature of the CHS-CS coded data regarding dementia is that the study used MRI 
neuroimagining and scores from cognitive performance instruments (3MSE, DSST, IQ CODE) 
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administered from 1991-1994 to determine the date of onset. Participants coded as having 
prevalent dementia, the actual onset of dementia could have been anytime from before the study 
started to up and including 1994, the final year of assessments to determine prevalence.   Using 
this measure of dementia status does not allow the accurate incorporation of time of onset into 
the model so it was not used as a primary impendent variable, but was tested in the sensitivity 
analysis for aim 1. 
The CHD variable was created using two clinical indicator variables of CHD, myocardial 
infarction (MI) and angina pectoris. In each year of the study, participants were asked is they had 
a (new) MI or angina.  If they answered positively for either question at the baseline interview 
the study, they were determined to have prevalent or existing CHD.  If they answered yes to 
either question in subsequent years, they were considered to have developed CHD in that study 
year.  CHD status was coded as a binary yes (1) and no (0) variable with the year of development 
initiating the change. For example, if a participant did not have angina or an MI in study years 2-
4, but developed angina in study year 5, the CHD variable for that participant would be coded as 
0,0,0,1,1,1,1,1,1,1 in study years 2-11. 
3.7 MULTIVARIABLE MODELING 
3.7.1 Model specification and functional form 
The greatest assets of longitudinal data are the stories that can be told about how a population 
changes over time and the possibility to distinguish key types of causality between the variables.  
Until fairly recently, researchers using longitudinal data have been limited in their strategies for 
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creating a model for analysis given the lack of random distribution of longitudinal data.  
Researchers were often forced to transform the dependent variable or use other methods of 
aggregating the dependent variable to approximate normality prior to analysis.  
 Creating the most appropriate model using longitudinal data and variables that are 
correlated within subjects can be a challenge. Failing to take into account correlated longitudinal 
data can lead to incorrect estimations of the model parameters.  For example, in the CHS-CS 
data, participants’ positive use of beta-blockers in study year 2 is highly correlated with their 
positive use in year 3 given that this particular medication taken for a chronic condition that 
persists over time. 
Successful model building is part science, part statistical method, part experience and 
theoretical knowledge about the problem.  Variables were selected based on the frameworks by 
Eddy and Andersen and based on their hypothesized impact of receipt of chemoprophylaxis for 
CHD. The goal is to provide a complete set of variables that can explain confounding effects in 
the dataset since some variables alone may not be significant, but taken collectively and 
combined with other variables, confounding could be present. 
This approach initially yielded 8 potential ways to measure the independent variable 
(dementia status) and 19 potential control variables in the constructs described above 
(predisposing, enabling, and care need).  The distribution and potential outliers of each variable 
were reviewed. Given the nature of the longitudinal data, none were excluded based on 
distribution alone.  
The age variable was considered an especially important predictor in this research given 
the epidemiology of dementia and the possible effect that age could have on the ongoing use of 
chemoprophylaxis.  The functional form for age was tested using age2, age3, age cut into 10 
 95 
groups and three groups (≤75, 76 -85, and ≥86), the proportion of the categorized age variable, 
and the age variable centered at the mean of the sample.  Based on univariate analyses and to 
adjust for multicolinearity the age centered on the mean was selected as the primary measure of 
age for all models.   
The level of education variable, while not highly correlated with the dependent variables, 
did not appear to be confounding or a strong predictor based on the bivariate analysis. The 
decision was made to keep that predisposing variable in the full multivariable models given the 
results from other CHS studies that showed level of education as a positive predictor of dementia 
(Fitzpatrick, 2004).   
3.7.2 Choosing a link function and distribution 
The analyses in this dissertation use a binomial distribution and logit link function given that all 
outcome variables have a binary response (i.e. taking an ACE inhibitor “yes or no”).  Using this 
link function allows for the regression equation to make the interval from 0 to 1 and is expressed 
as g(x)=log[μ/(1- μ)] (McCullagh, 1989). 
 
3.7.3 Choosing a correlation structure 
The generalized estimating equation (GEE) approach is becoming more popular in longitudinal 
studies. One reason it is cited as an optimal method is that a GEE models allow the use of a 
working correlation structure that may not be correct, yet the regression coefficients are still 
consistent and asymptotically normal (Pan, 2002). However with time-varying covariates, like 
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those in the CHS data, it is the working correlation matrix that allows GEEs to estimate the best 
models that account for the correlation of responses (Liang 1986). Using the wrong correlation 
structure is inefficient (Fitzmaurice, 1995), may violate an important assumptions in GEE, or 
produce biased estimates (Pan, 2002). Specification of the most accurate form of correlation of 
response within participants is an important process for the GEE model building.  
The variables in these analyses are correlated within participants’ over time. Given this, 
an autoregressive correlation structure was selected since it is specified to set the within-subject 
correlation as an exponential function of the lag period.  In an effort to retain as many of the 
correlations groups as possible, a lag period of 1 year was selected.  The theory behind this 
choice is the assumption that if a person is on a particular sub-class of chemoprophylaxis in t1, 
the likelihood of that person being on the same medication in t1+1 is correlated.  
3.8 MULTIVARIABLE ANALYTIC METHODS 
3.8.1 Generalized Estimating Equations 
This dissertation uses longitudinal panel data with repeated measures that are correlated within a 
participant over time.  To avoid making incorrect conclusions about the data and incorrect 
inferences about the regression coefficients, each analysis takes into account correlation within 
repeated observations on the same participant.  Fitzmaurice (1995) demonstrated that when faced 
with an independent variable that varies within a cluster (i.e. a time-dependent covariate in a 
longitudinal study), the efficiency of estimators declines with increasing correlation.  
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Additionally Fitzmaurice found that the errors are particularly large for cases in which the 
correlation within subject is highly positive or highly negative. 
Efficiency in the estimators was a major concern when preparing the data for analysis for 
this dissertation. It was determined that a repeated measures ANOVA approach to the problem 
was inadequate because it does not use a model of the covariates among related observations to 
increase the efficiency of the parameter estimates, which normally requires a balanced and 
complete data set that has normally distributed response variables.   
The generalized estimating equation (GEE) approach was selected based on the correlated, 
repeated measures of participants and the binary dependent variables. GEEs were developed by 
Liang and Zeger (1986) and Zeger and Liang (1986) as a means of testing hypotheses regarding 
the influences of factors on binary and other exponentially distributed response variables 
correlated within participants across time.  A GEE analysis produces marginal or “population 
averaged” estimates of effect . Estimates from this model are the log odds ratios of the 
population averaged effects of treatment. GEEs model the average value of the outcome variable 
for each subset of participants who share the same value of the predictor variable. They are an 
extension of Generalized Linear Models (GLM), which facilitates regression analyses on 
dependent variables that are not normally distributed (McCulloch, 2001; Nelder, 1972).  GEE 
also allows the researcher to specify a within-person correlation structure to account for within-
person correlations in the outcome variable over time. For every one-unit increase in the 
covariate across the population, the GEE model provides results of how much the average 
response would change (Zeger, 1988; Zorn, 2001). 
 98 
3.8.2 Analytic strategy 
Descriptive and univariate analyses were conducted for each dependent variable. Descriptive and 
bivariate analyses were conducted for each independent, control, and interaction variable within 
the three constructs (predisposing, enabling and care need).  To better understand the specific 
role of certain covariates as confounders for the association between dementia status and use of 
chemoprophylaxis, we examined the unadjusted odds ratio of chemoprophylaxis for each 
covariate, the change in the odds ratios after adjusting for dementia status, and the fully adjusted 
odds ratios controlling for the remaining covariates that demonstrated a significant association 
with use of chemoprophylaxis (p value ≤<0.10) in bivariate analysis and covariates that were 
forced into the model based on theoretical significance.  
Cut points for binary variables were reviewed and the continuous variables were 
reviewed to ensure the correct scale. Next, the models were reviewed for possible relevant 
interactions (e.g. dementia and age).  Only the independent and interaction variables differ in the 
full multivariate models for each research aim.  All dependent and control variables are the same 
for each full multivariable model across each aim.  
The initial inspection of the data revealed that because of two waves of CHS recruiting 
(1989 and 1992), subjects in each cohort were not equally contributing to the population 
averaged results. Sampling weights were created for each subject for each year based on the 
probability of each subject being missing for both cohorts.  Sampling weights are needed to 
correct for imperfections in the sample that might lead to bias and inaccurate parameter estimates 
and to compensate for unequal probabilities of selection. 
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3.9 SENSITIVITY ANALYSES 
Two types of sensitivity analyses was co were conducted.  The first compares the results from 
the final models that used the auto regressive correlation structure with those using an 
exchangeable correlation structure. The results for the final models using the exchangeable 
correlation structure are reported in Appendix C. As expected, we did not find any difference 
between the results from the two types of correlation structures.  
 The second sensitivity analyses include comparing the result for the full and final 
models with alternative measures of dementia status for each study aim.  Appendices F, G and H 
present the results for the full and final models. 
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4.0  RESULTS 
The empirical research conducted for this dissertation specifically tests the hypothesis that the 
rates of use of evidence-based chemoprophylaxis for CHD is different in patients with dementia 
compared to those who do not have dementia.  The methodology employed is a secondary data 
analysis of a longitudinal dataset that was originally collected as part of the Cardiovascular 
Health Study (CHS) to study risk factors for the development and progression of CHD. Detailed 
information on cognitive status was also collected in CHS and adjudicated and analyzed as part 
of the ancillary Cardiovascular Health Study-Cognition Study (CHS-CS). Chapter 4 presents the 
results of the research and is organized according to the three study aims as outlined in Table 3.2.  
Section 4.1 presents general descriptive data. Sections 4.2 and 4.3 present the results of the 
bivariate and multivariate analyses, respectively. Each section is organized by study aim and 
then by the results for each dependent variable (self-reported use of ACE inhibitors, beta-
blockers, lipid-lowering medications, antiplatelet medications, and compliance with 
medications).  
4.1 DESCRIPTIVE STATISTICS 
Descriptive statistics were calculated on all study variables. A total of 1087 participants in the 
CHS-CS cohort developed CHD during the study period, making them eligible for guideline-
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recommended secondary chemoprophylaxis for CHD. Of those, 973 (89.5%) were enrolled as 
the first cohort in 1989-90 and the additional 114 (10.5%), predominately African American 
participants, were enrolled as a second cohort in 1992-93. This dissertation uses ten years of data 
and adjusts for the delayed entry of the second cohort with sampling weights. Section 4.1.1 
presents the descriptive statistics of the sample. 
4.1.1 Independent variables 
At the baseline year, the mean age of the sample is 72.9 years (SD=5.05). In study year 5 
(baseline year for the second cohort) the mean age is 75.6 years (SD=5.21). By the end of the 
study (1999) 21.2% of the sample died. Gender is evenly split between male (52.5 %) and female 
(47.8%). Race is predominantly white (928 white; 157 black; 2 other).  The mean level of 
education was 13. 9 years (SD=4.6) with 57% of sample achieving a high school or higher levels 
of education. Income levels ranged from 5% reporting under $5,000 per year to 13% reporting 
$50,000 or more in annual income.  Sixty-three percent of the sample reported an annual income 
level of $24,999 or below. Information of supplemental insurance to Medicare is variable for 
study years 6, 7, 9, 10, and 11 only. In study year 6, 69% have private supplemental insurance, 
5% Medicaid, 13% report some other form of supplemental health insurance, and 7% report no 
insurance to supplement their Medicare coverage. Descriptive statistics, by dementia status, for 
study year 2 (1989), year 5 (1992; the first year of the second cohort), and year 11 (1999) are 
presented in Table 4.1.  
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Table 4.1: Sociodemographics by dementia status by year 
 
 
1989 (N=973) 1992 (N=1087) 1999 (N=862) 
 
 
 
Variable n (%) 
Participants 
without 
Dementia 
(n=948) 
Participants 
with 
Dementia 
(n=25) 
Participants  
without  
Dementia 
(n=1005) 
Participants 
with 
Dementia 
(n=82) 
Participants 
without 
Dementia 
(n=672) 
Participants 
with 
Dementia 
(n=190) 
Age, y,        
    ≤75 680 (72) 7 (28) 562 (55) 25 (30) 76 (11) 7 (4) 
    76-85 257 (27) 12 (48) 408 (41) 44 (54) 447 (67) 89 (47) 
    86-95 11 (0.1) 6 (24) 26 (3) 12 (14) 92 (14) 59 (31) 
    ≥96 0 0 9 (1) 1 (2) 56 (8) 35 (18) 
Sex       
    Male 517 (55) 18 (72) 517 (51) 50 (61) 335 (50) 89 (47) 
    Female 431 (45) 7 (28) 488 (49) 32 (39) 337 (50) 101 (53) 
Race       
    White 905 (95) 23 (92) 873 (87) 55 (67) 582 (87) 143 (75) 
    Other 43 (5) 2 (8) 132 (13) 27 (33) 90 (13) 47 (25) 
Educational Level       
    High school or less 116 (12) 8 (32) 112 (11) 28 (34) 62 (9) 37 (19) 
    More than high school 831 (88) 16 (64) 891 (89) 53 (64) 609 (91) 153 (81) 
Annual income       
    ≤$24,999 535 (56) 16 (64) 582 (58) 57 (70) 379 (56) 128 (67) 
    >$25,000 335 (44) 4 (16) 368 (37) 14 (17) 258 (38) 46 (24) 
Secondary Insurance       
    Private  NC NC NC NC 313 (38) 65 (34) 
    Medicaid NC NC NC NC 30 (4) 9 (5) 
    Other (VA, etc) NC NC NC NC 189 (28) 22 (12) 
    None NC NC NC NC 36 (5) 19 (10) 
ADL score, mean (SD) 0.09(.38) 0.16(.47) 0.17(.56) 0.5(1.13) 0.41(.93) 1.63(2.03) 
Abbreviations: NC, Not collected in this study year; ADL, Activities of daily living. 
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Investigating the effect of dementia on the use of chemoprophylaxis for CHD is the main 
empirical question in this research. To be included in the study sample, subjects had to be 
eligible for secondary chemoprevention for CHD sometime before or during 1999. While 100% 
of the sample developed CHD by 1999, subjects’ status could vary each year among the 
following four categories: no CHD and no dementia, dementia only, CHD only, both dementia 
and CHD, or death.  For example, during study year 5 (1992) 30.5% had no disease, 2.3% of the 
sample had dementia only, 62% had CHD only, and 5.2% had both diseases. By study year 11 
(1999), 61.4% developed CHD, 17.3% developed both CHD and dementia, and 21.2% were 
dead. Figure 4.1 presents the distribution of disease states for each study year. 
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Figure 4.1: Disease states by year. 
Study Year 
Died Dementia and CHD Dementia CHD No Disease 
2 
1989-1990 
3 
1990-1991 
4 
1991-1992 
5 
1992-1993 
6 
1993-1994 
7 
1994-1995 
8 
1995-1996 
9 
1996-1997 
10 
1997-1998 
11 
1998-1999 
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4.1.2 Dependent variables 
The dependent variables for this study include four sub-classes of guideline-recommended 
chemoprophylaxis for CHD and two variables that measure compliance with chemoprophylaxis.  
Unadjusted rates of use of guideline-recommended chemoprophylaxis for CHD for 
representative years are presented in Table 4.2. Unadjusted rates show that there are differences 
in use and compliance for those with dementia compared to those without dementia. In earlier 
study years, participants with dementia were more likely to report taking ACE inhibitors and 
antiplatelet medications. In later years as the cohort ages, those with dementia are less likely to 
report taking any of the four classes of medication and are more likely to be non-compliant with 
all four classes of medication.  
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Table 4.2: Unadjusted use of chemoprophylaxis for CHD by dementia status in three representative study years, No.(%)  
 1989 1992 1999 
 
 
VARIABLE 
 
Participants 
without 
Dementia 
(n=948) 
Participants 
with 
Dementia 
(n=25) 
Participants 
without 
Dementia 
(n=1005) 
Participants 
with 
Dementia 
(n=82) 
Participants 
without 
Dementia 
(n=672) 
Participants 
with 
Dementia 
(n=190) 
ACE Inhibitors 62 (6.5) 3 (12) 131(13) 15 (18.3) 146 (21.7) 35 (18.4) 
Beta-blockers 212 (22.3) 4 (16) 221(22) 8 (9.7) 220 (32.7) 36 (18.9) 
Lipid-lowering medications a 65 (6.8) 1 (4) 102 (10.1) 3 (3.6) 184 (27.3) 22 (11.5) 
Any antiplatelet medication b 421 (44.4) 15 (60) 527 (52.4) 39 (47.5) 373 (55.5) 72 (37.9) 
0% compliant with chemoprophylaxis 378 (39.8) 8 (32) 319 (31.7) 32 (39) 88 (13.1) 40 (21) 
50-100% compliant with chemoprophylaxis 168 (17.7) 6 (24) 266 (26.4) 15 (18.2) 300 (44.6) 50 (26.3) 
Abbreviations: CHD, Coronary Heart Disease; ACE inhibitors, Angiotensin- Converting Enzyme Inhibitors. 
a HMG0CoA Reductase Inhibitors 
b Aspirin and other anti-platelet drugs 
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4.2 BIVARIATE RESULTS 
The following section describes the first step of the model building process and results of the 
bivariate analyses, by study aim. For each study aim, the main independent variable, dementia 
status, could be measured a variety of ways. Tables 4.3, 4.5, and 4.7 present the results of 
possible specifications of dementia status for each aim.  
Using the sampling weights that were created for each subject for each year based on the 
probability of each subject being missing for both cohorts, weighted and non-weighted bivariate 
analyses were conducted for the all variables. Variables that were significant predictors at p≤0.1 
on the weighted bivariate analyses were retained for inclusion in the full multivariable model as 
were those that were not statistically significant, but important to the model based on theory and 
previous findings from the literature.  Variables that were not significant predictors in the 
bivariate analyses, but were found to be confounding variables that produced a >10% change in 
the beta coefficients were included in the full models. All bivariate analyses were performed 
using STATA software version 10.  Tables 4.4, 4.6, and 4.8 include the weighted bivariate 
results for study aims 1, 2 and 3, respectively. Appendix E contains results of the non-weighted 
bivariate analyses for each study aim.   
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4.2.1 Aim 1 
4.2.1.1 Main independent variable  
Study aim1 tests if Medicare beneficiaries with dementia and CHD less likely to take evidence-
based chemoprophylaxis for CHD compared to those with CHD but without dementia. The 
analytical model uses ten years of longitudinal data on subjects (n=1087) who have CHD at entry 
or who develop it sometime during the study, and compares the subjects’ use of 
chemoprophylaxis dependent on their dementia status. 
For study aim 1, time of dementia onset as it relates to the onset of CHD, is not controlled 
for in the model. Potential specifications of how to measure dementia status for this aim include:  
(1) the clinically adjudicated date of onset determined by the CHS study, (2) the presence of 
dementia at baseline based on date of onset and year of entry into the study, (3) prevalent 
dementia (the static CHS determination of prevalence that spans the first three years of entry for 
each cohort), or (4) cognitive scores based on the 3MSE scores and (5) DSST scores. All 
possible specifications of dementia status were tested independently with each dependent 
variable with and without the sampling weights.  Table 4.3 shows the results of the unadjusted, 
weighted bivariate GEE models for all possible specifications of dementia status for study aim 1. 
Appendix D.1 presents the non-weighted results.  
 
Results from the weighted bivariate analyses do not yield that one consistent measure of 
dementia status is stronger at predicting the use of chemoprophylaxis. The CHS determination of 
prevalent dementia is a significant predictor for three of the six dependent variables (lipid-
lowering medications, antiplatelet medications, and 50-100% compliance). A limitation of using 
this measure in the multivariable models is that it is a static variable that includes only those who 
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were determined by CHS to have dementia at entry into the study and does not accurately 
represent each subject’s dementia status for each year or account for those in the sample who 
developed dementia during the study. Given this limitation and a lack of consistent statistical 
significance for any other measure, the choice of the primary measure of dementia status was 
made based on the strongest measure that matches the research question. The model for study 
aim 1 is testing whether those with dementia at any time in the study are less likely to use 
chemoprophylaxis than those without dementia.  The dependent variable that captures “dementia 
status each year” (dementia present in that year) was selected as the primary independent 
variable for aim 1 because it accounts for dementia status each year, not just at entry, and is 
based on the clinically adjudicated date of onset.  Sensitivity analyses for study aim 1 include a 
test of all alternative specifications full and final multivariable models.  
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Table 4.3: Results of weighted bivariate analyses for all possible specifications of dementia status for study aim 1 
 
 
 
Dementia Measure 
 
 
ACE 
Inhibitors 
 
 
Beta-
blockers 
 
Lipid- 
Lowering 
Medications 
 
 
Antiplatelet 
Medications 
 
 
0% 
Compliance 
 
 
50-100% 
Compliance 
       
    Dementia (present in that year)† NS NS *(negative) NS NS NS 
    Dementia at baseline NS NS **(negative) NS NS *(negative) 
    Prevalent Dementia NS NS ***(negative) *(negative) NS *(negative) 
    3MSE Score Less than 80 NS NS **(negative) NS NS *(negative) 
    DSST Score Less than 30 NS NS NS NS NS NS 
† Primary independent variable   
Abbreviations: NS, not significant;3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test.  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.2.1.2 Control variables   
The predisposing variables, as defined by the Andersen model, that were tested bivariately in 
both a weighted and non-weighted model include age, sex, race, and level of education.  For 
some predisposing variables, such as age and education level, different log forms and alternative 
specifications were also analyzed to test the best functional form.  
Participant age, when measured continuously centered at the mean, was significant for 
only antiplatelet medications at p<0.1 indicating that older subjects were less likely to report 
taking an antiplatelet medication. For both compliance variables age was significant at p<0.05 
indicating that older patients were more likely to be 0% compliant with all four medications and 
younger subjects were more likely to be 50-100% compliant with all four medications.  
Categories of age were also tested bivariately. For all chemoprophylaxis, with the 
exception of beta-blockers, those aged ≥86 were less likely to report taking chemoprophylaxis 
and are the most likely to be 0% compliant with any of the four medications. 
The bivariate results for sex match those for age in that it was only a significant predictor 
for use of antiplatelet medications. Female subjects were 0.03 times as likely to report taking an 
antiplatelet medication (p≤0.05).  
Race was a statistically significant predictor at p<0.1 for all medications, except for beta-
blockers. Whites were more likely to report taking ACE inhibitors, lipid-lowering medications, 
and antiplatelet medications. The compliance variables confirmed this finding in that non-whites 
were more likely to report not taking any medications (0% compliant) and whites were more 
likely to report being compliant with at least two, three, or all four medications (p≤0.01). 
Level of education was tested as both a binary variable (less than high school) and as a 
categorical variable (less than high school, high school, more than high school). In the 
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unadjusted bivariate analyses, education was not a significant predictor of use for any of the four 
chemoprophylaxis or with the two compliance variables.   
Three control variables that are included which are considered enabling variables, based 
on the Andersen model, include income, insurance status and nursing home residence. Income 
was only a slightly significant predictor for ACE inhibitors, but statistically significant for lipid-
lowering medications among subjects with an income of less than $24,999 per year (p<0.01). 
Presence of supplementary insurance (to Medicare) was tested in two different ways: (1) as a 
categorical variable measuring supplemental insurance status each year and (2) as a binary 
variable measuring if a subject ever had a form of supplemental insurance. Insurance status was 
only collected in study year 6, 7, 9, 10, and 11, resulting in missing data for the other years.  
Including this variable in the GEE models dropped the number of analyzable observations by 
half, so it was not included in any of the full or final multivariable models.  The binary measure 
of insurance status measured if a subject ever had a type of secondary insurance. Ever having 
private insurance was the only significant predictor at p≤0.1 for antiplatelet medications.  People 
living in a nursing home are 2.4 times as likely to report taking an ACE inhibitor, but are only 
0.70 times as likely to report taking a beta-blocker, and 0.58 times as likely to report taking a 
lipid-lowering medication.  
Control variables for aim 1 that measure comorbidites and the level of care needed 
include activities of daily living (ADLs), history of hypertension, diabetes, kidney disease, or 
ever having a diagnosis of cancer.  Those needing more assistance with ADLs are more likely to 
report taking ACE inhibitors (p≤0.05) and those with hypertension and diabetes are more likely 
to report taking a beta-blocker (p≤0.0001) and lipid-lowering medication (p≤0.01). Table 4.4 
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presents the coefficients and odds ratios (ORs) for the weighted bivariate analyses for each 
dependent variable. Appendix E.1 presents the non-weighted results. 
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Table 4.4: Results of weighted bivariate analyses of chemoprophylaxis for CHD in participants with dementia and CHD 
 
Variable 
 
ACE Inhibitors 
 
Beta-blockers 
Lipid-lowering 
Medications 
 
Antiplatelet Medications 
Predisposing Variables β coefficient OR β coefficient OR β coefficient OR β coefficient OR 
    Dementia (in that year)  0.197 1.21 –0.067 0.93  –0.636* 0.52 –0.178 0.83 
    Dementia at baseline  0.878 0.41 –0.390 0.67   –1.591** 0.20 –0.224 0.79 
    Prevalent dementia   0.041 1.04 –0.518 0.59    –1.593*** 0.20 0.593* 0.04 
    3MSE Score <=80  0.183 1.20 –0.077 0.92    –0.413** 0.66 0.800 0.15 
    DSST Score <=30 –0.106 0.89 –0.133 0.87      –0.154 0.85 0.838 0.15 
    Age centered on the mean –0.003 0.99 –0.013 0.98 –0.001 0.99 0.979 0.14 
    Age categories (≤75) 
        76-85 
 
–0.133 
 
0.87 
 
–0.006 
 
0.99 
 
0.025 
 
1.02 
 
0.936 
 
0.65 
        86-102 –0.522 0.59 0.049 1.05    –1.042*** 0.35 0.647 0.07 
    Age and dementia interaction –0.014 0.98 0.009 1.00 –0.017 0.98 0.993 0.75 
    Study site (North Carolina) –0.229 0.80 0.050 1.05 –0.257 0.77 –0.103 0.90 
        California –0.418 0.65 –0.757 0.46   –0.804** 0.44 –0.166 0.84 
        Maryland –0.259 0.77 –0.416 0.65 –0.121 0.88 –0.309 0.73 
        Pennsylvania  –0.853* 0.42 0.076 1.07    –1.234*** 0.29 –0.306 0.73 
    Race (white)  0.406 1.50 –0.156 0.85   0.512* 1.67 –2.08*** 0.01 
    Gender (male)  0.217 1.24 0.258 1.29 –0.093 0.91 1.43* 0.03 
    Education  (HS or less)  0.125 1.13 0.033 1.03 –0.212 0.80 0.988 0.89 
Enabling Variables         
    Income (<$24,999/year) –0.389 0.67 –0.232 0.79 –0.296 0.74 0.631** 0.01 
    Insurance status (none)         
       Private   0.055 1.05 0.071 1.07  0.163 1.17 0.100 1.10 
       Medicaid –0.099 0 .90 –0.175 0.83 –0.420 0.65 –0.040 0.96 
       Other  0.147 1.15 0.094 1.09  0.198 1.21 0.025 1.02 
    Ever had private insurance   0.387 1.14 0.386 1.47  0.992 2.69 0.399 1.49 
    Ever had Medicaid  –0.037 0.96 –0.476 0.62 –1.691 0.93 –0.279 0.75 
    Ever had other insurance   0.284 1.32 –0.208 0.81 –0.024 0.97 –0.228 0.79 
    Ever without insurance –0.240 0.78 –0.276 0.75 –0.010 0.98 –0.327 0.72 
    Residing in Nursing Home    0.911* 2.48 –0.250*** 0.77     –0.537*** 0.58 0.915 0.90 
Care Need Variables         
    Activities of Daily Living  0.086* 1.09 0.000 1.00 –0.031 0.96 0.902 0.09 
    Hypertension 0.111 1.11 0.124*** 1.13     0.260** 1.29 1.01 0.72 
    Diabetes  0.173* 1.18 –0.120** 0.88  0.155 1.16 1.01 0.80 
    Renal Insufficiency     –0.162 0.85 0.327 1.38 –0.713 0.49 1.06 0.81 
    Ever treated for Cancer       0.236 1.26 0.488 1.63 –0.639 0.52 1.42 0.11 
Abbreviations: 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test; CHD, Coronary Heart Disease. 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.2.2 Aim 2 
4.2.2.1 Main independent variable  
Study aim 2 tests if Medicare beneficiaries who develop dementia first then develop CHD less 
likely to take evidence-based chemoprophylaxis for CHD compared to those who develop CHD 
first then develop dementia. In this aim, the hypothesis is that the timing of disease onset has an 
effect on the use of chemoprophylaxis for CHD.  The sample is limited to participants who 
develop both diseases by the end of the study (n=261) and the tests specifically if developing 
dementia first yields less use of chemoprophylaxis for CHD.  Excluded from the analyses are 
participants who develop dementia and CHD in the same year including those with both diseases 
at baseline. 
Possible measures of dementia status include specifications that model the time of onset 
of each disease. They include: (1) a static binary variable indicating if the year of onset for 
dementia is prior to the year of onset for CHD, (2) a categorical variable that measures disease 
status for both conditions in each study year (i.e. no disease, CHD only, dementia only, both 
diseases). This variable captures the time points in the study when participant become eligible to 
be in different comparison groups in the analysis, (3) the number of years since the dementia 
diagnosis, with year 1 at the year of onset.  Table 4.5 presents the results of the unadjusted 
weighted bivariate analyses for all possible specifications of dementia status for aim 2. Appendix 
D.2 presents the non-weighted results. 
Results from the weighted bivariate analysis indicate that the static binary measure of 
dementia status is a significant predictor for three of the six dependent variables (beta-blockers, 
lipid-lowering medication, and 0% compliance). Additionally, the categorical variable that 
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measures disease state each year is a strong predictor for all outcomes.  Number of years since 
the dementia diagnosis was consistently not a significant predictor. Based on these results, the 
static binary measure of dementia status was selected as the main independent variable for aim 2. 
Additionally, the dynamic categorical variable was selected for inclusion in the multivariate 
model as a way to test any possible differences within the various categories (disease states).  
Included in the sensitivity analysis are all specifications, which were tested independently in the 
full and final models for aim 2. 
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Table 4.5: Results of weighted bivariate analyses for all possible specifications of dementia status for study aim 2 
 
 
Dementia Measure 
 
ACE 
Inhibitors 
 
Beta-
blockers 
Lipid –
lowering 
Medications 
 
Antiplatelet 
Medications 
 
0% 
Compliance 
 
50-100% 
Compliance 
       
    Dementia before CHD † NS **(negative) ***(negative) NS ***(positive) NS 
    Disease status each year        
        No disease (suppressed category)       
        CHD only NS ***(positive) ***(positive) ***(positive) ***(negative) ***(positive) 
        Dementia only  NS NS NS **(positive) **(negative) ***(positive) 
        Both diseases *(positive) **(positive) **(positive) ***(positive) ***(negative) ***(positive) 
    No. of years since dementia diagnosis NS NS NS NS NS NS 
† Primary independent variable 
Abbreviations: NS, not significant; CHD, coronary heart disease. 
P values: *p≤0.05;**p≤ 0.01;*** p≤ 0.001. 
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4.2.2.2 Control variables  
Following the same methodology as outlined for aim 1 in Section 4.2.1.1, predisposing variables 
were tested bivariately in both a weighted and non-weighted models. They include age, sex, race, 
and level of education.  Different log forms and specifications were tested for age and education 
level. 
The interaction variable of participant age and dementia status is significant predictor for 
lipid-lowering medications at p<0.01. The bivariate results for sex and race indicate that non-
whites are less likely to report taking an antiplatelet medication (p<0.05) while females are more 
likely (p<0.05). 
Three control variables, that are considered enabling variables based on the Andersen 
model, include income, insurance status and nursing home residence. Income was not 
statistically significant predictor, but living in a nursing home was significant for ACE inhibitors, 
beta-blockers, and lipid-lowering  medications (p<0.05)  indicating that those living in a nursing 
home were more likely to report taking ACE inhibitors, but less likely to report taking a beta-
blocker or lipid-lowering medication. Presence of supplementary insurance was tested in two 
different ways: (1) as a categorical variable measuring insurance status each year and (2) as a 
binary variable measuring if a subject ever had a form of secondary insurance (in addition to 
Medicare). The binary measure of insurance status measured if a subject ever had a type of 
secondary insurance. Ever having private insurance was the only significant predictor (p<0.05) 
for use of antiplatelet medications.   
The control variables bivariately tested for aim 2 measure comorbidites and the level of 
care needed. They include activities of daily living (ADLs), history of hypertension, diabetes, 
kidney disease, or ever having a diagnosis of cancer.  Those needing more assistance with ADLs 
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are more likely to report taking ACE inhibitors and antiplatelet medications, and those with 
hypertension are more likely to report taking a beta-blocker. Table 4.6 shows the coefficients and 
odds ratios (ORs) from the weighted bivariate analyses for each dependent variable. Appendix 
E.2 presents the non-weighted results. 
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Table 4.6: Results of weighted bivariate analysis of chemoprophylaxis for CHD for participants with dementia before CHD 
 
Variable 
 
ACE Inhibitors 
 
Beta-blockers 
Lipid-lowering 
Medications 
 
Antiplatelet Medications 
Predisposing Variables β coefficient OR β coefficient OR β coefficient OR β coefficient OR 
    Dementia before CHD –0.124 0.88 –1.810*** 0.16  –3.005*** 0.04 –0.632 0.53 
    Disease status each year  
           (none) 
        
        CHD only 1.146 3.14 2.191*** 8.94    1.526*** 4.60 1.573*** 4.82 
        Dementia only 0.785 2.19 0.768 2.15     –0.222 0.80 3.070** 3.07 
        Both diseases 1.361* 3.90 2.040** 7.69  1.065** 2.90 1.614*** 5.02 
    No. of years since dementia     
    diagnosis 
 
–0.124 
 
0.08 
 
–1.810 
 
0.16 
 
–0.008 
 
0.99 
 
0.003 
 
1.00 
    Age centered on the mean –0.012 0.98 0.004 1.00 –0.001 1.00 0.017 1.01 
    Age categories (≤75) 
        76-85 
 
  –0.1461 
 
0.86 
 
0.087 
 
1.09 
 
0.068 
 
1.07 
 
0.190 
 
1.20 
        86-102 –0.397 0.67 0.229 1.25  –0.864** 0.42 0.185 1.20 
    Age and dementia interaction –0.040 0.96 –0.052 0.94  –0.082** 0.92     –0.010 0.98 
    Study site (North Carolina)         
        California –0.030 0.97 0.353 1.42 –0.662 0.52 0.271 1.31 
        Maryland   0.134 1.14 –0.007 0.99 1.293 3.65 0.116 1.12 
        Pennsylvania –0.934 0.39 0.358 1.43 –0.291 0.74 0.007 1.00 
    Race (white)   0.757 2.13 –0.011 0.98  0.068 1.07 –0.916* 2.50 
    Gender (male)   0.338 1.40 –0.317 0.72 –0.493 0.61 0.636* 1.88 
    Education  (HS or less)   0.257 1.29 0.165 1.17 –0.138 0.87     –0.125 0.88 
Enabling Variables         
    Income (≤$24,999/year) –0.014 0.98 –0.406 0.66 0.083 1.08 –0.418 0.65 
    Insurance status (none)         
        Private  0.113 1.12 0.207 1.23  0.025 1.02 0.096 1.10 
        Medicaid 0.275 1.31 –0.209 0.81 –0.333 0.71      –0.235 0.78 
       Other 0.092 1.09 0.177 1.19 –0.206 0.81 0.389 1.47 
    Ever had private insurance  0.313 1.36 0.785 2.19    2.292** 9.90 0.187 1.20 
    Ever had Medicaid       –0.126 0.88 –1.076** 0.34 1.285 3.61 0.043 1.04 
    Ever had other insurance  0.415 1.51     –0.672 0.51 –1.375* 0.25 0.077 1.08 
    Ever without insurance –0.194 0.82 0.626 0.53 0.202 1.22  –0.519** 0.59 
    Residing in Nursing Home    0.987* 2.68  –0.294** 0.74 –0.384* 0.68 0.252 1.28 
Care Need Variables         
    Activities of Daily Living  0.085* 1.08 0.069 1.07 –0.107 0.89 –0.037 1.03 
    Hypertension 0.110 1.11  0.144* 1.15 –0.090 0.91 –0.050 0.95 
    Diabetes 0.235 1.26 0.063 1.06 –0.011 0.98  0.183 1.20 
    Renal Insufficiency     –0.100 0.90 0.475 1.60   –1.836** 0.16 –0.252 1.28 
    Ever treated for Cancer  0.874* 2.39 0.562 1.75   –1.720** 0.17  0.183 1.20 
Abbreviations: CHD, Coronary Heart Disease; No., number; HS, high school.    P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.2.3 Aim 3 
4.2.3.1 Main independent variable  
Study aim 3 tests if Medicare beneficiaries who develop CHD first are more likely to discontinue 
evidence-based chemoprophylaxis for CHD after they develop dementia. The sample for the 
analyses is limited to participants who develop dementia before CHD and who use 
chemoprophylaxis for at least one study year.  Excluded from the analyses are participants who 
develop dementia before CHD, those who develop dementia and CHD in the same year 
(including those with both diseases at baseline), and the observations for participants before their 
first documented use of chemoprophylaxis (e.g. they must start to be eligible to discontinue). 
The analysis is restricted to those who develop dementia after CHD, possible measures of 
dementia status include:  (1) the number of years since the clinically adjudicated date of onset 
(with year of onset as “1”), (2) cognitive function scores based on the 3MSE scores, and (3) 
cognitive function scores based on DSST scores. All possible specifications of dementia status 
were tested independently with and without the sampling weights. The number of years since the 
dementia diagnosis is reported as the main measure for the multivariable models. Using this 
measure allows us to model the time with dementia as a possible indication of severity of 
disease.  Table 4.7 presents the results of the weighted bivariate analyses for all possible 
specifications of dementia status for study aim 3. Appendix D.3 presents the non-weighted 
results. 
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Table 4.7: Results of weighted bivariate analyses for all possible specifications of dementia status for study aim 3 
 
 
Dementia Measure 
 
 
ACE Inhibitors 
 
 
Beta-blockers 
 
Lipid -lowering 
Medications 
 
Antiplatelet 
Medications 
     
    No. of years since dementia diagnosis †  NS NS **(negative) **(negative) 
    3MSE Score Less than 80 NS NS NS **(negative) 
    DSST Score Less than 30 NS NS **(negative) NS 
† Primary independent variable 
Abbreviations: NS, not significant; 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test. 
P values: P values: *p≤0.05;**p≤ 0.01;*** p≤ 0.001. 
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4.2.3.2 Control variables  
Predisposing variables were tested bivariately in both a weighted and non-weighted models. 
They include age, sex, race, and level of education.  Different log forms and specifications were 
tested for age and education level. 
Participant age, when measured continuously centered at the mean, was not a significant 
predictor for use of chemoprophylaxis. Participants ≥86 years old were 0.52 as likely to report 
taking a lipid-lowering medication (p≤0.001).  
Results for race indicate that non-whites are less likely to report taking an ACE inhibitor 
and antiplatelet medication (p<0.05) while females are more likely.  Gender and level of 
education were statistically significant predictor for use of antiplatelet medications (p≤0.001).   
Three enabling variables controlled for in the model include income, insurance status and 
nursing home residence. Income statistically predicted use of antiplatelets.  Participants living in 
a nursing home were three times as likely to report taking an ACE inhibitor and 0.86 as likely to 
report taking an lipid-lowering medication (p≤0.05). Supplemental insurance was tested two 
different ways in the bivariate analysis: as a categorical variable measuring insurance status each 
year and as a binary variable measuring if a subject ever had some form of supplementary 
insurance.  Given the amount of missing data for the categorical variable it was not included in 
any of the full multivariable models.  Ever having private insurance or ever having Medicaid 
were significant predictors for use of lipid-lowering medications at p≤0.001.   
Control variables measuring comorbidites and the level of care needed include activities 
of daily living (ADLs), history of hypertension, diabetes, kidney disease, or ever having a 
diagnosis of cancer. Also included was a variable that controlled for the number of years with 
CHD. This variable is important to control for effect of length of disease on use of 
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chemoprophylaxis.  For all four sub-classes of medications, the longer the amount of time with 
CHD the less likely to report using the medication. Participants with kidney disease and a history 
of cancer were less likely to report taking a lipid-lowering medication (p≤0.01).  Table 4.8 
displays the coefficients and odds ratios (ORs) from the weighted bivariate analyses for each 
dependent variable. Appendix E.3 includes the non-weighted results. 
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Table 4.8: Results of weighted bivariate analysis of chemoprophylaxis for CHD in participants with CHD before dementia 
 
Variable 
 
ACE Inhibitors 
 
Beta-blockers 
Lipid-lowering 
Medications 
 
Antiplatelet Medications 
 
Predisposing Variables 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
    No. of yrs since dementia  –0.270 0.76 –0.233 0.79   –0.467** 0.62 –0.336*** 0.71 
    3MSE Score <=80 –0.971 0.38  0.030 1.03 –1.352 0.26     –0.994** 0.37 
    DSST Score <=30 –2.505 0.08  –0.035 0.96   –1.870** 0.15     –0.120 0.89 
    Age centered on the mean –0.141 0.87  –0.122* 0.88 0.208 1.02     –0.064* 0.94 
    Age categories 76-85 –0.120 0.89  0.055 1.06 0.110 1.12     –0.197 0.82 
        86-102 –1.771* 0.17 –0.894 0.41 –0.984 0.37     –0.409 0.66 
    Age and yrs since dementia  
    interaction 
 
–0.042* 
 
0.95 
 
–0.030* 
 
0.97 
 
0.016 
 
1.01 
 
–0.025** 
 
0.98 
    Age and dementia interaction –0.135* 0.87 –0.028 0.97 0.173 1.19  –0.089*** 0.92 
    Study Site (North Carolina)         
        California 1.181 3.26  –2.114** 0.12   0.127** 1.14      –0.882 0.92 
        Maryland  1.131* 3.10 –1.739* 0.18 2.314 10.12 0.354 1.43 
        Pennsylvania 0.754 2.13 –1.382 0.25 0.186 1.91 0.177 1.19 
    Race (white) 0.049 1.05 –1.326 0.27   2.020** 7.53  0.677* 1.97 
    Gender (male) 0.608 1.84  0.093 1.10 1.750* 5.75 0.194 1.21 
    Education (HS or less) 0.745 2.11 –0.429 0.65 –1.000 0.37      –0.229 0.80 
Enabling Variables         
    Income (<$24,999/year) 0.370 1.45 –0.361 0.70 –0.627 0.53 –0.853** 0.43 
    Insurance status          
        Private  0.152 1.16  0.172 1.19 –0.457 0.64 0.525 1.69 
       Medicaid      –0.383 0.68 –0.085 0.92   0.973* 2.65 0.560 1.75 
       Other        0.775 2.17  0.147 1.16 –0.174 0.84 0.764 2.15 
    Ever had private insurance 0.088 1.09  0.434 1.54    1.526** 4.60 0.239 1.27 
    Ever had Medicaid  –0.707 0.49 –0.256 0.77   2.907* 18.29 –0.585 0.56 
    Ever had other insurance  0.683 1.98 –0.554 0.57 –0.579 0.56  0.058 1.06 
    Ever had no secondary ins –0.415 0.66 –0.174 0.84  0.838 2.31 –0.452 0.64 
    Residing in Nursing Home –0.233 0.80 –0.380 0.68 –0.567 0.56 –1.293 0.27 
Care Need Variables         
    Activities of Daily Living 0.193 1.21    –0.193*** 0.82   –0.294** 0.75      –0.217* 0.80 
    No. of yrs since CHD –0.192* 0.83   –0.262*** 0.77   –0.161** 0.85   –0.220*** 0.80 
    Hypertension 0.127 1.13 0.032 1.03     –-0.254 0.76      –0.063 0.94 
    Diabetes 0.313 1.37     –0.184 0.83  0.311 1.36      –0.124 0.88 
    Renal Insufficiency 0.352 1.42 0.310 1.36 –0.722 0.49      –0.218 0.80 
    Ever treated for Cancer 0.106 1.11 0.866 2.38  0.297 1.35 0.225 1.25 
    Any arthritis     –0.048 0.95 0.680 1.97 –0.915 0.40 0.227 1.25 
Abbreviations: 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test; CHD, Coronary Heart Disease; No, number.  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.3 MULTIVARIABLE RESULTS 
4.3.1 Aim 1 
Study aim1 tests if Medicare beneficiaries with dementia and CHD less likely to take evidence-
based chemoprophylaxis for CHD compared to those with CHD but without dementia. 
Multivariable analyses for study aim 1 included weighted generalized estimating equations 
(GEE) models for four chemoprophylaxis dependent variables (ACE inhibitors, beta-blockers, 
lipid-lowering medications, and antiplatelet medications) and two measures of compliance with 
chemoprophylaxis (0% compliance for those who have CHD and do not report taking any of the 
medications and 50-100% compliance for those with CHD who report taking at least two, three 
or all four).  Odds ratios (ORs) and accompanying 95% confidence intervals (CI) were calculated 
to represent the strength of association between use of chemoprophylaxis and the presence of 
dementia.  
The GEE method was used to account for the repeated measures of the longitudinal data 
on the exposure of interest (dementia status) and outcomes (chemoprophylaxis use).  Each model 
includes sample weights to adjust the probability of being in either of the two cohorts recruited in 
two different study years.  
The full multivariable model for aim 1 includes 17 variables (independent and control) 
for ACE inhibitors, beta-blockers and lipid-lowering medication, and 18 variable for antiplatelet 
and the compliance dependent variables. The predisposing variables include age, dementia and 
age interaction, sex, race, study site, and level of education (above or below high school). 
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Enabling variables included income, insurance status, and residing in a nursing home.  The full 
multivariate models also control for care needs (functional status and co-morbidities) including, 
activities of daily living (ADLs), history of hypertension, diabetes or kidney disease.  The 
antiplatelet and compliance models additionally control for arthritis as a comorbid condition.  
All of the variables were forced into the logistical GEE models for each medication sub-class 
and for the two measures of compliance measures. The following sections describe the results of 
the full and final multivariable models for study aim 1. 
4.3.1.1 ACE inhibitors  
Using the full multivariable logistic GEE model, there was no statistically significant differences 
in the use of ACE inhibitors between those with and without dementia. Having private 
supplemental insurance to Medicare as was the only control variable that significantly predicted 
use of ACE inhibitors (p≤ 0.05; OR=2.11; 95% CI =1.02-4.37). 
To create the final model, variables were added into the unadjusted model one at a time. 
They were selected if they were p≤0.1 on the bivariate analyses, were theoretically important, or 
if they were confounding and yielded a >10% difference on the dementia coefficient between the 
unadjusted model and the crude model.  
The final model for ACE inhibitors controlled for age, race, sex, study site, and a 
dementia and age interaction variable. Results do not support the hypothesis that those with 
dementia are less likely to report taking an ACE inhibitor (p=0.06). The Pennsylvania study site 
was the only control variable in the final model that significantly predicted less use of ACE 
inhibitors (p≤ 0.05; OR=0.45; 95% CI= 0.23-0.88). Table 4.9 presents the results of the full and 
final analyses for the use of ACE inhibitors among those with and without dementia.  
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Table 4.9: Multivariable results for use of ACE inhibitors for participants with CHD and dementia 
 
Variable 
 
ACE Inhibitors 
 Full Model Final Model 
 
Predisposing Variables 
 
β coefficient 
 
OR 
 
95% CI 
 
β coefficient 
 
OR 
 
95% CI 
    Dementia (in that year) 0.170 1.18 0.77-1.80 0.380 1.45 0.97-2.16 
    Age (centered)  0.017 1.01 0.97-1.06 0.003 1.00 0.96-1.04 
    Age and dementia interaction –0.019 0.98 0.93-1.02 –0.043 0.95 0.90-1.01 
    Study site (North Carolina)       
         California –0.219 0.80 0.36-1.75 –0.394 0.67 0.36-1.25 
        Maryland 0.148 1.15 0.58-2.29 –0.277 0.76 0.40-1.41 
        Pennsylvania –0.613 0.54 0.24-1.18 –0.800* 0.45 0.23-0.88 
    Race (white) 0.248 1.28 0.61-2.65 0.330 1.40 0.71-2.70 
    Gender (male) 0.077 1.08 0.65-1.78 0.176 1.19 0.74-1.91 
    Educational Level (HS or less)  0.216 1.24 0.72-2.12    
Enabling Variables       
    Income (≤$24,999) –0.108 0.89 0.49-1.61    
    Ever had private insurance  0.750* 2.11 1.02-4.37    
    Ever had Medicaid  0.212 1.23 0.62-2.44    
    Ever had other insurance 0.260 1.23 0.79-2.10    
    Ever without insurance 0.203 1.29 0.65-2.30    
    Residing in a Nursing Home  0.358 1.43 0.71-2.86    
Care Need Variables       
    Activities of daily living 0.084 1.08 0.95-1.24    
    Hypertension 0.054 1.05 0.90-1.22    
    Diabetes  0.169 1.18 0.95-1.47    
    Renal insufficiency  –0.428 0.65 0.34-1.23    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.1.2 Beta-blockers  
The effect of dementia on the use of beta-blockers was assessed using a weighted GEE model. 
The full theoretical model included 17 predisposing, enabling and care need variables. There was 
no statistically significant difference in use of beta-blockers among those with and without 
dementia. Four control variable in the full model significantly predicted use of beta-blockers.  
Participants from the California(as compared to those in North Carolina) were less likely to 
report use (p≤0.001; OR=0.28; 95% CI=0.14 -0.58) as were those living in a nursing home 
(p≤0.05; OR=0.53; 95% CI=0.30-0.92), and those with diabetes (p≤0.01; OR=0.85; 95% 
CI=0.77-0.95). Participants with a history of hypertension were more likely to report taking a 
beta-blocker (p≤0.001; OR=1.15; 95% CI=1.08-1.23).  These findings are consistent with CPGs 
that recommend, based on the evidence, that people with hypertension should take a beta-
blocker, irrespective of their CHD status (VA/DoD, 2004) yet there is no evidence to support 
that those with diabetes and CHD benefit from a beta-blocker (Kaiser Permanente Care 
Management Institute, 2005).  
The final model for beta-blockers controlled for age, race, sex, study site, an age and 
dementia interaction variable, and hypertension. Table 4.10 presents the coefficients, ORs, and 
CIs for the full theoretical and final model for use of beta-blocker. 
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Table 4.10: Multivariable results for use of beta-blockers for participants with CHD and dementia 
 
Variable 
 
Beta-blockers 
 Full Model Final Model 
 
Predisposing Variables 
 
β coefficient 
 
OR 
 
95% CI 
 
β coefficient 
 
OR 
 
95% CI 
    Dementia (in that year)  0.801 1.08 0.60-1.93      –0.064 0.94 0.62-1.41 
    Age (centered)  –0.000 1.00 0.96-1.04 –0.016 0.98 0.94-1.02 
    Age and dementia interaction  0.001 1.00 0.94-1.06  0.033 1.03 0.98-1.08 
    Study site (North Carolina)       
        California    –1.247*** 0.28 0.14-0.58 –0.583 0.56 0.24-1.27 
        Maryland –0.617 0.53 0.24-1.19 –0.400 0.70 0.29-1.53 
        Pennsylvania –0.547 0.57 0.25-1.29  0.078 1.08 0.46-2.51 
    Race (white) –0.396 0.67 0.30-1.47  0.089 0.91 0.43-1.91 
    Gender (male) 0.168 1.18 0.66-2.10  0.291 1.33 0.77-2.30 
    Educational Level (HS or less)  0.088 1.09 0.45-1.58    
Enabling Variables       
    Income ( ≤$24,999) –0.167 0.84 0.45-1.58    
    Ever had private insurance   0.143 1.15 0.48-2.75    
    Ever had Medicaid  –0.575 0.56 0.24-1.28    
    Ever had other insurance –0.255 0.77 0.48-1.24    
    Ever without insurance –0.229 0.79 0.37-1.68    
    Residing in a Nursing Home   –0.632* 0.53 0.30-0.92    
Care Need Variables       
    Activities of daily living 0.042 1.04 0.90-1.20    
    Hypertension     0.145*** 1.15 1.08-1.23   0.135*** 1.14 1.07-1.22 
    Diabetes   –0.154** 0.85 0.77-0.95    
    Renal insufficiency  0.458 1.58 0.77-3.21    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.3.1.3 Lipid-lowering medications  
Included in the full multivariate model for lipid-lowering medications are all 17 independent, 
control and interaction variables.  Results for the main independent variable in the full model 
show that participants with dementia are less likely to report taking a lipid-lowering medication, 
although not statistically significant.  Variables that significantly predict lower rates of use of 
lipid-lowering medications in the full model include study site, California (p≤0.01; OR=0.34; 
95% CI=0.17-0.69), and Pennsylvania (p≤0.001; OR=0.24; 95% CI=0.11 -0.50) compared to 
North Carolina, and living in a nursing home (p≤0.05; OR=0.37; 95% CI=0.17 -0.81).  Control 
variables that significantly predicted more use of lipid-lowering medications include white race 
(p≤0.05; OR=2.18; 95% CI=1.06-4.47), private supplemental insurance (p≤0.01; OR=4.08; 95% 
CI=1.41-11.77), or no supplemental insurance sometime during the study (p≤0.01; OR=2.93; 
95% CI=1.27-6.75), and a history of hypertension (p≤0.01; OR=1.43; 95% CI=1.10-1.86). 
The final predictive model controlled for age, race, sex, study site, an interaction variable 
for age and dementia. Dementia significantly predicted less use of lipid-lowering medications 
(p≤0.05; OR=0.38; 95% CI=0.16-0.90), as well as the California (p≤0.01; OR=0.40; 95% 
CI=0.21-0.73) and Pennsylvania (p≤0.001; OR=0.26; 95% CI=0.13-0.50) study sites.  The 
results support the hypothesis that those with dementia are less likely to report taking a lipid-
lowering medication (p≤0.05). Table 4.11 presents the results for the full theoretical and final 
predictive model for lipid-lowering medications. 
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Table 4.11: Multivariable results for use of lipid-lowering medications for participants with CHD and dementia 
 
Variable 
 
Lipid-lowering Medications 
 Full Model Final Model 
 
Predisposing Variables 
 
β coefficient 
 
OR 
 
95% CI 
 
β coefficient 
 
OR 
 
95% CI 
    Dementia (in that year) –0.135 0.87 0.46-1.62 –0.945* 0.38 0.16-0.90 
    Age (centered)  –0.017 0.98 0.92-1.03 0.001 1.00 0.95-1.04 
    Age and dementia interaction –0.013 0.98 0.92-1.04 0.050 1.05 0.96-1.14 
    Study site (North Carolina)       
        California  –1.060** 0.34 0.17-0.69   –0.927** 0.39 0.21-0.73 
        Maryland 0.018 1.01 0.42-2.43 –0.211 0.81 0.36-1.80 
        Pennsylvania   –1.427*** 0.24 0.11-0.50    –1.350*** 0.26 0.13-0.50 
    Race (white)  0.781* 2.18 1.06-4.47  0.091 1.10 0.59-2.02 
    Gender (male)        –0.078 0.92 0.48-1.76 –0.144 0.86 0.47-1.56 
    Educational Level (HS or less)         –0.545 0.57 0.29-1.12    
Enabling Variables       
    Income (   ≤$24,999)       –0.269 0.76 0.38-1.51    
    Ever had private insurance    1.406** 4.08 1.41-11.77    
    Ever had Medicaid   0.292 1.33 0.41-4.29    
    Ever had other insurance        –0.189 0.82 0.44-1.52    
    Ever without insurance   1.077** 2.93 1.27-6.75    
    Residing in a Nursing Home  –0.985* 0.37 0.17-0.81    
Care Need Variables       
    Activities of daily living 0.024 1.02 0.83-1.25    
    Hypertension   0.363** 1.43 1.10-1.86    
    Diabetes  0.182 1.20 0.98-1.46    
    Renal insufficiency         –0.768 0.46 0.17-1.21    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.3.1.4 Antiplatelet medications  
The full theoretical model for antiplatelet medications controlled for 18 predisposing, enabling, 
and care need variables. This includes all of the variables included in the ACE inhibitors, beta-
blockers and lipid-lowering models (17) with the addition of a variable that controls for any form 
of arthritis since aspirin is a common medication used to treat the symptoms of arthritis. In the 
full model, dementia did not significantly predict the use of antiplatelet medications.  
Variables that significantly predicted less use of antiplatelet medications in the full model 
include age (p≤0.05; OR=0.96; 95% CI=0.93 -0.99), Maryland study site (compared to North 
Carolina) p≤0.05; OR=0.55; 95% CI=0.32 -0.93), and needing more assistance with activities of 
daily living p≤0.05; OR=0.87; 95% CI=0.77 -0.99). 
Variables that significantly predicted more use of antiplatelet medications in the full 
model the interaction between age and dementia (p≤0.05; OR=1.07; 95% CI=1.00 -1.15), white 
race (p≤0.05; OR=1.73; 95% CI=1.03-2.92), and a history of hypertension (p≤0.05; OR=1.16; 
95% CI=1.01 -1.33).  
To create the final model, variables were added into the unadjusted model one at a time. 
They were selected if they were p≤0.1 on the bivariate analyses, were theoretically important, or 
if they were confounding and yielded a >10% difference on the dementia coefficient between the 
unadjusted model and the crude model.  
History of arthritis measure was forced into the final model.  Control variables that 
significantly predicted higher use of antiplatelet medication include white race (p≤0.01; 
OR=2.00; 95% CI 1.25 -3.17). Older participants were less likely to report taking an antiplatelet 
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medication (p≤0.01; OR=0.96; 95% CI=0.93-0.97). Table 4.12 provides the coefficients, ORs, 
and CIs for the full and final models for antiplatelet medications. 
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Table 4.12: Multivariable results for use of antiplatelet medications for participants with CHD and dementia 
 
Variable 
 
Antiplatelet Medications 
 Full Model Final Model 
 
Predisposing Variables 
 
β coefficient 
 
OR 
 
95% CI 
 
β coefficient 
 
OR 
 
95% CI 
    Dementia (in that year) 0.018 1.01 0.57-1.80 –0.061 0.95 0.61-1.45 
    Age (centered)  –0.039* 0.96 0.93-0.99   –0.044** 0.94 0.93-0.97 
    Age and dementia interaction  0.077* 1.07 1.00-1.15 0.001 1.00 0.91-1.10 
    Study site (North Carolina)       
        California –0.442 0.64 0.37-1.09 –0397 0.67 0.50-1.27 
        Maryland  –0.591* 0.55 0.32-0.93 –0.562 0.56 0.40-1.03 
        Pennsylvania –0.315 0.72 0.42-1.15 –0.370 0.70 0.47-1.20 
    Race (white)   0.551* 1.73 1.03-2.92    0.691** 2.00 1.25-3.17 
    Gender (male) 0.319 1.37 0.94-2.00 0.164 1.20 0.84-1.65 
    Educational Level (HS or less)  –0.029 0.97 0.64-1.45    
Enabling Variables       
    Income ( ≤$24,999) –0.279 0.75 0.49-1.216    
    Ever had private insurance   0.233 1.26 0.71-2.22    
    Ever had Medicaid   0.160 1.17 0.71-1.91    
    Ever had other insurance –0.342 0.71 0.51-1.39    
    Ever without insurance –0.166 0.985 0.51-1.39    
    Residing in a Nursing Home   0.832 2.29 0.11-49.14    
Care Need Variables       
    Activities of daily living –0.136* 0.87 0.77-0.99    
    Hypertension  0.149* 1.16 1.01-1.33    
    Diabetes  0.092 1.08 0.92-1.27    
    Renal insufficiency          –0.131 0.87 0.51-1.48    
    Any arthritis 0.046 1.04 0.81-1.35 –0.001 1.00 0.79-1.25 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.1.5 Compliance with medications  
In addition to the four sub-classes of guideline-recommended chemoprophylaxis, two additional 
dependent variables were tested that measure compliance with chemoprophylaxis. One measure 
labeled participants as non-compliant (0%) if they had CHD but did not report taking any of the 
four mediations.  The second approach was to label people as at least 50% compliant or greater if 
they had CHD and reported taking two, three or all four of the medications. Similar to the 
antiplatelet model, the full compliance models included 18 independent, control and interaction 
variables.  Dementia status did not statistically predict compliance in the full model testing 0% 
compliance.  Participants at the California study site were significantly more likely to be 0% 
non-compliant (p≤0.05; OR=1.75; 95% CI=1.00-3.07) as were those who reported having some 
form of supplemental insurance during the study (p≤0.05; OR=1.52; 95% CI=1.02 -2.27). White 
race (p≤0.01; OR=0.40; 95% CI=0.22-0.72), history of hypertension (p≤0.001; OR=0.77; 95% 
CI=0.64-0.87), and having private insurance at some point during the study significantly 
predicated a lesser likelihood of being 0% compliant) (p≤0.05; OR=1.04; 95% CI=1.01-1.07). 
Dementia status did not statistically predict compliance in the full model testing 50-100% 
compliance.  Participants at the California study site (p≤0.01; OR=0.40; 95% CI=0.21-0.78) and 
Pittsburgh (p≤0.05; OR=0.42; 95% CI=0.21-0.83) study site were significantly less likely to be 
50-100% compliant compared to those from North Carolina.  Participants with a history of 
hypertension were more likely to be 50%-100% compliant with chemoprophylaxis (p≤0.001; 
OR=1.22; 95% CI=1.09-1.37). 
 The final predictive models for compliance control for age, race, sex, site, age and 
dementia interaction and a history of hypertension. In the final model predicting 0% compliance, 
dementia status did not significantly predict compliance, although results indicate that those who 
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are older (p≤0.05; OR=1.04; 95% CI=1.01-1.07) and from the California study site (p≤0.05; 
OR=2.00; 95% CI=1.16-3.33) and Maryland study site (p≤0.05; OR=1.70; 95% CI=1.00-2.85)  
sites are more likely to be 0% compliant with chemoprophylaxis. White race (p≤0.001; 
OR=0.36; 95% CI=0.22-0.58) and a history of hypertension (p≤0.0001; OR=0.76; 95% CI=0.67-
0.88) significantly predicted a lower likelihood of being 0% compliant.  
Dementia status significantly predicated compliance in the final model for ≥50% 
compliance. Those with dementia and CHD are 0.60 as likely to be 50%-100% compliant with 
chemoprophylaxis compared to those without dementia (p≤0.05), controlling for age, sex, age 
and dementia interaction, study site and a history of hypertension. White race (p≤0.05; OR=1.86; 
95% CI=1.07-3.24), the interaction between age and dementia (p≤0.001; OR=1.20; 95% CI 1.02-
1.17), and a history of hypertension (p≤0.001; OR=1.16; 95% CI=1.05-1.31) significantly 
predicated higher likelihood of being 50%-100% compliant. The Pennsylvania study site 
compared to North Carolina (p≤0.001; OR=0.52; 95% CI=0.27-0.98) significantly predicted a 
lower likelihood of being 50%-100% compliant. Tables 4.13 and 4.14 present the results for the 
full theoretical model and final predictive models for 0% compliance and 50-100% compliance. 
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Table 4.13: Multivariable results of 0% compliance with chemoprophylaxis for participants with CHD and dementia 
 
Variable 
 
0% Compliance 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    Dementia (in that year) –0.221 0.70 0.37-1.69 0.115 1.12 0.62-2.02 
    Age (centered)  0.025 1.02 0.99-1.06 0.040* 1.04 1.00-1.07 
    Age and dementia interaction –0.007 1.00 0.91-1.08 –0.019 0.98 0.91-1.05 
    Study site (North Carolina)        
        California 0.560* 1.75 1.00-3.07 0.677** 1.97 1.16-3.33 
        Maryland 0.303 1.35 0.77-2.35 0.523* 1.68 0.99-2.85 
        Pennsylvania 0.131 1.13 0.65-1.97 0.276 1.31 0.76-2.26 
    Race (white) –0.907** 0.40 0.22-0.72 –1.021*** 0.36 0.91-1.05 
    Gender (male) –0.141 0.87 0.57-1.31 –0.179 0.84 0.56-1.23 
    Educational Level (HS or less)  –0.041 0.99 0.62-1.50    
Enabling Variables       
    Income (≤$24,999) 0.223 1.25 0.77-2.02    
    Ever had private insurance  –0.606* 0.54 0.31-0.97    
    Ever had Medicaid  –0.139 0.87 0.51-1.48    
    Ever had other insurance 0.422* 1.52 1.02-2.27    
    Ever without insurance –0.101 0.90 0.50-1.61    
    Residing in a Nursing Home  –0.165 0.85 0.05-14.46    
Care Need Variables       
    Activities of daily living –0.006 0.99 0.82-1.19    
    Hypertension –0.289*** 0.77 0.64-0.87 –0.265*** 0.76 0.67-0.88 
    Diabetes  –0.135 0.87 0.71-1.08    
    Renal insufficiency  0.204 1.22 0.64-2.33    
    Any arthritis  –0.144 0.97 0.88-1.05    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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Table 4.14: Multivariable results of 50-100% compliance with chemoprophylaxis for participants with CHD and dementia 
 
Variable 
 
50-100% Compliance 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    Dementia (in that year) –0.208 0.81 0.44-1.50  –0.520* 0.60 0.35-0.99 
    Age (centered)  –0.022 0.97 0.94-1.01 –0.035 0.97 0.92-1.00 
    Age and dementia interaction  0.051 1.05 0.97-1.13   0.94** 1.10 1.02-1.17 
    Study site (North Carolina)       
        California   –0.907** 0.40 021-0.78 –0.598 0.55 0.29-1.03 
        Maryland –0.378 0.68 0.35-1.30 –0.370 0.70 0.37-1.27 
        Pennsylvania –0.870* 0.42 0.21-0.83  –0.654* 0.52 0.27-0.98 
    Race (white)  0.335 1.40 0.68-2.83   0.625* 1.86 1.07-3.24 
    Gender (male)  0.203 1.22 0.76-1.97  0.192 1.21 0.78-1.86 
    Educational Level (HS or less)  –0.090 0.91 0.54-1.51    
Enabling Variables       
    Income (≤$24,999) –0.162 0.85 0.50-1.44    
    Ever had private insurance   0.598 1.81 0.94-3.50    
    Ever had Medicaid  –0.249 0.78 0.36-1.68    
    Ever had other insurance –0.340 0.71 0.47-1.07    
    Ever without insurance  0.415 1.451 0.83-2.75    
    Residing in a Nursing Home   0.723 2.106 0.48-8.81    
Care Need Variables       
    Activities of daily living 0.031 1.03 0.91-1.16    
    Hypertension     0.203*** 1.22 1.09-1.37   0.161*** 1.18 1.05-1.31 
    Diabetes  0.134 1.14 0.96-1.36    
    Renal insufficiency          –0.180 0.83 0.45-1.55    
    Any arthritis 0.052 1.13 0.90-1.43    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001
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4.3.1.6 Alternative specifications of main independent variable aim 1  
The primary models for study aim 1 used the binary variable measuring dementia status in each 
year (yes or no) as the main independent variable. The determination of dementia was based on 
the clinically adjudicated date of onset by the CHS study. Once a participant was coded as 
having dementia (year of onset) they remained in that state until death or the end of the study.  
Two similar binary measures of dementia status were tested in a sensitivity analysis of the main 
models.  The first was a binary measure of dementia of the Alzheimer’s type and the second for 
vascular dementia. In final predictive models controlling for age, sex, race, and dementia and age 
interaction, vascular dementia significantly predicted use of three sub-classes of 
chemoprophylaxis. Dementia of the Alzheimer’s type did not significantly predict use. Those 
with vascular dementia were more likely to report use of ACE inhibitors (p≤0.001; OR=4.76; 
95% CI=1.64-13.78), and less likely to report use of beta-blockers (p≤0.05; OR=0.48; 95% 
CI=0.26-0.87), lipid-lowering medications (p≤0.0001; OR=0.21; 95% CI=0.93 -0.46).  These 
results are interesting in that appears type of dementia may have a particular effect on use of 
chemoprophylaxis.  For those with CHD and Alzheimer’s disease, dementia did not have an 
effect. For those with CHD and vascular dementia, the presence of dementia predicted the use of 
chemoprophylaxis.  
As described section 4.2.1.1 alternative forms of measuring dementia status were tested 
for aim 1.  These include: dementia at baseline, prevalent dementia, 3MSE score <80, and DSST 
score < 30.  Each alternative specification was tested in the full theoretical model and final 
predictive model. Table 4.15 presents the results of the alternative specifications of dementia for 
each model.  Odds ratios and 95% confidence intervals for these models can be found in 
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Appendix F. An important finding is that results from the primary models do not vary from the 
model results using the alternative specification of dementia status. 
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Table 4.15: Multivariable results of alternative specifications of independent variable for aim 1 
 
 
 
Dementia Measure 
 
 
ACE 
Inhibitors 
 
 
Beta-
blockers 
 
Lipid- 
Lowering 
Medications 
 
 
Antiplatelet 
Medications 
 
 
0% 
Compliance 
 
 
50-100% 
Compliance 
Full Model       
    Dementia (in that year)† NS NS NS NS NS NS 
    AD Dementia (in that year) NS NS NS NS NS NS 
    Va Dementia (in that year) NS NS NS NS NS NS 
    Dementia at baseline NS NS NS NS NS NS 
    Prevalent Dementia NS NS **(negative) NS NS NS 
    3MSE Score Less than 80 NS NS **(negative) NS NS *(negative) 
    DSST Score Less than 30 NS NS NS NS *(positive) NS 
Final Model       
    Dementia (in that year) † NS NS *(negative) NS NS *(negative) 
    AD Dementia (in that year) NS NS NS NS NS NS 
    Va Dementia (in that year) **(positive) *(negative) ***(negative) NS NS NS 
    Dementia at baseline NS NS **(negative) *(positive) NS *(negative) 
    Prevalent Dementia NS NS ***(negative) NS NS **(negative) 
    3MSE Score Less than 80 NS NS **(negative) NS NS NS 
    DSST Score Less than 30 NS NS NS NS NS NS 
† Primary independent variable 
Abbreviations: AD, Alzheimer’s disease; Va, Vascular, NS, not significant; 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol 
Substitution Test.  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.2 Aim 2 
Multivariable analyses for study aim 2 include weighted, generalized estimating equations (GEE) 
for ACE inhibitors, beta-blockers, lipid-lowering medications, antiplatelet medications and for 
compliance with chemoprophylaxis to test if Medicare beneficiaries who develop dementia 
before CHD are less likely to take evidence-based chemoprophylaxis for CHD compared to 
those who develop dementia after CHD.  Odds ratios (ORs) and accompanying 95% confidence 
intervals (CI) were calculated to represent the strength of association between use of 
chemoprophylaxis and timing of the onset of dementia in relation to the onset of CHD.  
The full models for ACE inhibitors, beta-blockers and lipid-lowering medications 
controlled for 18 independent, control and interaction variables. The antiplatelet and compliance 
models included for 19 dependent variables.  The predisposing variables include age, gender, 
race, level of education (above or below high school), study site, and age and dementia 
interaction, enabling variables include income, insurance status, and residing in a nursing home.  
The GEE models also control for other co-morbidities and care needs including, activities of 
daily living (ADLs), the presence of hypertension, diabetes or kidney disease and arthritis for the 
antiplatelet and compliance models.   All of these variables were forced into the logistical GEE 
models for each class of chemoprophylaxis and for two measures of compliance with the 
medications.  
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4.3.2.1 ACE inhibitors  
In the full model, the onset of dementia before CHD did not significantly predict use of ACE 
inhibitors. Additionally, no control variables in the model were statistically significant 
predictors.  
To build the final predictive model, control variables that had a >10% confounding effect 
or were p≤0.1 on the bivariate analyses or were theoretically important (e.g. age) were added into 
the model one by one. The final model for ACE inhibitors controlled for age, race, sex, age and 
dementia interaction, study site, disease status each year, and ADLs. Dementia onset before 
CHD did not statistically predict use of ACE inhibitors (p=0.151).  More limitations of ADLs 
significantly predicted more use of ACE inhibitors (p≤0.05; OR=1.00; 95% CI=1.00-1.20)  For 
the categorical variables that measured disease status each year, those who had CHD, but had not 
yet developed dementia were four times more likely to report taking an ACE inhibitor than those 
without either disease (p≤0.05). Participants with both diseases were five times more likely to 
report taking an ACE inhibitor as compared to those who had not yet developed either disease 
(p≤0.05). Post estimation analyses of the categorical variable for timing of disease onset variable 
shows that among those with CHD only, the use of ACE inhibitors is not significantly different 
compared to those who have both CHD and dementia. Tables 4.16 present the results for the full 
model and final model for use of ACE inhibitors for those with dementia before CHD. 
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Table 4.16: Multivariable results for use of ACE inhibitors for participants who develop dementia before CHD 
 
Variable 
 
ACE Inhibitors 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    Dementia before CHD 0.340 1.40 0.36-5.49 0.910 2.48 0.72-8.61 
    Disease timing variable (no disease)       
       CHD only 1.680 5.36 0.69-41.65  1.511* 4.53 0.97-21.06 
       Dementia only 1.530 4.61 0.89-23.73 1.007 2.73 0.90-8.28 
       Both diseases 1.861 6.43 0.85-48.64  1.734* 5.66 1.16-27.60 
    Age (centered)  –0.020 0.95 0.92-1.04 –0.034 0.96 0.91-1.02 
    Age and dementia interaction –0.050  0.80-1.12 –0.056 0.94 0.70-1.12 
    Study site (North Carolina)       
        California  0.750 2.11 0.63-7.04 –0.110 0.89 0.28-2.86 
        Maryland  0.423 1.52 0.59-3.89 –0.107 0.89 0.34-2.32 
        Pennsylvania –0.293 0.74 0.21-2.58 –0.817 0.44 0.15-1.29 
    Race (white)  0.763 2.14 0.70-6.55  0.613 1.84 0.71-4.78 
    Gender (male)  0.031 1.03 0.47-2.24  0.574 1.77 0.85-3.68 
    Educational Level (HS or less)   0.365 1.44 0.56-3.66    
Enabling Variables       
    Income (≤$24,999) 0.229 1.25 0.48-3.29    
    Ever had private insurance  0.557 1.74 0.60-5.05    
    Ever had Medicaid  0.245 1.27 0.43-3.78    
    Ever had other insurance 0.189 1.20 0.54-2.68    
    Ever without insurance 0.434 1.54 0.58-4.10    
    Residing in a Nursing Home  0.297 1.34 0.71-2.52    
Care Need Variables       
    Activities of daily living 0.066 1.06 0.94-1.20 0.094* 1.00 1.00-1.20 
    Hypertension 0.030 1.03 0.76-1.37    
    Diabetes  0.205 1.22 0.83-1.80    
    Renal insufficiency  0.109 1.11 0.49-2.52    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.3.2.2 Beta-blockers  
The full theoretical model for beta-blockers includes 16 independent, control and interaction 
variables.  Two variables (education level and income) would not converge in the model. Table 
4.3.2.2 shows all variables included in the full model and the corresponding coefficients, CIs, 
and ORs.  Dementia onset before CHD, the main independent variable, did not significantly 
predict use of beta-blockers. The categorical variable measuring the timing of disease onset each 
year predicts use of beta-blockers in the full model indicating that those with both CHD only, 
even after controlling for all factors, are almost eight times as likely to report taking a beta-
blocker compare to those without disease (p≤0.001) and those with both CH D and dementia are 
nine times as likely to report using a beta-blocker compared to those without either disease 
(p≤0.05).  Post estimation analyses of the timing of disease onset control variable shows that 
among those with CHD only, the use of beta-blockers is not significantly different compared to 
those who have both CHD and dementia. Other statistically significant predictors in the full 
model show that those living in a nursing home were 0.33 as likely to report using a beta-blocker 
(p≤0.01; OR=0.33; 95% CI=0.18-0.93).  
The final model for beta-blockers was developed using the same method described above 
in section 4.3.2.1. The final predictive model for beta-blockers controlled for age, race, sex, age 
and dementia interaction, study site, disease status each year, ADLs, and hypertension. Results 
from the final model show that those who develop dementia before they develop CHD are 0.25 
as less likely to report taking a beta-blocker than those who develop dementia after CHD 
(p≤0.001; OR=0.25; 95% CI=0.07-0.89). Table 4.17 presents the coefficients, CI, and ORs for 
the full theoretical and final predictive model for beta-blocker use.   
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Table 4.17: Multivariable results for use of beta-blockers for participants who develop dementia before CHD 
 
Variable 
 
Beta-blockers 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    Dementia before CHD -1.171 0.31 0.09-1.00 –1.372* 0.25 0.07-0.89 
    Disease timing variable       
               CHD only   2.072** 7.94      1.81-35.10  2.154* 8.62     1.48-50.06 
               Dementia only 0.806 2.623 0.67-10.34 1.011 3.03 0.61-14.95 
        Both diseases  2.214* 9.15        1.67-56.11  2.230* 9.31        1.26-68.49 
    Age centered on mean –0.033 0.96 0.88-1.03 –0.036 0.964 0.89-1.04 
    Age and dementia interaction  0.052 1.05 0.96-1.18  0.054 1.05 0.94-1.17 
    Study site (North Carolina)       
        California  0.701 2.01 0.41-9374  0.883 2.42 0.42-13.82 
        Maryland  0.138 1.14 0.25-5.19  0.305 1.35 0.24-7.48 
        Pennsylvania  0.744 2.10 0.45-9.89 1.121 3.07 0.61-15.43 
    Race (white) –0.189 0.82 0.19-2.59  0.026 1.03 0.27-3.86 
    Gender (male) –0.179 0.83 0.26-2.34 –0.418 0.66 0.21-2.01 
    Education (HS or less) a       
Enabling Variables       
    Income ( ≤$24,999)a       
    Ever had private insurance   0.272 1.31 0.67-6.02    
    Ever had Medicaid  –1.162 0.31 0.10-1.04    
    Ever had other insurance –0.527 0.59 0.20-1.71    
    Ever without insurance –0.496 0.60 0.23-1.60    
    Residing in a Nursing Home   –1.085** 0.33 0.18-0.93    
Care Need Variables       
    Activities of daily living  0.085 1.08 0.90-1.31  0.080 1.08 0.91-1.28 
    Hypertension  0.102 1.10 0.95-1.25  0.112 1.11 0.98-1.27 
    Diabetes  –0.010 0.98 0.78-1.24    
    Renal insufficiency   0.347 1.41 0.38-5.26    
a Not included in the model because of convergence  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.2.3 Lipid-lowering medications  
Results from the full model support the hypothesis that those who develop dementia before CHD 
are less likely to report taking a lipid-lowering medication (p≤0.001; OR=0.07; 95% CI=0.01 -
0.42).  Other variables that significantly predicated a lower likelihood of use of lipid-lowering 
medications in the full model include the presence of some other (non-private or non-Medicaid) 
supplemental insurance (p≤0.01; OR=0.16; 95% CI 0.04-0.54), living in a nursing home (p≤0.05; 
OR=0.34; 95% CI=0.13-0.88), and kidney disease (p≤0.05; OR=0.17; 95% CI=0.04 -0.80). 
Control variables that significantly predicted higher use of lipid-lowering medications include 
the Maryland study site (p≤0.01; OR=8.34; 95% CI=1.88 -37.06), having private supplemental 
insurance at some point in the study (p≤0.0001; OR=39.34; 95% CI=6.07 -254.74), or Medicaid 
as supplemental insurance at some point in the study (p≤0.00 1; OR=8.92; 95% CI=2.47-32.15), 
or being without any supplemental insurance at some point in the study (p≤0.001; OR=7.10; 95% 
CI=2.15-23.4). 
In the full model, the categorical variable measuring time of disease onset showed that 
those with CHD only are three times more likely to report taking a lipid-lowering medication 
compared to those without CHD and dementia (p≤0.001). Participants with both CHD and 
dementia are four times more likely to report using a lipid-lowering medication compared to 
those with either disease (p≤0.001).  Post estimation analyses of the timing of disease onset 
control variable shows that among those with only CHD, the use of lipid-lowering medication is 
not significantly different compared to those who have both CHD and dementia. 
For the final predictive model, control variables that had a >10% confounding effect or 
were p≤0.1 on the bivariate analyses or were theoretically important (e.g. age) were added into 
the model one by one. The final model for lipid-lowering medications controlled for disease 
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statues each year, age, race, sex, age and dementia interaction, study site, and ADLs.  Having 
dementia before CHD significantly predicted less use of lipid-lowering medications (p≤0.01; 
OR=0.09; 95% CI=0.19-0.46) as well as non-white race (p≤0.5; OR=0.26; 95% CI=0.91-0.78).  
Disease status and the Maryland study site significantly predicted more use of lipid-lowering 
medications (p≤0.01).  Table 4.18 presents the results for the full theoretical and final predictive 
model for lipid-lowering medications.  
 150 
Table 4.18: Multivariable results for use of lipid-lowering medications for participants who develop dementia before CHD 
 
Variable 
 
Lipid-lowering Medications 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR     95% CI 
    Dementia before CHD –2.616** 0.07 .01-.42   –2.356** 0.09 0.02-0.46 
    Disease timing variable       
             CHD only   1.170*** 3.22 1.81-5.73      1.750*** 5.75 3.55-9.32 
             Dementia only        –0.593 0.55 0.02-12.96  –1.005 0.36 0.01-14.19 
       Both diseases   1.478*** 4.38 1.81-10.60     0.296** 3.65 1.62-8.23 
    Age centered on the mean 0.002 1.00 0.92-1.08 –0.019 0.98 0.91-1.05 
    Age and dementia interaction 0.165 1.18 0.80-1.72  0.081 1.08 0.74-1.58 
    Study site (North Carolina)       
        California –0.939 0.39 0.07-2.04 –0.274 0.66 0.27-2.10 
        Maryland    2.122** 8.34 1.88-37.06   1.715** 5.55 1.70-18.18 
        Pennsylvania –0.757 0.46 0.09-2.40 –0.392 0.67 0.23-1.94 
    Race (white) –0.067 0.93 0.17-4.86  –1.318* 0.26 0.09-0.78 
    Gender (male) –0.650 0.52 0.19-1.44 –0.416 0.66  
    Education (HS or less)   0.179 1.19 0.25-5.70    
Enabling Variables       
    Income (≤$24,999)         –0.980 0.37 0.06-2.14    
    Ever had private insurance      3.672**** 39.34 6.07-254.74    
    Ever had Medicaid    2.188*** 8.92 2.47-32.15    
    Ever had other insurance –1.815** 0.16 0.04-0.54    
    Ever without insurance   1.960*** 7.10 2.15-23.40    
    Residing in Nursing Home  –1.087** 0.33 0.12-0.87    
Care Need Variables       
    Activities of daily living –0.085 0.92 0.66-1.27 –0.192 0.82 0.65-1.04 
    Hypertension a       
    Diabetes a       
    Renal insufficiency  –1.753* 0.17 0.03-0.79    
a Not included in the model because of convergence  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
 151 
4.3.2.4 Antiplatelet medications  
The full model testing the effect of dements before CHD on the use of antiplatelet medications 
controlled for 19 independent, control and interaction variables. The main independent variable, 
dementia before CHD, did not significantly predict use of antiplatelet medication (p=0.9). 
To build the final predictive model, control variables that had a >10% confounding effect 
or that were p≤0.1 on the bivariate analyses or were theoretically important (e.g. history of 
arthritis) were added into the model one by one. The final model controlled for disease status 
each year, age, race, sex, age and dementia interaction, study site, ADLs, and any form of 
arthritis was forced into the model.  In the final model, the developing dementia before CHD was 
not a significant predictor of the use of antiplatelet medications.  As in the other models, the 
categorical variable measuring disease status at each year was a significant predictor for more 
use of antiplatelet medication (p≤0.05) for each category. Table 4.19 displays the coefficients, 
CIs and ORs for the full and final model for antiplatelet medications. 
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Table 4.19: Multivariable results for use of antiplatelet medications for participants who develop dementia before CHD 
 
Variable 
 
Antiplatelet  Medications 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    Dementia before CHD –0.206 0.81 0.28-2.29 –0.048 0.95 0.32-2.81 
    Disease timing variable       
               CHD only    1.491** 4.44 1.39-14.11  1.646** 5.18 1.54-17.36 
                Dementia only   1.152* 3.16 1.07-9.36       1.071 2.92 0.93-9.09 
                Both diseases    1.699** 5.47 1.78-16.74    1.872*** 6.50 2.05-20.61 
    Age centered on the mean  –0.000 1.00 0.95-1.05 –0.009 0.99 0.94-1.04 
    Age and dementia interaction –0.033 0.97 0.83-1.11 0.011 1.01 0.87-1.16 
    Study site (North Carolina)       
        California –0.540 0.58 0.29-1.15 0.080 1.08 0.48-2.43 
        Maryland –0.613 0.54 0.25-1.13 0.030 1.03 0.44-2.37 
        Pennsylvania –0.352 0.70 0.31-1.58 0.321 1.37 0.58-3.23 
    Race (white) 1.233** 3.43 1.37-8.59   0.746* 2.10 0.99-4.45 
    Gender (male) 0.760** 2.14 1.23-3.71 0.330 1.39 0.78-2.45 
    Education (HS or less)  –0.862** 0.42 0.21-0.82    
Enabling Variables       
    Income (≤$24,999) –0.330 0.71 0.34-1.53    
    Ever had private insurance  0.012 1.01 0.50-2.05    
    Ever had Medicaid  0.569 1.76 0.80-3.92    
    Ever had other insurance 0.003 1.00 0.53-1.89    
    Ever without insurance 0.474 1.60 0.70-3.64    
    Residing in Nursing home  0.329 1.33 0.11-15.67    
Care Need Variables       
    Activities of daily living 0.033 1.03 0.86-1.24 0.011 1.01 0.84-1.20 
    Hypertension –0.002** 1.00 0.81-1.21    
    Diabetes  0.222 1.24 0.87-1.78    
    Renal insufficiency  0.070 1.07 0.46-2.47    
    Any arthritis 0.158 1.17 0.71-1.93 –0.043 0.95 0.66-1.38 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.2.5 Compliance with medications  
In addition to the four sub-classes of guideline recommended chemoprophylaxis for CHD, two 
dependent variables that measure compliance with chemoprophylaxis were tested. Participants 
with CHD who did not report taking any of the four medications were labeled as 0% compliant.  
Inversely, those with CHD who report taking two, three or all four of the medications are 
considered 50-100% compliant with guideline-recommended chemoprophylaxis.  Similar to the 
antiplatelet model, 19 variables were tested. The main independent variable, dementia before 
CHD, did not significantly predict compliance at 0% (p=0.1) or at 50%-100% compliance 
(p=0.7)   
 The final models for compliance controlled for disease status each year, age, race, 
sex, age and dementia interaction, study site, ADLs, and history of hypertension. Having 
dementia before CHD did not significantly predict compliance. Control variables that 
significantly predict non-compliance at 0% compliance include race as well as the categorical 
control variable that measures disease status each year.  Results show that whites are less likely 
to 0% compliant (p≤0.01; OR=0.32 95% CI 0.15-0.68) as are those in all three disease states 
(p≤0.01).   
Having dementia before CHD does not significantly predict compliance at the 50%-100% 
rate, but the results indicate that those who have CHD only, dementia only, and both disease are 
more likely to be 50-100% as compared to those without either disease (p≤0.01). Post estimation 
analyses show that these three states of disease status are statistically different from each other 
with regard to compliance.   Table 4.20 presents the results for the 0% compliance dependent 
variable models and Table 4.21 for 50-100% compliance for the full theoretical model and final 
model.  
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Table 4.20: Multivariable results for 0% compliance with chemoprophylaxis for participants who develop dementia before CHD 
 
Variable 
 
0% Compliance 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
 Dementia before CHD 0.790 2.20 0.85-5.64 0.253 1.28 0.50-3.28 
 Disease timing variable       
            CHD only   –2.191*** 0.11 0.03-0.35    –2.453*** 0.08 0.03-0.21 
            Dementia only   –1.720*** 0.12 0.07-0.45  –1.358** 0.25 0.09-0.71 
            Both diseases   –2.200*** 0.11 0.04-0.33    –2.387*** 0.09 0.03-0.23 
   Age centered on the mean 0.006 1.00 0.99-1.07 0.022 1.02 0.97-1.10 
   Age and dementia interaction 0.114 1.12 0.96-1.30 0.021 1.02 0.88-1.17 
   Study site (North Carolina)       
        California –0.165 0.84 0.33-2.15 –0.413 0.66 0.30-1.43 
        Maryland  0.131 1.14 0.49-2.62 –0.106 0.90 0.40-1.99 
        Pennsylvania  0.163 1.17 0.51-2.76 –0.118 0.89 0.35-2.24 
    Race (white)    –1.520*** 0.22 0.08-0.54   –1.138** 0.32 0.15-0.68 
    Gender (male) –0.324 0.72 0.39-1.33 –0.250 0.77 0.41-1.44 
    Education (HS or less)   0.262 1.30 0.63-2.66    
Enabling Variables       
    Income (≤$24,999) –0.014 0.98 0.45-2.28    
    Ever had private insurance  –0.263 0.77 0.34-1.67    
    Ever had Medicaid  –0.704 0.50 0.22-1.10    
    Ever had other insurance  0.300 1.34 0.66-2.72    
    Ever without insurance –0.684 0.50 0.21-1.19    
    Residing in Nursing home   0.360 1.43 .06-35.30    
Care Need Variables       
    Activities of daily living –0.211 0.81 0.64-1.02 –0.189 0.82 0.67-1.00 
    Hypertension  –0.263* 0.77 0.60-0.99 –0.205 0.81 0.64-1.01 
    Diabetes  –0.037 0.96 0.64-1.45    
    Renal insufficiency   0.105 1.11 0.43-2.90    
    Any arthritis –0.195 0.82 0.43-1.54    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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Table 4.21: Multivariable results for 50%-100% compliance with chemoprophylaxis for participants who develop dementia before CHD 
 
Variable 
 
50-100% Compliance 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    Dementia before CHD –0.234 0.79 0.22-2.75 –0.326 0.72 0.16-3.21 
    Disease timing variable       
        CHD only 3.183*** 24.12 5.71-101.90 2.642*** 14.05 4.27-46.20 
               Dementia only 2.466*** 11.77 2.65-52.33 2.129*** 8.41 2.66-26.57 
        Both diseases 3.251*** 25.82 5.28-126.25 2.593*** 13.3 3.94-45.34 
    Age centered on the mean –0.051 0.95 0.88-1.02 –0.019 0.98 0.92-1.04 
    Age and dementia interaction –0.060 0.94 0.79-1.12 0.058 1.06 0.88-1.26 
    Study site (North Carolina)       
        California –0.433 0.64 0.24-1.72 0.791 2.21 0.65-7.43 
        Maryland 0.192 1.21 0.43-3.37 0.532 1.70 0.58-4.96 
        Pennsylvania –0.229 0.80 0.21-2.94 0.580 1.78 0.54-5.90 
    Race (white) 0.621 1.86 0.45-7.58 0.943 2.57 0.84-7.79 
    Gender (male) 0.339 1.40 0.68-2.87 0.151 1.16 0.53-2.55 
    Education (HS or less)  –0.407 0.66 0.26-1.68    
Enabling Variables       
    Income (≤$24,999) –0.231 0.73 0.3431-1.71    
    Ever had private insurance  0.995* 2.70 1.04-7.01    
    Ever had Medicaid  0.065 1.06 0.34-3.31    
    Ever had other insurance –0.593 0.55 0.26-1.18    
    Ever without insurance 0.661 1.93 0.75-4.90    
    Residing in Nursing home  0.494 1.63 0.33-8.02    
Care Need Variables       
    Activities of daily living 0.042 1.04 0.88-1.23 0.050 1.05 0.87-1.26 
    Hypertension 0.080 1.08 0.84-1.39 0.095 1.10 0.91-1.33 
    Diabetes  0.311 1.36 0.97-1.91    
    Renal insufficiency  –0.153 0.86 0.127-2.62    
    Any arthritis 0.415 1.51 0.94-2.43    
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001
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4.3.2.6 Alternative specifications of main independent variable aim 2  
The primary independent variable for aim 2 was measured as a static binary variable indicting if 
the onset of dementia occurred before the onset of CHD (yes or no). The sub-sample for analysis 
in aim 2 included those who developed both CHD and dementia by the end of the study period, 
but given that time of development varied, a time-varying categorical variable that captured 
disease status in each year was included as a control variable.  Alternative forms of measuring 
dementia status were also tested.  Sensitivity analyses for aim 2 tested alternative specifications 
for the dementia status independent variable. They include: the time-varying variable categorical 
variable alone in the model and a continuous of the number of years with the dementia diagnosis.  
Each alternative specification was tested with the full theoretical and final models. Table 4.22 
presents the results of the alternative specifications of dementia for each model.  Odds ratios and 
95% confidence intervals for these models can be found in Appendix G. It is important to note 
that findings on strength of association for predicting use of chemoprophylaxis did not vary 
between the alternative specifications and the primary measure of dementia status for aim 2. 
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Table 4.22: Multivariable results of alternative specifications of independent variable for aim 2 
 
 
Dementia Measure 
 
ACE 
Inhibitors 
 
Beta-
blockers 
Lipid –
lowering 
Medications 
 
Antiplatelet 
Medications 
 
0% 
Compliance 
 
50-100% 
Compliance 
Full model       
    Dementia before CHD† NS NS **(negative) NS NS NS 
    Disease status each year        
        No disease (suppressed category)       
        CHD only NS ***(positive) ***(positive) ***(positive) ***(negative) ***(positive) 
        Dementia only  NS NS NS *(positive) **(negative) ***(positive) 
        CHD and dementia *(positive) **(positive) ***(positive) ***(positive) ***(negative) ***(positive) 
    No. of years since dementia diagnosis NS NS NS NS NS NS 
Final model       
    Dementia before CHD† NS *(negative) **(negative) NS NS NS 
    Disease status each year       
        No disease (suppressed category)       
        Has CHD only NS ***(positive) ***(positive) ***(positive) ***(negative) ***(positive) 
        Dementia only  NS NS NS **(positive) **(negative) ***(positive) 
        CHD and dementia *(positive) **(positive) **(positive) ***(positive) ***(negative) ***(positive) 
    No. of years since dementia diagnosis NS **(negative) NS NS NS NS 
† Primary independent variable 
Abbreviations: NS, not significant; CHD, coronary heart disease. 
P values: *p≤0.05;**p≤ 0.01;*** p≤ 0.001. 
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4.3.3 Aim 3 
Study aim 3 tests if Medicare beneficiaries who develop CHD before dementia more likely to 
discontinue evidence-based chemoprophylaxis. The analytic sub-sample for aim 3 included only 
participants who developed CHD before dementia and their observations starting with the first 
year they were on the medication. It was restricted to only those years since to discontinue a 
medication they must have started in some previous year. Review of the patterns of 
discontinuation showed that, on average, of those who discontinued a medication 60% 
discontinued permanently.  Multivariable analyses included weighted generalized estimating 
equations (GEE) models ACE inhibitors, beta-blockers, lipid-lowering medications, and 
antiplatelet medications. Compliance variables were not included as dependent variables since 
the goal of aim 3 was to investigate the effect of dementia on discontinuation of each sub-class 
of chemoprophylaxis.  
The main independent variable was the number of years since the onset of dementia. This 
continuous variable started with “1” in the study year of the diagnosis determined by CHS. All 
years prior to onset are measured by a “0”.  Odds ratios (ORs) and accompanying 95% 
confidence intervals (CI) were calculated to represent the strength of association between use of 
chemoprophylaxis and the number of years since the onset of dementia.  
Construction of the full models varied for each sub-class of medication based on the best 
theoretical fit of the variable with the medication the model, their significance or confounding 
characteristics, and limitations on model convergence.  
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4.3.3.1 ACE inhibitors  
Using the logistic GEE models to account for repeated measures, the number of years with 
dementia did not significantly use of ACE inhibitors (p=.9).  Age predicted less use of ACE 
inhibitors as age and the number of years with dementia increase (p≤0.01 ; OR=0.70; 95% 
CI=0.53-0.92).  The California and Maryland study sites (p≤0.05) significantly predicted use of 
ACE inhibitors as the number of years with dementia increases. 
To build the final predictive model to test discontinuation of ACE inhibitors after the 
diagnosis of dementia, control variables that had a >10% confounding effect or were p≤0.1 on 
the bivariate analyses or were theoretically important (e.g. age) were added into the model one 
by one.  
The final model for ACE inhibitors controlled for age, race, sex, study site, and the 
number of years with CHD. Results do not support the hypothesis that the number of years with 
dementia would predict less use of ACE inhibitors (p=0.9). Control variables that significantly 
predicted less use of ACE inhibitors as the number of years with dementia increases include 
older age (p≤0.05; OR=0.88; 95% CI=0.78-0.99) and the greater number of years with CHD 
(p≤0.05; OR=0.75; 95% CI=0.59-0.96).  Control variables that significantly predicted more use 
as the number of years with dementia increased include the Maryland, California, and 
Pennsylvania study sites (Compared to the North Carolina site) and being female (p≤0.001; 
OR=4.04; 95% CI=1.39-11.7). Table 4.23 presents the results of the full and final models for 
predicting discontinuation of ACE inhibitors. 
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Table 4.23: Multivariable results for discontinuation of ACE inhibitors among participants who develop dementia after CHD 
 
Variable 
 
ACE Inhibitors 
 Full Model Final Model 
Predisposing Variables β coefficient OR 95% CI β coefficient OR 95% CI 
    No. of years since the dementia  
    diagnosis 
–0.033 0.97 0.46-2.01 0.012 1.01 0.62-1.63 
    Age (centered)   –0.352** 0.70 0.53-0.92 –0.118* 0.88 0.78-0.99 
    Age and dementia interaction  0.065 1.10 0.98-1.15    
    Study site (North Carolina)       
        California 4.723* 112.60 2.036-6225.3  2.639** 14.00 1.95-100.00 
        Maryland  4.080* 59.15 1.88-1859.0   2.587*** 13.29 3.26-54.00 
        Pennsylvania       2.700 14.80 0.31-690.15 1.978* 7.23 1.35- 38.70 
    Race (white)      –0.807 0.44 0.01-27.04     –1.200 0.30 0.04-2.16 
    Gender (male)        2.100 8.15 0.92-71.91  1.398** 4.04 1.39-11.7 
    Educational Level (HS or less)       –0.012 1.00 0.19-5.08    
Enabling Variables       
    Income (≤$24,999)  1.322 3.75 0.59-23.70    
    Ever had private insurance         1.570 4.80 0.15-150.39    
    Ever had Medicaid        –0.773 0.46 0.01-10.89    
    Ever had other insurance   2.112* 8.26 0.96-71.13    
    Ever without insurance    3.336** 28.12 2.02-391.28    
    Residing in a nursing home         0.187 1.20 0.13-11.00    
Care Need Variables       
    No. of years since the CHD diagnosis –0.305 0.73 0.50-1.07  –0.2817* 0.75 0.59-0.96 
    Hypertension –0.446 0.64 0.24-1.67    
    Diabetes  –0.410 0.66 0.25-1.74    
    Renal Insufficiency  –1.200 0.30 0.01-5.15    
Abbreviations: No, number. 
a Not included in the model because of convergence  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.3.3.2 Beta-blockers  
In the full weighted logistic GEE model, more years with dementia predicts more use of beta-
blockers, contrary to the hypothesis of discontinuation..  Race and study site, education, private 
supplemental insurance and the numbers of years with CHD significantly predict less use as the 
number of years with dementia increase in the full model. 
To build the final predictive model for beta-blockers, control variables that had a >10% 
confounding effect or were p≤0.1 on the bivariate analyses or were theoretically important (e.g. 
age) were added into the model one by one.  
The final model for beta-blockers controlled for age, race, sex, study site, age and 
dementia interaction, the number of years with CHD, and hypertension. Results do not support 
the hypothesis in that the number of years with dementia did not predict less use of beta-blockers 
(p=0.1). Control variables that significantly predicted less use of beta-blockers as the number of 
years with dementia increases include the number of years with CHD (p≤0.05; OR=0.77; 95% 
CI=0.59-0.99) and the Maryland (p≤0.05; OR=0.18; 95% CI=0.03-0.91), California (p≤0.05; 
OR=0.12; 95% CI 0.02- 0.68), and Pennsylvania (p≤0.05; OR=0.15; 95% CI=0.02-1.00)  study 
sites (p≤0.05) (compared to North Carolina ). Table 4.24 presents the results of the full and final 
models for predicting discontinuation of beta-blockers. 
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Table 4.24: Multivariable results for discontinuation of beta-blockers among participants who develop dementia after CHD 
 
Variable 
 
Beta-blockers 
 Full model Final Model 
Predisposing variables β coefficient OR 95% CI β coefficient OR 95% CI 
    No. of years since the dementia diagnosis 0.375** 1.45 1.10-1.92 0.242 1.27 0.92-1.75 
    Age (centered)  0.086 1.09 0.94-1.25 –0.008 0.99 0.87-1.12 
    Age and dementia interaction –0.042 0.95 0.90-1.01 –0.016 0.98 0.93-1.03 
    Study site (North Carolina)       
        California –2.275* 0.10 0 .01-0.66 –2.090* 0.12 0.02- 0.68 
        Maryland –1.614 0.20 0.02-1.58 –1.706* 0.18 0.03-0.91 
        Pennsylvania –2.125* 0.12 0.01-0.87 –1.894* 0.15 0.02-1.00 
    Race (white) –3.984* .018 0.01-0.47 –1.492 0.98 0.02-1.90 
    Gender (male) 1.102 3.01 0.87-10.36 –0.131 0.87 0.31-2.42 
    Educational level (HS or less)  –1.871* .153 0.03-0.74    
Enabling variables       
    Income (≤$24,999)  –0.003 1.00 0.37-2.63    
    Ever had private insurance  1.264* 3.54 1.10-11.32    
    Ever had Medicaid  0.481 1.61 0.35-7.417    
    Ever had other insurance  –0.237 0.79 0.21-2.90    
    Ever without insurance  –0.433 0.65 0.17-2.38    
    Residing in a nursing home  –0.694 .499 0.14-1.70    
Care need variables       
    No. of years since the CHD diagnosis –0.420* 0.66 0.45-0.94 –0.260* 0.77 0.59-0.99 
    Hypertension 0.330 1.39 0.88-2.19 0.019 1.21 0.84-1.74 
    Diabetes  –0.414 0.66 0.37-1.15    
    Renal insufficiency  –0.786 0.45 0.09-2.11    
Abbreviations: No., number. 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.3.3 Lipid-lowering medications  
In the full weighted logistic GEE model for lipid-lowering medications, number of years with 
dementia did not significantly predict use (p=.3).  No control variables significantly predicted 
use of lipid-lowering medications.  Level of education, income, and the supplemental insurance 
status variables did not converge in the model due to the limited number of observations per 
participant.  
Using the same model building method described for ACE inhibitors and beta-blockers, 
control variables that had a >10% confounding effect or were p≤0.1 on the bivariate analyses or 
were theoretically important (e.g. age) were added into the model one by one.  
The final model for lipid-lowering medications controlled for age, race, sex, study site, 
age and dementia interaction, and the number of years with CHD. The main independent 
variable, number of years with dementia, did not significantly predict use of lipid-lowering 
medications (p=0.2). Additionally, no control variables that significantly predicted 
discontinuation of lipid-lowering medications include the greater number of years with CHD. 
Table 4.25 presents displays the beta coefficients, ORs and 95% CIs for the full and final model 
of use of lipid-lowering medications for participants who develop dementia after CHD. 
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Table 4.25: Multivariable results for discontinuation of lipid-lowering medications among participants who develop dementia after CHD 
 
Variable 
 
Lipid-lowering Medications 
 Full Model Final Model 
Predisposing variables β coefficient OR 95% CI β coefficient OR 95% CI 
    No. of years since the dementia 
    diagnosis 
–0.747 0.47 0.11-2.038 –0.777 0.45 0.13-1.62 
    Age (centered)  0.031 1.03 0.74-1.42 0.111 0.89 0.68-1.17 
    Age and dementia interaction 0.193 1.21 0.86-1.69 0.128 1.13 0.95-1.30 
    Study site (North Carolina)       
        California –2.647 0.07 0.00-23.59 –2.360 0.09 0.01-16.33 
        Maryland –0.757 0.47 0.00-82.1 –1.146 0.32 0.01-51.80 
        Pennsylvania –0.658 0.51 0.01-18.80 –2.141 0.12 0.01-11.10 
    Race (white) 3.268 26.26 0.15-4437.00 3.554 34.96 0.35-3413 
    Gender (male) 0.625 1.87 0.33-10.43 0.971 2.64 0.42-16.30 
    Educational level (HS or less)        
Enabling variables       
    Income (≤$24,999)        
    Ever had private insurance        
    Ever had Medicaid        
    Ever had other insurance        
    Ever without insurance        
    Residing in a nursing home  –14.827 3.63 3.59-3.68    
Care need variables       
    No. of years since the CHD diagnosis –0.358 0.70 0.39-1.228 –0.270 0.76 0.55-1.05 
    Hypertension –0.358 0.50 0.18-1.381    
    Diabetes  –0.700 1.01 0.52-1.956    
    Renal insufficiency  –1.606 0.20 00.00-13.16    
Abbreviations: No., number. 
a Not included in the model because of convergence  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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4.3.3.4 Antiplatelet medications  
The full model for antiplatelet medications included 17 independent, control and interaction 
variables. In the full model, the number of years with dementia did not significantly predict 
discontinuation of antiplatelet medications (p=0.6).  The number of years with CHD (p≤0.01; 
OR=0.76; 95% CI 0.64-0.90), the California (p≤0.01; OR=0.20; 95% CI 0.07 -0.55), and 
Pennsylvania (p≤0.05; OR=0.37; 95% CI 0.13-1.00), study sites were significant predictors for 
less use of antiplaetlet medications as the number of years with dementia increases. 
The final predictive model to test the effect of the number of years with dementia on the 
use of antiplatelet medications controlled for age, race, sex, study site, the number of years with 
CHD, and a history of any arthritis. The number of years with dementia did not predict 
discontinuation of antiplatelet medications. (p=0.1). No control variables were significant 
predictors for use of antiplatelet medications. Table 4.26 presents the results of the full and final 
models for predicting discontinuation of antiplatelet medications. 
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Table 4.26: Multivariable results for discontinuation of antiplatelet medications among participants who develop dementia after CHD 
 
Variable 
 
Antiplatelet Medications 
 Full Model Final Model 
 
Predisposing Variables 
 
β coefficient 
 
OR 
 
95% CI 
 
β coefficient 
 
OR 
 
95% CI 
    No. of years since the dementia diagnosis –0.100 0.90 0.62-1.31 –0.280 0.75 0.54-1.05 
    Age (centered)  0.004 1.00 0.93-1.07 –0.038 0.96 0.89-1.03 
    Age and dementia interaction 0.011 1.01 0.97-1.05  0.012 1.10 0.98-1.04 
    Study site (North Carolina)  –1.585** 0.20 0.07-0.55 –0.196 0.82 0.29-2.27 
        California –0.272 0.76 0.28-2.02  0.230 1.24 0.42-3.74 
        Maryland –0.981* 0.37 0.13-1.02  0.123 1.13 0.35-3.61 
        Pennsylvania  0.704 2.02 0.80-5.09  0.550 1.73 0.87-3.46 
    Race (white)  0.507 1.66 0.88-3.12  1.10   0.55-2.22 
    Gender (male) –0.453 0.63 0.34-1.16    
    Educational level (HS or less)        
Enabling variables –0.483 0.61 0.32-1.15    
    Income (≤$24,999)   –0.191 0.82 0.28-2.35    
    Ever had private insurance   0.205 1.22 0.42-3.54    
    Ever had Medicaid   0.212 1.23 0.65-2.32    
    Ever had other insurance   0.235 1.23 0.56-2.84    
    Ever without insurance   –1.432 0.23 0.03-2.00    
    Residing in a nursing home        
Care need variables  –0.270** 0.76 0.65-0.90 –0.035 0.96 0.82-1.12 
    No. Of years since the CHD diagnosis 0.186 1.20 0.87-1.66    
    Hypertension –0.204 0.81 0.52-1.26    
    Diabetes  –0.274 0.76 0.39-1.45    
    Renal insufficiency   0.090 1.09 0.62-1.91 0.174 1.19 0.65-2.16 
Abbreviations: No., number. 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001.
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4.3.3.5 Alternative specifications of main independent variable aim 3  
The sub-sample for the aim 3 analyses are restricted to only participants who developed 
dementia after CHD. In the main models for aim 3, the independent variable, was measured on a 
continuous scale based on the number of years a subject had dementia (“0” for every year before 
onset and “1” starting in the year of onset, then 2, 3….). Alternative forms of measuring 
dementia status were tested for aim 3 these include: 3MSE score less than 80 and DSST score 
less than 30.  Each alternative specification was tested for the full theoretical model and final 
model. Table 4.27 presents the results of the alternative specifications of dementia for each 
model.  A graphical display of the odds ratios and 95% confidence intervals for these models can 
be found in Appendix H. 
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Table 4.27: Multivariable results for the full and final models testing alternative specifications of dementia status for aim 3 
 
 
Dementia Measure 
 
 
ACE Inhibitors 
 
 
Beta-blockers 
 
Lipid -lowering 
Medications 
 
Antiplatelet 
Medications 
Full model     
    No. of years since dementia diagnosis† NS **(positive) NS NS 
    3MSE Score Less than 80 NS NS NS NS 
    DSST Score Less than 30 NS NS NS NS 
Final model     
    No. of years since dementia diagnosis† NS NS NS NS 
    3MSE Score Less than 80 NS NS NS NS 
    DSST Score Less than 30 NS NS NS NS 
† Primary independent variable 
Abbreviations: NS, not significant; 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test. 
P values: P values: *p≤0.05;**p≤ 0.01;*** p≤ 0.00
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5.0  SUMMARY AND DISCUSSION 
This dissertation investigates the effect of dementia on whether patients receive guideline-
recommended secondary chemoprevention for CHD. Drawing from the literature on predictors 
of use of health care services and conceptual frameworks regarding physician-related factors for 
evidence-based medical decision making and patient-level predictors, the analyses compare 
utilization of chemoprophylaxis for CHD for those with and without dementia. We also examine 
whether the timing of dementia onset in relation to CHD affects the use of chemoprophylaxis. 
Although causes for potential variation in use are not empirically tested, the literature reviewed 
presents theories and data from previous research as to why patients with dementia might be 
treated differently than those without dementia.  
Data from the Cardiovascular Health Study-Cognition Study (CHS-CS) was used to 
perform a series of sixteen primary analyses that examine differences in the use of 
chemoprophylaxis for CHD.  The main findings are from multivariable analyses focused on 
different measures of dementia status and on relevant predisposing, enabling, and care need co-
variates. Advanced methods were employed to reduce bias and improve the efficiency of the 
model estimates. 
 Section 5.1 summarizes the results of the dissertation’s three research aims.  
Section 5.2 discusses and interprets these findings and addresses the limitations. Section 5.3 
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includes a discussion of the clinical implications from the findings and Section 5.4 discusses the 
policy implications. Section 5.5 suggests opportunities for future research.   
5.1 SUMMARY OF RESULTS 
Lipid-lowering medications were the only sub-class of chemoprophylaxis consistently found to 
be used less among patients with dementia. The following section discusses the general findings 
on utilization between those with and without dementia and presents the summary of the impact 
of timing of disease onset on use of chemoprophylaxis.  
5.1.1 Effect of dementia on use of guideline-recommended chemoprophylaxis for CHD 
Study aim 1 investigated if Medicare beneficiaries with dementia and CHD were less likely to 
report use of evidence-based chemoprophylaxis for CHD compared to those with only CHD. The 
sub-sample included all participants in the CHS-CS who entered the study with CHD or who 
developed CHD at some point during the study.  For this aim dementia was measured as a binary 
variable, dementia “yes or no” based on the CHS date of onset. Having dementia does not 
significantly predict use of use of ACE inhibitors, beta-blockers, or antiplatelet medications.  
Additionally, dementia was not a significant predictor when compliance when measured as 
taking none of the four medications (0%) “yes or no”.  
In contrast, dementia does statistically significant predict less use of lipid-lowering 
mediations after controlling for age, race, sex, and the interaction between age and dementia and 
study site.  Results indicate that the chances of those with dementia and CHD report taking a 
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lipid-lowering medication are only 38% of the odds of those with CHD only (p<0.05). These 
findings are consistent with the only other study that has looked at the effect of dementia on the 
use of lipid-lowering medications (Rodriguez, 2002) that found that among community-dwelling 
seniors with cognitive impairment, those with dementia were less likely to report taking the 
medication (OR=0.39, 95% CI=0.16-0.95). 
The second finding from our study that supports the hypothesis that dementia has a 
negative effect on use of chemoprophylaxis is that those with CHD and dementia are only 0.60 
times as likely to be 50%-100% compliant with chemoprophylaxis as those with only CHD 
(p<0.05). Figure 5.1 displays the ORs and 95% CI for each sub-class of chemoprophylaxis and 
both compliance measures (p≤0.05). 
 
Figure 5.1: Chemoprophylaxis Use Among Participants with CHD and Dementia. 
Sensitivity analyses were conducted to investigate if our results depend on the type of 
dementia.  Of the participants who developed both CHD and dementia, 61% developed dementia 
of the Alzheimer’s type, 32% developed vascular dementia and 7% some other form of 
dementia. The sample was stratified by type of dementia an analyses for aim 1 were repeated for 
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those with Alzheimer’s types and CHD (vs. CHD only) and for those with vascular dementia and 
CHD (vs. CHD only). Results from the stratified model for Alzheimer’s type dementia is 
consistent with the model for any form of dementia  in that it predicts being less likely to be 
50%-100% compliance with all four sub-classes of chemoprophylaxis (p≤0.05). No sub-class of 
medication, when tested independently, is a significant predictor. Figure 5.2 displays the ORs 
and 95% CIs for each sub-class of chemoprophylaxis and both compliance measures for those 
with Alzheimer’s type dementia and CHD. 
 
Figure 5.2: Chemoprophylaxis Use Among Participants with CHD and Alzheimer’s Disease. 
 
Results from the analysis testing the effect of vascular dementia on the use of 
chemoprophylaxis were opposite of those from the primary model testing (non-specified) 
dementia and the model specifying dementia of the Alzheimer’s type.  Each sub-class of 
medication is a statistically significant predictor of use.  Additionally, those with vascular 
dementia were less likely to be 0% compliant (p≤0.05), and more likely to be 50%-100% 
compliant, although not statistically significant. Participants with vascular dementia were 4.76 
0.1 1 10
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACE inhibitors
Odds Ratios
 173 
times as likely to report using an ACE inhibitor (p≤0.01; OR=4.76; 95% CI=1.64-13.78) after 
controlling for age, sex, race, study site, and an age and dementia interaction.  In contrast, 
vascular dementia is a significant predictor for less use of beta-blockers (p≤0.01; OR=0.48; 95% 
CI=0.26-0.87), lipid-lowering medications (p≤0.01; OR=0.46; 95% CI=0.21-0.93), and 
antiplatelet medication (p≤0.01; OR=0.38; 95% CI=0.18-0.80). Figure 5.3 displays the ORs and 
95% CIs for use of chemoprophylaxis for those with CHD and vascular dementia. 
 
Figure 5.3: Chemoprophylaxis Use Among Participants with CHD and Vascular Dementia. 
 
Results from the analyses testing the effect of vascular dementia on use of 
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Figure 5.4 shows how the predicted probability of a person with vascular dementia and CHD 
using an ACE inhibitor changes as their age increases. Use of ACE inhibitors among those with 
CHD only stays relatively constant over time. 
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 Figure 5.4: Predicted Probability of ACE Inhibitor Use Among those with Vascular 
Dementia and CHD and CHD Only. 
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Figure 5.5 shows that the predicted probability of using a beta-blockers increases with age for 
patients with vascular dementia while those without dementia use of beta-blockers declines.  
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 Figure 5.5: Predicted Probability of Beta-blocker Use Among those with Vascular Dementia 
and CHD and CHD Only. 
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Figure 5.6 shows the predicted probability of using a lipid-lowering medication for those with 
and without vascular dementia. The probability of use slightly increases with among those with 
and without vascular dementia, yet those with vascular dementia have lower probability of use. 
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Figure  5.6.  Figure 5.6: Predicted Probability of Use of Lipid-lowering Medications Among those with 
Vascular Dementia and CHD and CHD. 
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Figure 5.7 shows that the predicted probability for the use of antiplatelet medications is similar to 
that for beta-blockers. The probability of using of antiplatelet medication increases more sharply 
with age for patients with vascular dementia than for patients with only CHD. 
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 Figure 5.7: Predicted Probability of Use of Antiplatelet Medications Among those with 
Vascular Dementia and CHD and CHD. 
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5.1.2 Impact of timing of disease onset 
The analyses for aim 2 tested if Medicare beneficiaries who develop dementia before CHD are 
less likely to report use of evidence-based chemoprophylaxis for CHD compared to those who 
develop dementia after CHD.  Dementia status was measured as a binary variable of dementia 
before CHD (yes or no).  The results of the analyses show that developing dementia before CHD 
significantly predicts less use of beta-blockers and lipid-lowering medications. The time of 
disease onset does not significantly predict the use of ACE inhibitors, antiplatelet medications or 
compliance with the group of chemoprophlaxis. Based on these findings, and those from the aim 
1 analyses, dementia, overall and before CHD, has a negative effect on use of lipid-lowering 
medications. Figure 5.8 presents the ORs and 95% CIs for use of chemoprophylaxis when the 
development of dementia precedes the development of CHD.  
 
 
Figure 5.8: Chemoprophylaxis Use Among Participants with Dementia before CHD. 
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5.1.3 Not starting chemoprophylaxis vs. discontinuing chemoprophylaxis 
Results from the analyses for aim 3 indicate that developing dementia after CHD does not 
significantly predict discontinuation of chemoprophylaxis. Developing dementia after CHD was 
not a significant predictor for discontinuing any type of medication. Figure 5.9 presents the ORs 
and 95% CIs for use of chemoprophylaxis for those who develop dementia after already starting 
chemoprophylaxis for CHD.  
 
Figure 5.9: Discontinuation of Chemoprophylaxis among Participants with CHD before Dementia. 
 
 
The absence of discontinuations of chemoprophylaxis after the development of dementia 
is consistent with what we know from the literature about the infrequency of physicians stopping 
medications that have already been started (Rhymes, 2000). Traditionally, bioethicists have not 
made a moral distinction between stopping a treatment versus not starting a treatment if the 
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outcomes of the action have similar benefits and burdens on the patient. Physicians, on the other 
hand, do see a distinction between the two (Rhymes, 2000).  
Additional social and emotional factors may also affect the difference in rates of not 
initiating vs. stopping therapy for patients with dementia. For instance, some physicians may not 
be comfortable initiating discussions about stopping medications as doing so may be seen as a 
sign of “giving up” on a patient.  Additionally, physicians may view advice to patients to stop 
taking a medication contradicts their advice about the importance of adhering to treatment, 
especially for secondary prevention of an MI. Despite these pressures, physicians may also 
overestimate patients’ discomfort with stopping medications (Straand, 2001).  For patients who 
are more severely demented and have family participating in medical decision making, the 
family’s inertest in continuing treatment may reflect the need to have a sense of control over a 
terminal illness by still “actively” treating other comorbidities. The pressure to continue (or 
initiate) treatment from patients and families may also be a response to the increase in direct-to-
consumer advertising for medications (Kravtiz, 2005). 
This study, like all others, has limitations that are important to note when considering the 
implications of the results.  Broadly these limitations include measurement of the independent 
and dependent variable. The dependent variables, use of four sub-classes of chemoprophylaxis, 
were based on the self-reported use by the study participants. Previous research on medication 
use among older adults has found that this method of measuring medication often under 
estimates what physicians are actually prescribing. Findings from the literature also report that, 
on average, older patients’ compliance with prescription medication ranges from 57-70%. 
Additionally, there is a negative correlation between the number of total prescriptions that a 
person is prescribed and compliance with any of them (Cline, 1999; Claessens, 1999). 
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Compliance with medications may be especially challenging for patients with dementia and 
CHD because of the high number of medications they take and other factors that influence 
compliance, such as memory, cognitive capacity, executive function and access to getting 
prescriptions filled (Murray, 2004).   Based on previous findings, use of chemoprophylaxis 
modeled in this study is likely lower than the actual rate of prescribed chemoprophylaxis for 
patients with CHD and for those with CHD and dementia.  
The second limitation includes the measurement of the main independent variable, 
dementia status. Measures of dementia for this study were based on detailed diagnostic data with 
an expert committee designated to clinically adjudicate all dementia diagnoses. As noted above, 
the outcome of interest, use of chemoprophylaxis, was based on participant self-report and not 
what they were prescribed by their community physician. Based on the data from previous 
research about physicians’ level of awareness of their patient’s cognitive status, it likely that a 
majority of the physicians prescribing the chemoprophylaxis were unaware of what that status 
was. Data suggests as many as 30-50% of patients have their impaired cognitive status 
unrecognized by their community physician, therefore the status would have no effect on how 
physicians’ treat non-dementia illnesses.  While the design of the study may mirror clinical 
reality, findings about the effect of dementia on use of evidence-based chemoprophylaxis may be 
affected by the lack of awareness of cognitive status.   
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5.2 DISCUSSION 
 
Among the CHS-CS sample of community-dwelling Medicare beneficiaries, we anticipated 
finding that those with dementia and CHD would consistently be less likely to report using 
chemoprophylaxis. Additionally, we hypothesized that among the sample with both diseases, the 
timing of disease onset would impact use and that those who developed dementia first would 
have lower rates compared to those who developed CHD first. Additionally, we believed that 
among those who developed CHD first, use of chemoprophylaxis would decline due to 
discontinuation once the person developed dementia. The hypotheses were based on a number of 
findings from the literature about possible factors that may lead to less aggressive care for 
patients with dementia compared to their peers without dementia.    
Our findings show that for lipid-lowering medications there was lower use across aims 1 
and 2.  Also, the findings regarding the group with vascular dementia may provide the most 
interesting results in that CHD is a known risk factor for developing vascular dementia, yet use 
for all sub-classes, with the exception of ACE inhibitors, is lower overall and is highly related to 
patient age. Our hypotheses were based on three beliefs for why those with dementia may be 
treated less aggressively. First are the unique features of dementia on both physical and cognitive 
abilities and its impact on life expectancy, second, the imposition of physician value judgments 
about the quality of life of a person with dementia, and third, the impact of less aggressive 
patient and family goals for care on the choices for treatment. Our findings from the empirical 
analyses do not provide causal evidence, they support the overall theory that the presence of 
dementia, comorbid with CHD, may result in less use of some types of chemoprophylaxis as 
well as overall compliance with chemoprophylaxis.   
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First, we anticipated finding different rates of utilization of chemoprophylaxis because of 
clinical factors that make dementia an unusually complex disease. These include the interaction 
of cognitive and functional symptoms that overtime decrease life expectancy and quality of life 
(Boustani, 2003; Fried, 2002).  When physicians make treatment decisions for patients with 
CHD and dementia, medically relevant factors, such as life expectancy, the inability to adhere to 
treatment recommendations, and the increased risk of harm from a treatment impact their 
decisions and, we believe, decrease the likelihood of them recommending evidence-based 
chemoprophylaxis (Brauner, 2000; Monette, 1997). For example, a physician might consider that 
the patient’s life expectancy is less than the expected benefit from a particular treatment.  Also,  
that a patient’s cognitive disabilities and memory problems could result in them not following 
the correct prescribing recommendations, hence putting them at high risk of adverse events. An 
example may be the risk of a fall for someone taking an antiplatelet medication, such as a 
subdural hematoma, which may render the patient with dementia in a worse state (Karnath, 
2004).  Another example is that the number of competing biomedical, functional, and behavioral 
issues that the dementia patient may be experiencing “pushes” the treatment of CHD to a lower 
priority for the physician, as well as for the patient, or family (Silverman, 1997).   
The second belief that shaped our hypotheses of lower use of chemoprophylaxis is the 
effect of dementia on the progressive loss of cognitive abilities. Dementia erodes the 
characteristics that define us as human, such as memory, personality, and awareness of self and 
others. These manifestations of the disease make patients with dementia vulnerable to negative 
perceptions and judgments about their quality of life and social worth. The judgments are likely 
to impact physician decision-making. We know from the literature that patients’ cognitive 
abilities and sociological features may negatively influence treatment (Crane, 1975; Eisenberg, 
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1979; Marwill, 1996). The imposition of value judgments on the decision-making process, 
without any input from the patient, could affect what evidence about the optimal treatment is 
analyzed and how information about those treatments is presented to patients and families.   
The third reason we believed that patients with dementia would have lower rates of some 
sub-classes of guideline-recommended chemoprophylaxis is that the patients’ prefer less 
aggressive care. If this preference is communicated to the physician, it may impact treatment and 
result in lower rates of utilization. We recognize that the literature on the impact of patient 
preferences on treatment outcomes is inconsistent, at best, and that it assumes that physician, 
patients, and families have had some discussion about goals of care. Nonetheless, it is an 
important factor to consider given that dementia is a terminal disease and that patient compliance 
with chemoprophylaxis requires that they take an active role (i.e. filling prescriptions and taking 
the medications).  The literature on the effect of patient preferences on receipt of intense 
hospital-based treatment at the end-of-life shows that patient preferences tend to have little 
impact on the treatments that patients’ actually receive (Teno, 1997). In contrast, some studies 
have shown that less aggressive goals of care that are discussed between the physician and 
patient result in lower rates of out-patient planned care such as primary preventive procedures 
(Flood, 2006).  Although no studies have looked at the effect of patient preferences on the use of 
chemoprophylaxis for CHD, we believe that for patients with dementia, patient preferences may 
have an effect on utilization for two reasons. The first is based on the idea stated above, that 
dementia is a terminal disease, with a progressive decline, that many believe leads to a life with 
little quality.  Because of this, physicians, patients and families may be more open to talking 
about preferences and actively incorporating them into treatment plans for other conditions.  
Second, compliance with chemoprophylaxis requires that patients take an active role and, if the 
 185 
intended or anticipated outcomes of the use of chemoprophylaxis (i.e. reduce the risk of 
mortality from an MI) are not aligned with patient goals, physicians may be less inclined to be 
compliant with evidence-based guidelines. Physicians and families may believe that treating the 
CHD may only prolong their existence with dementia and rob them of the benefit of dying 
sooner and more suddenly from an MI rather than decline over a period of years with dementia. 
5.2.1 Lack of variation in use of chemoprophylaxis 
We hypothesized lower rates of utilization of chemoprophylaxis for patients with dementia and 
CHD. Our findings for lipid-lowering medications and 50-100% compliance with all sub-classes 
support this hypothesis, as do the findings on the effect of vascular dementia on utilization. But, 
the remainder of the findings for the other sub-classes from this study are predominantly 
negative. For example, dementia does not appear to negatively impact the use of ACE inhibitors.  
We believe there are three primary explanations for the negative findings. The first is the lack of 
knowledge of the prescribing physician about a patient’s cognitive status. Second is the medical 
uncertainty that dementia may add to the decision-making process for treating comorbidites, and 
third is the low level of burden and risk that chemoprophylaxis for CHD pose to patients.  
It has been documented in the literature that primary care physicians’ awareness of a 
patient’s cognitive status is often not accurate, especially in the earlier stages of dementia 
(Chodosh, 2004; Valcour, 2000). It has been estimated that nearly 35% of patients with dementia 
have their disease go unrecognized or undiagnosed by their primary care physician (Valcour, 
2000). As a result, physicians may treat patients with CHD and dementia the same as those 
without dementia and not question providing guideline-recommended treatment.  No data exists 
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on the level of cardiology sub-specialists’ awareness of cognitive status when making treatment 
decisions for older adults with CHD.  
In this study, the main independent variable, dementia status, has a clinically adjudicated  
date of dementia onset based on neuroimaging (MRI), multiple cognitive measures, and medical 
record review by trained neurologists (Lopez, 2003).  This level of diagnostic testing for 
dementia is uncommon in the community, even for patients who complain of memory loss and 
present to their primary care physician with signs of dementia (Bounstani, 2003).   The main 
dependent variables for this study are four sub-classes of cardiovascular medications that are 
reported as being used by the participants, but presumably prescribed by a provider in the 
community who did not have access to the detailed cognitive status information collected by 
CHS.  Data on the community physicians’ knowledge of the study participants’ cognitive status 
was not collected by the CHS.  Based on these two measures, and what we know from the 
literature, it is possible that the physician’s who recommended or prescribed chemoprophylaxis 
were not aware the patient’s dementia status (Lopez, 2008).  If the lack of variation in 
chemoprophylaxis is an accurate representation of what occurs in practice, it may explain 
variation in treatment for patients with CHD and dementia in the community, such as those 
observed by Hanlon (1996).  
The second possible reason for the lack of variation in chemoprophylaxis may be the 
medical uncertainty and complexity that a patient’s cognitive impairment adds to the medical-
decision making process. For example, the presence of dementia can affect the patient’s ability to 
give an accurate medical history (Adams, 2005) and to report symptoms and adverse events from 
medications (Brauner, 2000).  The literature on variation has demonstrated that physician 
uncertainty often leads to more conservative treatment, more testing and increased use of 
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diagnostic procedures (Eddy, 1984). For patients with dementia and CHD, therapeutic caution 
may cause physicians to pay more attention to clinical practice guidelines and more likely to 
follow evidence-based recommendations (Adams, 2005).  
The third reason for finding similar use of chemoprophylaxis may be the low initial 
burden and long-term burden of taking chemoprophylaxis for CHD.  Medical and surgical health 
care services include a range of interventions from primary preventive screening and diagnostics 
to intensive, life-sustaining treatments.  All interventions involve some risk and burden on the 
patient, but the medical community demands that there be a reasonable expectation of benefits 
and the magnitude of the benefits should be commensurate with the probability and degree of 
risk (Brock, 1995). Use of chemoprophylaxis (1) is proven to reduce mortality from MI, but 
require ongoing use for the patient to continue to receive benefit; (2) is low-burden, oral 
medications with few side-effects and a low probability of adverse events; and (3) is relatively 
inexpensive. Secondary chemoprophylaxis is different from other treatments, in that the 
assumption, based on the evidence, is that strict adherence with chemoprophylaxis may reduce 
the risk of a subsequent MI, although the exact reduction in risk is not known. It is assumes that 
the risk of a subsequent MI is increased if the patient does not take chemoprophylaxis, but that 
exact rate is also unknown.  In between each of these extremes are an array of possible 
outcomes, many of which we do not know exact information on their chance of occurring and 
are very difficult to align with patients goals of care.  
The array of outcomes of treating (or not treating) CHD and aligning those outcomes 
with patient goals is different and much more difficult than deciding whether to conduct primary 
screening.  For example, a decision not tp perform a mammogram on a patient who would not 
consider any treatment even if a cancer was detected is easily justified because does not align 
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with the screening benefit or the patient’s goals. Unless a patient has clear and explicit goals that 
they want to discontinue all treatments in the hope of dying sooner from something other than 
dementia, it is more difficult to align use with patient goals.   
Chemoprophylaxis for CHD also differs from intensive, life-sustaining interventions that 
must be continued indefinitely for the patient to receive continued benefit. Such interventions 
include long-term ventilatory support or hemodialysis. The burden of these treatments is high 
and the impact on quality of life is greater (Rhymes, 2000). These treatments often pose 
substantial risks, but without the treatment the patient will die either immediately or shortly after 
withdrawing the treatment (or after not initiating treatment.) In the studies by Marwill (1996) and 
Sloan (2004), patients with dementia had lower rates of surgical resection for breast cancer and 
catheterization, coronary angioplasty, and cardiac bypass surgery for CHD.   In each of these 
studies the intervention was surgical, burdensome and put the patient at risk of complications and 
iatrongenic events. Neither Sloan nor Marwill investigated casual factors for the lower rates for 
patients with dementia, but we hypothesize that the parties involved in the decision-making 
process determined that the benefit gained for the patient, extension of life, did not outweigh the 
risks of immediate death or complications that could decrease the quality of the remaining years 
of life. 
5.3 CLINICAL IMPLICATIONS 
As people age the incidence of morbidities from life-limiting illnesses increases and as these 
illnesses progress it is not uncommon that people’s goals of care shift from curative to disease- 
modifying to the management of symptoms (Fox, 1997). We believe that reevaluating the use of 
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health services to fit changing goals of care is an essential component of quality care for patients 
with dementia. To improve care for people with dementia, many medications previously 
indicated for the treatment of a comorbid condition may need to be altered or even discontinued 
in order to better align treatments with patient goals, promote quality of life, reduce the burden 
on the patient and family and reduce the risk of adverse effects (Hajjar 2007). Some studies have 
shown that people with dementia are at greater risk of receiving overly aggressive care that does 
not align with their goals of therapy (Mitchell, 2004; Mehta, 2010) and of under treatment of 
symptoms that could decrease symptom burden and improve quality of life (Frampton, 2003). 
The successful alignment of goals of care with the use of chemoprophylaxis is an 
essential element in the medical decision-making process for patients with CHD and dementia. 
To implement this in clinical practice requires the consideration and discussion of all likely 
outcomes for the patient with and without treatment. This includes determining whether a 
reasonable benefit has already been achieved from the medications the patient has been using 
and whether any additional benefit is anticipated or desired based on the patient’s goals of care 
(Holmes, 2006). Also a consideration in the decision-making process should be time-until-an 
adverse event is likely to occur. This occurs when the likelihood of experiencing a risk from the 
treatment is as likely as achieving a benefit based on the patient’s condition. 
To determine the time-until-benefit or the likely-time-until-adverse event requires 
analysis of the evidence. The Eddy framework for evidence-based decision-making includes this 
important step, but we believe that in making medical decisions for people with dementia, the 
Eddy model does not account for the array of outcomes that could occur without an intervention 
and for a variety of different interventions. Our interpretation of the Eddy model assumes that a 
single problem has been identified and prioritized by the physician and that there is one best 
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evidence-based solution to “fix it” (Lynn, 1991). This approach is not helpful for making 
treatment decisions for patients with dementia and CHD given the possibilities of various 
outcomes of both diseases and their dependence on how or if they are treated. Identifying the 
array of outcomes of treatment is not always easy and describing them to patients and their 
families may be more difficult. Nonetheless these steps are critically important for quality care 
because the treatment chosen is likely to have a substantial impact upon the length and nature of 
their remaining years. A recent study by Mitchell (2010) suggests that family members of 
patients with advanced dementia would be far less likely to favor particular treatments, 
especially those considered high risk and burdensome, if they had a better understanding of 
dementia as a progressive disease that attacks the body, as well as the mind, and if they 
understood the implications of the treatments on the progression of dementia.  
A medical decision-making framework developed by Holmes (2006) for prescribing 
medications for patients’ late in life is particularly useful when considering medication 
management for patients with dementia. The model takes into account whether a patient it likely 
to benefit from a particular medication by comparing the patient’s estimated remaining life 
expectancy with the time until the medication benefit is achieved. In addition, the medication 
must fit into a logical treatment plan as determined by the concordance between the patient’s 
goals of care and the treatment targets of the medication.  
5.4 POLICY IMPLICATIONS 
This study has added to the body of previous work by controlling for type of dementia, severity 
of cognitive status, functional status, and length of time with the dementia and CHD.  Unlike 
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intense, life-sustaining treatments, guideline-recommend chemoprophylaxis is low burden, low 
risk, and low cost. Yet, they differ from life-sustaining treatments and primary preventive 
screening in that it is more difficult to predict health outcomes with and without treatment and 
align those outcomes with patient goals of care. 
The data used for this study were collected prior to Medicare Part D and quality 
improvement initiatives within Medicare that link payment for health services with health 
outcomes based on the evidence. The introduction of value-based purchasing, such as pay-for-
performance (PFP) in health care, has been presented as a model to reform the current payment 
structure within Medicare. In traditional Medicare, physicians are reimbursed on a fee-for-
service model which is based on the number and complexity of services provided, without regard 
to quality, efficiency, or impact on their patient’s health outcomes. Pay-for-performance, and 
other programs that link health outcomes to payments, are designed to promote the actuation of 
evidence-based medicine with the goals of improving quality and reducing waste within the 
system.  Clinical practice guidelines for the secondary prevention of CHD were available to 
physicians during the time that the CHS data were collected, but with the exception of the 
Veterans Administration Health Care System (Walter, 2001), physicians had no incentive to 
follow the guidelines.   Despite this, our study consistently found similar patterns of use for ACE 
inhibitors and antiplatelet medications.  
The impact of PFP on health services utilization for patients with dementia has not been 
studied.  There is concern that PFP could result in a reduction in quality of care for older patients 
with comorbidites if the unique needs of this population are not appropriately accounted for in 
the performance measures.  In recent study by Ryan (2010), results from one Medicare PFP 
Demonstration project did not reduce access to cardiovascular care for older minority patients 
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who were admitted with an MI. Although the CHS data were collected before PFP, we believe 
that, if replicated in the present environment rates of use for all sub-classes of chemoprophylaxis 
would be similar for those with and without dementia, indicating a lack of opportunity or 
disincentives for physicians to adjust their medical decision-making and treatment 
recommendations based on the array of outcomes that are appropriate for patients with dementia 
and CHD.  
In 2005, Medicare (combined with Medicaid) spent $112 billion for care of patients with 
dementia (Alzheimer’s Association, 2007). Pay-for-performance programs in Medicare have the 
potential to improve quality and reduce the cost of health services for people with dementia, but 
it is essential that measures of performances be based not only on the evidence, but also account 
for the convergence of possible outcomes of each disease with and without particular treatments. 
Additionally, PFP programs in Medicare must not unwittingly lead to a decrease in access to care 
for patients with dementia if their goals of care translate into less aggressive treatment or care 
plans that deviate from evidence-based care that are not financially rewarded within the 
Medicare system.  
5.5 FUTURE RESEARCH 
This study serves as the basis for future work in a number of areas. One area includes research 
on medical decision-making and the disentanglement of physician, patient and environmental 
factors on the use of health services for older adults with dementia. This work could provide 
valuable information for heightening physicians’ awareness of their personal influence on the 
process and provide preliminary information for interventions that improve how physicians 
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present information about treatment options and outcomes to patients with dementia and other 
comorbidities.  
Based on our findings it is also important that any study designed to identify factors that 
influence medical decision-making for patients with dementia must address the issue of 
physician awareness of a patient’s cognitive status. For example, a study question may be, does 
increasing the primary care physician’s awareness of a patient’s cognitive status affect treatments 
for non-dementia chronic diseases? Is there an impact on clinical outcomes or mortality or 
quality of life outcomes? 
As described in chapter 2, the guideline-recommended, evidence-based treatments 
investigated in this research are grounded in a robust evidence base with data about the 
effectiveness of these medications from multiple clinical trials, yet, none of the trials included 
patients with dementia. It was assumed for this research that the use of chemoprophylaxis 
reduces the risk of subsequent MIs in patients with and without dementia at the same level. 
Research that compares the outcomes of treatments for different groups is needed. The purpose 
of this type of research is twofold. It would help physicians make informed decisions about the 
treatment options they offer and discuss with patients. Second, it would help patient and families 
understand a more realizable benefit of treatment. Research that strengthens the evidence-base 
and is available to facilitate better health care choices could improve the quality of health care 
for patients with dementia. An example of such a study would be the effectiveness of the use of 
pacemakers for sinus node dysfunction among patients with dementia or the effectiveness of 
warfarin for the secondary prevention of strokes for patients with vascular dementia. This line of 
research is important to understand the optimal decisions for care of patients with dementia and 
could produce a more profound understanding of the effectiveness of treatments for patients with 
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dementia, their impact on quality of life, and the clinical factors that influence medical decision-
making for patients with dementia and other comorbidities.  
Finally, an area for future research is to investigate the role of families of in the medical 
decision-making process when the treatment choices have uncertain outcomes that are not easily 
aligned with the patient’s perceived goals. An example of a research question would be do 
families make explicit decisions about compliance with secondary chemoprophylaxis?  Medical 
decision making for patients’ with dementia frequently falls upon the family, with guidance from 
physicians. Factors such resources available to families and differences in perception of quality 
of life between clinicians and caregivers may affect decisions (Fitzpatrick, 2004).  Advance 
directives and other documented wishes regarding health services may aid families in decision-
making, but they do not adequately represent the family's preference for how the patient should 
be treated.  This is especially true for treatments that have uncertain and varied outcomes that 
may impact both quantity and quality of life. 
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APPENDIX B 
UNADJUSTED USE OF CHEMOPROPHYLAXIS AMONG PARTICIPANTS WITH CHD STUDY YEARS 2-11, NO. (%) 
Dependent 
Variable 
Study 
Year 2 
Study 
Year 3 
Study 
Year 4 
Study 
Year 5 
Study 
Year 6 
Study 
Year 7 
Study 
Year 8 
Study 
Year 9 
Study 
Year 10 
Study 
Year 11 
 
ACE inhibitors 
 
41 
(8) 
 
55 
(10) 
 
78 
(13) 
 
110 
(15) 
 
120 
(16) 
 
138 
(18) 
 
151 
(20) 
 
151 
(21) 
 
175 
(24) 
 
181 
(24) 
 
 
 
Beta-blockers  
 
 
153 
(30) 
 
 
159 
(29) 
 
 
161 
(27) 
 
 
185 
(26) 
 
 
197 
(26) 
 
 
207 
(27) 
 
 
203 
(27) 
 
 
213 
(29) 
 
 
239 
(32) 
 
 
256 
(35) 
 
 
Lipid-lowering 
medications 
 
 
46 
(9) 
 
 
56 
(10) 
 
 
66 
(11) 
 
 
84 
(12) 
 
 
107 
(14) 
 
 
113 
(15) 
 
 
125 
(17) 
 
 
146 
(20) 
 
 
181 
(24) 
 
 
206 
(28) 
 
 
Antiplatelet 
medications 
 
 
286 
(56) 
 
 
327 
(60) 
 
 
376 
(63) 
 
 
445 
(62) 
 
 
457 
(62) 
 
 
475 
(63) 
 
 
455 
(62) 
 
 
419 
(59) 
 
 
443 
(62) 
 
 
445 
(65) 
Abbreviations: CHS-CS, Cardiovascular Health Study-Cognition Sample; ACE Inhibitors, Angiotensin- Converting Enzyme Inhibitors
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APPENDIX C 
ODDS RATIOS AND 95% CIS FOR FINAL PREDICTIVE MODELS USING 
EXCHANGEABLE CORRELATION STRUCTURE 
C.1: Odds Ratios and 95% Confidence Intervals for Final Aim 1 model of 
Chemoprophylaxis use for Participants with Dementia using Exchangeable Correlation 
Structure 
 
0.0 0.5 1.0 1.5 2.0 2.5
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
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C.2: Odds Ratios and 95% Confidence Intervals for final aim 2 model of 
Chemoprophylaxis use for Participants with Dementia before CHD using Exchangeable 
Correlation Structure 
 
0 2 4 6 8
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
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C.3: Odds Ratios and 95% Confidence Intervals for final aim 3 model of 
Chemoprophylaxis use for Participants with Dementia after CHD using Exchangeable 
Correlation Structure 
 
0.0 0.5 1.0 1.5 2.0
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
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APPENDIX D 
RESULTS OF NON-WEIGHTED BIVARIATE ANALYSES FOR ALL POSSIBLE SPECIFICATIONS OF DEMENTIA 
STATUS 
D.1: Results non-of weighted bivariate analyses for all possible specifications of dementia status for study aim 1 
 
 
 
 
Dementia Measure 
 
 
ACE 
Inhibitors 
 
 
Beta-
blockers 
 
Lipid- 
Lowering 
Medications 
 
 
Antiplatelet 
Medications 
 
 
0% 
Compliance 
 
 
50-100% 
Compliance 
       
    Dementia (present in that year)† *(positive) NS NS NS *(positive) NS 
    Dementia at baseline NS **(negative) *(negative) **(negative) ***(positive) ***(negative) 
    Prevalent Dementia NS **(negative) ***(negative) *(negative) ***(positive) **(negative) 
    3MSE Score Less than 80 NS NS *(negative) **(negative) **(positive) *(negative) 
    DSST Score Less than 30 ***(positive) NS NS ***(negative) **(positive) NS 
† Primary independent variable   
Abbreviations: NS, not significant;3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test.  
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
 
 
 
 201 
 
 
D.2: Results of non-weighted bivariate analyses for all possible specifications of dementia status for study aim 2 
 
 
 
Dementia Measure 
 
ACE 
Inhibitors 
 
Beta-
blockers 
Lipid –
lowering 
Medications 
 
Antiplatelet 
Medications 
 
0% 
Compliance 
 
50-100% 
Compliance 
       
    Dementia before CHD † NS *(negative) **(negative) ***(negative) ***(positive) **(negative) 
    Disease status each year        
        No disease (suppressed category)       
        CHD only **(positive) ***(positive) **(positive) ***(positive) ***(negative) ***(positive) 
        Dementia only  NS NS NS NS NS NS 
        Both diseases ***(positive) **(positive) ***(positive) ***(positive) ***(negative) ***(positive) 
    No. of years since dementia diagnosis NS NS NS NS NS NS 
† Primary independent variable 
Abbreviations: NS, not significant; CHD, coronary heart disease. 
P values: *p≤0.05;**p≤ 0.01;*** p≤ 0.001 
 
 
 
APPENDIX D.3: Results of non-weighted bivariate analyses for all possible specifications of dementia status for study aim 3 
  
 
 
Dementia Measure 
 
ACE Inhibitors 
 
Beta-blockers 
 
Lipid -lowering 
Medications 
 
Antiplatelet 
Medications 
     
    No. of years since dementia diagnosis †  NS ***(negative) NS **(negative) 
    3MSE Score Less than 80 NS NS NS **(negative) 
    DSST Score Less than 30 NS NS NS **(negative) 
† Primary independent variable 
Abbreviations: NS, not significant; 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test. 
P values: P values: *p≤0.05;**p≤ 0.01;*** p≤ 0.001. 
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APPENDIX E 
RESULTS OF NON-WEIGHTED BIVARIATE ANALYSES 
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E.1: Results of Non-Weighted Bivariate Analysis of Chemoprophylaxis for CHD in Participants with Dementia and CHD (AIM 1) 
 
Variable 
 
ACE Inhibitors 
 
Beta-blockers 
Lipid-lowering 
Medications 
 
Antiplatelet Medications 
Predisposing variables β coefficient OR β coefficient OR β coefficient OR β coefficient OR 
    Dementia (in that year) 0.227** 1.26 -0.128 0.88 -0.080 0.92 -0.087 0.92 
    Dementia at baseline -0.461 0.63 -1.125** 0.33 -1.000* 0.37 -0.600** 0.55 
    Prevalent dementia  0.206 1.23 -0.841*** 0.43 -1.450*** 0.23 -0.389* 0.68 
    3MSE Score <=80 -0.031 0.97 -0.030 0.97 -0.220* 0.80 -0.184* 0.83 
    DSST Score <=30 0.215** 1.24 -0.083 0.92 -0.102 0.90 -0.232*** 0.79 
    Age centered on the mean 0.430*** 1.04 -0.025** 0.98 0.008 1.01 -0.163* 0.98 
    Age categories (≤75) 
        76-85 
0.166** 1.18 -0.074** 0.93 -0.220* 0.80 -0.671 0.94 
        86-102 0.343 1.41 -0.213 0.81 -0.102 0.90 -0.390** 0.68 
    Age and dementia interaction 0.013 1.01 0.041 1.00 -0.026 0.97 -0.004 1.00 
    Study site (North Carolina)         
        California -0.019 0.98 -0.293 0.74 -0.046 0.95 -0.133* 0.73 
        Maryland 0.077 1.08 -0.227 0.79 -0.266 0.76 -0.375* 0.68 
        Pennsylvania 0.305 0.73 -0.121 0.88 -0.270 0.76 -0.177 0.83 
    Race (white) -0.010 0.99 0.001 1.00 0.278 1.32 0.342** 1.41 
    Gender (male) 0.381** 1.46 -0.188** 0.83 -0.142 0.87 0.433*** 1.54 
    Education  (HS or less) 0.081 1.08 -0.029 0.97 0.050 1.05 -0.068 0.93 
Enabling Variables         
    Income (<$24,999/year) -0.463 0.76 -0.226 0.80 -0.422** 0.66 -0.453*** 0.636 
    Insurance status (none)         
       Private  -0.010 0.98 0.143 1.15 -0.038 0.96 0.206 1.22 
       Medicaid -0.067 0.93 -0.105 0.90 -0.331 0.71 0.257 1.29 
       Other 0.064 1.06 0.186 1.20 0.057 1.05 0.199 1.22 
    Ever had private insurance  -0.163 0.84 0.284 1.32 0.379 1.46 0.428 1.53 
    Ever had Medicaid  -0.125 0.88 -0.177 0.83 -0.094 0.91 -0.356** 0.70 
    Ever had other insurance 0.049 1.05 0.057 1.05 0.251 1.28 -0.005 0.99 
    Ever without insurance 0.144 1.15 -0.138 0.87 -0.234 .079 -0.361** 0.69 
    Residing in Nursing Home 0.660** 1.93 -0.153 0.86 -0.215 0.81 -0.500 0.61 
Care Need Variables         
    Activities of daily living 0.080** 1.082 0.005 1.01 -0.050 0.95 -0.137*** 0.87 
    Hypertension 0.222*** 1.25 0.116*** 1.12 0.105*** 1.11 0.005 1.00 
    Diabetes 0.156*** 1.17 -0.076 0.93 0.010 1.01 -0.137 0.87 
    Renal Insufficiency 0.371* 1.45 0.104 1.11 0.007 1.01 0.037 1.04 
    Ever treated for Cancer 0.027 1.03 0.247 1.28 -0.135 0.87 -0.066 0.94 
Abbreviations: 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test; CHD, Coronary Heart Disease. 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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E.2: Results of Non-Weighted Bivariate Analysis of Chemoprophylaxis for CHD in Participants with Dementia before CHD (AIM 2) 
 
Variable 
 
ACE Inhibitors 
 
Beta-blockers 
Lipid lowering 
Medications 
 
Antiplatelet Medications 
 
Predisposing variables 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
    Dementia before CHD -0.346 0.71 -0.663* 0.52 -1.369** 0.25 -0.747*** 0.47 
    Disease status each year  
           (none) 
        
        CHD only 0.875** 2.40 1.134*** 3.11 1.500** 4.48 1.010*** 3.00 
        Dementia only 0.236 1.27 -0.396 0.96 0.384 1.47 0.409 1.50 
        Both diseases 1.111*** 3.04 1.073** 2.93 1.710*** 5.53 1.172*** 3.23 
    No. of years since dementia     
    diagnosis 
0.102** 1.11 -0.022 0.98 0.487 1.05 0.014 1.01 
    Age centered on the mean 0.292 1.03 -0.005 0.99 0.128 1.01 0.020 1.02 
    Age categories (≤75) 
        76-85 
0.142 1.15 -0.347 0.97 0.322 1.38 0.139 1.15 
        86-102 0.087 1.10 -0.074 0.93 0.847 1.09 0.239 1.27 
    Age and dementia interaction -0.008 0.99 0.215 1.02 -0.158 0.98 0.020 1.02 
    Study site (North Carolina)         
        California -0.212 0.81 -0.103 0.90 -0.457 0.63 -0.270 0.76 
        Maryland -0.077 0.93 -0.121 0.89 -0.339 0.71 -0.400 0.67 
        Pennsylvania -0.539 0.58 0.024 1.02 -0.520 0.59 -0.336 0.71 
    Race (white) -0.164 0.85 0.470 1.60 -0.317 0.73 0.571** 1.77 
    Gender (male) 0.543* 1.72 -0.061 0.94 -0.235 0.79 0.646*** 1.91 
    Education  (HS or less) 0.014 1.01 -0.052 0.95 -0.123 0.88 -0.162* 0.85 
Enabling Variables         
    Income (<$24,999/year) 0.003 1.00 -0.293 0.75 -0.153 0.86 -0.657*** 0.52 
    Insurance status (none)         
        Private  0.065 1.07 0.310 1.36 -0.120 0.89 0.179 1.20 
        Medicaid 0.117 1.12 0.132 1.14 -0.028 0.97 -0.028 0.97 
       Other 0.312 1.37 0.387* 1.47 -0.043 0.96 0.154 1.17 
    Ever had private insurance  -0.404 0.67 0.739* 2.09 0.925 2.52 0.468* 1.60 
    Ever had Medicaid  -0.221 0.98 -0.151 0.86 0.350 1.42 -0.384 0.68 
    Ever had other insurance 0.204 1.23 0.290 1.34 -0.193 0.82 0.163 1.18 
    Ever without insurance 0.139 1.15 -0.441 0.64 0.074 1.08 -0.467** 0.63 
    Residing in Nursing Home -0.403 1.50 -0.041 0.96 -0.357 0.70 -0.268 0.76 
Care Need Variables         
    Activities of Daily Living 0.070* 1.07 -0.003 1.00 -0.070 0.93 -0.028 0.97 
    Hypertension 0.118* 1.13 0.151 1.16 0.030 1.03 -0.026 0.97 
    Diabetes 0.206** 1.23 0.002 1.00 0.040 1.04 0.052 1.05 
    Renal Insufficiency 0.452 1.57 -0.256 0.77 -0.320 0.73 0.250 1.28 
    Any arthritis -0.192** 0.83 -0.904 0.91 -0.019 0.98 -0.177 0.84 
    Ever treated for Cancer 0.218 1.24 -0.193 0.82 -0.147 0.87 -0.039 0.96 
Abbreviations: CHD, Coronary Heart Disease; No., number; HS, high school.    P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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E.3:Results of Non-Weighted Bivariate Analysis of Chemoprophylaxis Discontinuation for CHD in Participants with Dementia after CHD (AIM 3) 
 
Variable 
 
ACE Inhibitors 
 
Beta-blockers 
Lipid lowering 
Medications 
 
Antiplatelet Medications 
 
Predisposing variables 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
 
β coefficient 
 
OR 
    No. years since dementia 
    diagnosis 
–0.145 0.86 –0.261*** 0.77 –0.217 0.81 –0.145** 0.87 
    3MSE Score <=80 –0.479 0.62 0.043 1.04 –0.430 0.65 –0.435** 0.65 
    DSST Score <=30 –0.833 0.43 –0.272 0.76 0.213 1.24 –0.562** 0.57 
    Age centered on the mean –0.146** 0.86 –0.134*** 0.87 –0.089 0.92 –0.067*** 0.93 
    Age categories 76-85 0.002 1.00 –0.418 0.66 –0.528 0.59 –0.509* 0.60 
        86-102 –1.782** 0.17 –1.162* 0.31 –1.254* 0.29 –0.954** 0.39 
    Age and yrs since dementia  
    interaction 
–0.071* 0.93 –0.060** 0.94 –0.122 0.99 –0.043 0.96 
    Study Site         
        Davis –0.538 0.58 –0.461 0.63 –0.998 0.37 –0.597 0.55 
        Hopkins –0.263 0.77 –0.591 0.55 –0.441 0.64 –0.456 0.63 
        Pittsburgh –0.700 0.50 –0.090 0.91 –0.419 0.66 –0.282 0.75 
    Race –0.064 0.94 –0.216 0.81 –0.218 0.80 0.242 1.28 
    Gender 0.859 2.36 –0.035 0.97 1.168* 3.21 0.684*** 1.98 
    Education (HS or less) –0.316 0.73 –0.075 0/93 0.302 1.35 –0.163 0.85 
Enabling Variables         
    Income (<$24,999/year) 0.107 1.11 0.300 1.34 –0.484 0.62 –0.505* 0.60 
    Insurance status          
        Private  0.669 1.95 0.449 1.57 0.190 1.21 –0.072 0.93 
       Medicaid 0.586 1.06 0.043 1.04 0.916*** 2.50 –0.191 0.83 
       Other 1.192 3.29 0.441 1.55 0.279 1.32 –0.091 0.91 
    Ever had private insurance 0.298 1.35 0.409 1.51 1.079*** 2.94 0.488* 1.63 
    Ever had Medicaid  –0.185 0.83 0.191 1.21 1.512 4.54 –0.630 0.53 
    Ever had other insurance 0.029 1.03 0.146 1.16 0.074 1.08 0.127 1.14 
    Ever had no secondary ins 0.113 1.12 –0.219 0.80 –0.217 0.80 –0.246 0.78 
    Residing in Nursing Home –0.286 0.75 –0.465 0.96 –0.020 0.97 –1.228** .029 
Care Need Variables         
    Activities of Daily Living –.0479 0.95 –0.128** 0.88 –0.204* 0.82 –0.216 0.81 
    No of yrs since CHD –0.193** 0.82 –0.255*** 0.77 –0.156 0.86 –0.203 0.82 
    CHD at baseline 0.433 1.54 0.240 1.27 0.600 1.82 0.186 1.02 
    Hypertension –0.148 0.86 0.049 1.05 –0.216 0.81 –0.374 0.69 
    Diabetes –0.038 0.96 –0.134 0.87 0.447* 1.56 –0.236 0.79 
    Renal Insufficiency –0.091 0.91 –0.500 0.61 –0.344 0.71 –0.843 0.92 
    Ever treated for Cancer 0.010 1.01 0.055 1.06 0.858 2.36 0.280 1.32 
    Any arthritis –0.156 0.86 –0.064 0.94 –0.048 0.95 –0.087 0.92 
Abbreviations: 3MSE, Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test; CHD, Coronary Heart Disease. 
P values: *p≤ 0.05; **p≤0 .01;*** p≤0.001. 
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APPENDIX F 
ODDS RATIOS AND 95% CONFIDENCE INTERVALS FOR USE OF 
CHEMOPROPHYLAXIS FOR PARTICIPANTS WITH CHD AND DEMENTIA USING 
ALTERNATIVE SPECIFICATIONS OF INDEPENDENT VARIABLE 
F.1: Dementia at Baseline 
 
FULL MODEL 
 
 
 
0 1 2 3 4
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
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FINAL MODEL 
F.2 : Prevalent Dementia 
 
 
FULL MODEL 
 
 
0 1 2 3
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
0 1 2 3
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
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FINAL MODEL 
F.3: 3MSE SCORE <80 
 
 
FULL MODEL 
 
 
0 1 2 3
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
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Odds Ratios
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FINAL MODEL 
F.4: DSST Score <30 
 
 
FULL  MODEL 
 
0.0 0.5 1.0 1.5 2.0 2.5
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
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Odds Ratios
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FINAL MODEL 
 
0.0 0.5 1.0 1.5 2.0
Compliance (50-100%)
Compliance (0%)
Antiplatelet medications
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APPENDIX G 
ODDS RATIOS AND 95% CONFIDENCE INTERVALS FOR USE OF 
CHEMOPROPHYLAXIS FOR PARTICIPANTS WITH DEMENTIA BEFORE CHD 
USING ALTERNATIVE SPECIFICATIONS OF INDEPENDENT VARIABLE 
G.1: Number of years with Dementia 
 
FULL MODEL 
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FINAL MODEL 
 
 
0.0 0.5 1.0 1.5
50-100% Compliance
0% Compliance
Antiplatelet medications
Lipid-lowering medications
Beta-blockers
ACEi
Odds Ratios
 213 
APPENDIX H 
ODDS RATIOS AND 95% CONFIDENCE INTERVALS FOR DISCONTINUATION OF 
CHEMOPROPHYLAXIS FOR PARTICIPANTS WITH DEMENTIA AFTER CHD 
USING ALTERNATIVE SPECIFICATIONS OF INDEPENDENT VARIABLE 
H.1 3MSE SCORE <80 
 
FULL MODEL 
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Antiplatelet medications
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Odds Ratios
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FINAL MODEL 
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Antiplatelet medications
Lipid-lowering medications
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